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Cord	  blood	  transplantation	  
Hematopoietic	   stem	   cell	   transplantation	   (HST)	   is	   used	   as	   a	   treatment	   for	   patients	  with	  
blood	   related	   disorders.	   In	   Europe,	   around	   40,000	   HST	   are	   performed	   annually.	   1	  
Depending	   on	   the	   disorder,	   its	   stage	   and	   earlier	   treatment	   response,	   HST	   is	   performed	  
with	  autologous	  hematopoietic	   stem	  cells	   (HSC)	  or	  allogeneic	  HSC.	  HSC	  can	  be	  obtained	  
via	   direct	   bone	   marrow	   aspiration	   (BM	   grafts)	   or	   by	   (nowadays	   much	  more	   common)	  
mobilizing	  the	  HSC	  via	  injecting	  the	  patient	  or	  donor	  with	  G-­‐CSF	  and	  subsequent	  harvest	  
of	   the	   cells	   by	   apheresis	   (mobilized	   peripheral	   blood	   stem	   cell	   grafts,	   PBSC	   grafts).	  
Autologous	   transplantation	   is	   mostly	   used	   for	   lymphoproliferative	   disorders	   such	   as	  
myeloma	  and	  (non)-­‐Hodgkin’s	  lymphoma.	  Allogeneic	  HST,	  accounting	  for	  around	  42%	  of	  
all	   HST,	   is	   mostly	   used	   for	   patients	   with	   inherited	   disorders	   like	   hemoglobinopathies,	  
inborn	   errors	   of	   metabolism	   where	   allogeneic	   hematopoiesis	   will	   correct	   the	   defect.	  
Otherwise	   allogeneic	  HST	   is	   needed	   for	   patients	  with	   e.g.	   leukemia	  where	   the	   so	   called	  
graft	  versus	  leukemia	  effect	  (GvL)	  mediated	  by	  donor	  lymphocytes	  is	  the	  only	  cure	  left.	  If	  a	  
patient	  requires	  an	  allogeneic	  transplantation,	  the	  search	  for	  a	  suitable	  donor	  is	  first	  done	  
within	   the	   immediate	   family	   of	   the	   patient.	   The	   suitability	   of	   a	   donor	   depends	   on	   the	  
number	  of	  HLA-­‐A,	  HLA-­‐B,	  HLA-­‐C,	  HLA-­‐DRB1	  and	  DQ	  alleles	  that	  match	  between	  the	  donor	  
and	   the	  patient.	   The	  number	   of	  matched	   alleles	   is	   associated	  with	   overall	   survival	   after	  
HST,	   2-­‐4	   and	   transplantations	   are	   preferably	   done	   with	   fully	   matched	   (10/10	   or	   9/10)	  
donor	   stem	   cells.	   The	   chance	   of	   having	   a	   suitable	   family	   donor	   is	   relatively	   small,	   and	  
therefore	   around	   70%	   of	   the	   patients	   require	   an	   alternative	   donor.	   Although	   recently	  
haploidentical	  related	  donors	  are	  increasingly	  used	  as	  alternative	  donors,	  5-­‐7	  the	  majority	  
of	  patients	  still	  rely	  on	  unrelated	  volunteer	  donors.	  The	  search	  for	  an	  unrelated	  donor	  is	  
done	   via	   international	   bone	  marrow	   registries	   such	   as	   Bone	  Marrow	  Donor	  Worldwide	  
(BMDW	   8)	   or	   via	   national	   coordinating	   centers	   such	   as	   Europdonor	   9	   the	   bone	  marrow	  
registry	   for	   the	  Netherlands.	  BMDW	  is	  an	   international	   collaboration	  of	  most	  accredited	  
bone	  marrow	  registries	  in	  the	  world.	  Bone	  marrow	  registries	  maintain	  a	  database	  of	  HLA	  
typed	   donors	   that	   can	   be	   accessed	   by	   the	   affiliated	   transplantation	   centers.	   However,	  
despite	  over	  25	  million	  registered	  donors	  worldwide,	  often	  no	  HLA-­‐matched	  donor	  may	  
be	   found,	   particularly	   for	   non-­‐Western	   European	   patients.	   10	   In	   the	   United	   States	   for	  
approximately	  50%	  of	  the	  patients	  with	  a	  European	  descent	  a	  10/10	  HLA	  matched	  donors	  
could	  be	  found,	  but	  for	  patients	  with	  a	  non-­‐European	  descent	  this	  percentage	  dropped	  to	  
just	  over	  20%.	  11	  	  
When	   there	   is	   no	   HLA	   matched	   donor	   available,	   patients	   can	   be	   transplanted	   with	  
umbilical	   cord	   blood	   (CB).	   CB	   was	   identified	   as	   a	   source	   for	   hematopoietic	   stem	   cells	  
(HSC)	  over	  2	  decades	  ago,	  12	  followed	  by	  the	  first	  successful	  transplantation	  of	  CB	  HSC	  in	  a	  
patient	  with	  Fanconi’s	  anemia	  in	  1989.	  13	  The	  immune	  cells	  in	  CB	  are	  more	  immature	  and	  
are	   therefore	   less	   potent	   in	   causing	   graft	   versus	   host	   disease	   (GvHD)	   as	   compared	   to	  
transplantation	  with	  bone	  marrow	  (BM)	  or	  mobilized	  peripheral	  blood	  stem	  cell	   (PBSC)	  
grafts.	   14-­‐16	   CB	   therefore	   allows	   for	  more	  mismatches	   in	  HLA	   alleles	   between	   the	   donor	  
and	   the	   patients.	   CB	   is	   generally	  matched	   for	   HLA-­‐A/B	   on	   a	   serological	   level	   and	  HLA-­‐
DRB1	   on	   a	   high	   resolution	   level.	   Another	   advantage	   of	   CB	   is	   the	   fact	   that	   CB	   cells	   are	  
cryopreserved	  and	  banked,	  allowing	   for	  quality	   control	  measurements	  and	  making	  a	  CB	  
graft	  more	  readily	  available	  for	  transplantation.	  In	  contrast,	  the	  timespan	  that	  is	  needed	  to	  
select	  an	  unmatched	  donor	  and	  the	  final	  availability	  of	  its	  mobilized	  peripheral	  blood	  graft	  
is	  several	  weeks	  since	  the	  donor	  has	  to	  be	  counseled	  for	  donor	  and	  patient	  safety	  aspects	  
and	   take	   a	   course	  of	   stem	  cell	  mobilizing	   agents	   such	   as	  G-­‐CSF	  over	   a	  period	  of	  5	  days,	  
prior	  to	  harvesting	  of	  the	  cells	  with	  apheresis.	  	  
Currently	  there	  are	  over	  600,000	  CB	  units	  stored	  worldwide	  and	  CB	  transplantations	  (CB	  
HST)	  account	  for	  approximately	  6%	  of	  all	  HST	  performed	  in	  Europe.	  1	  However,	  CB	  units	  
4 
	  
contain	  a	  relatively	   low	  number	  of	  stem	  cells	  compared	  to	  BM	  or	  PBSC	  grafts	  17	  and	   	  no	  
additional	   T-­‐cells	   for	   donor	   lymphocyte	   infusion	   (DLI)	   can	   be	   obtained	   after	  
transplantation.	   This	   translates	   into	   several	   disadvantages	   when	   compared	   to	  
transplantation	  of	  BM	  or	  PBSC	  grafts.	  CB	  HST	  is	  associated	  with	  an	  increased	  risk	  of	  graft	  
failure	   and	   hematopoietic	   engraftment	   is	   delayed,	   which	   lengthens	   the	   median	   time	   to	  
neutrophil	  and	  platelet	  recovery.	  16,18	  Furthermore,	  immune	  reconstitution	  is	  delayed	  19,20,	  
making	  infections,	  especially	  in	  the	  first	  3	  months	  after	  transplantation,	  the	  largest	  cause	  
of	  non-­‐transplant	  related	  mortality	  in	  CB	  recipients.	  	  
While	   the	   last	   20	   years	   the	   overall	   survival	   after	   cord	   blood	   transplantation	   improved	  
significantly,	   21-­‐23	   the	   total	   costs	   for	   treatment	   of	   a	   hematological	  malignancy	  with	   a	   CB	  
graft	   HST	   remain	  much	   higher	   than	   treatment	   with	   a	   PBSC	   graft.	   Including	   a	   one	   year	  
follow	  up	  period,	  the	  total	  cost	  for	  a	  CB	  graft	  HCT	  amounts	  to	  €	  254,000,	  compared	  to	  €	  
171,000	   for	   transplantation	  of	  unrelated	  PBSC	  grafts.	   24	  While	   the	  cost	   for	  selection	  and	  
harvesting	   of	   a	   graft	   between	   unrelated	   allogeneic	   PBSC	   grafts	   and	   CB	   grafts	   is	  
approximately	  equal,	  around	  €	  65,000	  per	  graft,	  the	  hospital	  admission	  period	  of	  patients	  
that	   receive	   CB	   transplants	   in	   this	   respect	   is	   on	   average	   twice	   as	   long	   compared	   to	  
patients	  that	  receive	  a	  PBSC	  graft	  because	  of	  the	  previously	  mentioned	  delay	  in	  peripheral	  
blood	  cell	  recovery	  24.	  This	  shows	  that	  also	  from	  this	  cost	  effectiveness	  point	  of	  view,	  it	  is	  
extremely	  important	  to	  improve	  the	  engraftment	  capacity	  of	  cord	  blood	  cells.	  	  
	  
Methods	  to	  improve	  the	  outcome	  of	  cord	  blood	  transplantation	  
The	  overall	  survival	  after	  cord	  blood	  transplantation	  is	  related	  to	  two	  factors:	  the	  degree	  
of	  matching	  for	  HLA-­‐A,	  B	  and	  DRB1	  between	  the	  cord	  blood	  unit	  and	  the	  patient	  and	  the	  
total	  nucleated	  cell	  dose	  or	  HSC	  dose	  of	  a	  CB	  graft.	  25-­‐27	  While	  equally	  matched	  BM	  and	  CB	  
HST	  showed	  an	  equal	  probability	  of	  neutrophil	   and	  platelet	   recovery,	   18	   this	  probability	  
drops	   considerably	  when	   the	   CB	   unit	   has	   1	   or	   2	  mismatches	   (i.e.	   a	   5/6	   or	   4/6	  match),	  
especially	   when	   the	   unit	   has	   a	   low	   cell	   dose.	   18,25	   Patients	   transplanted	   with	   fully	   6/6	  
matched	   CB	   grafts	   have	   the	   best	   chance	   of	   survival,	   followed	   by	   recipients	   of	   1	   allele	  
mismatched	   CB	   grafts	   with	   a	   medium	   cell	   dose	   (TNC=2.5x107	   –	   4.9x107	   cells/kg)	   and	  
recipients	  of	  2	  allele	  mismatched	  CB	  grafts	  with	  a	  high	  cell	  dose	  (TNC>5.0x107	  cells/kg).	  25	  
Interestingly,	   recipients	  of	  2	  allele	  mismatched	  CB	  grafts	  with	  a	  high	  cell	  dose	  engrafted	  
sooner	  than	  recipients	  of	  a	  1	  allele	  mismatched	  graft	  with	  a	  medium	  cell	  dose.	  	  
The	  outcome	  of	  CB	  HST	  can	   thus	  be	   improved	  by	  better	  HLA	  matching,	  between	   the	  CB	  
unit	   and	   the	   patient,	   and	   the	   transplantation	   of	   high	   doses	   of	   cells.	   Moreover,	   more	  
extensive	   HLA	   typing	   for	   e.g.	   HLA-­‐C	   has	   been	   shown	   to	   lead	   to	   better	   recovery	   and	  
reduced	   non-­‐relapse	   mortality.	   28	   Interestingly,	   in	   cord	   blood	   transplantation	   the	   HLA	  
pattern	  of	  the	  parents	  also	  seems	  to	  play	  a	  role.	  During	  pregnancy,	  fetal	  cells	  are	  exposed	  
to	   non-­‐inherited	   maternal	   antigens	   (NIMA)	   which	   can	   induce	   tolerance	   towards	   these	  
antigens.	   29	  Matching	   for	   donor	  NIMAs	   can	   increase	   the	   number	   of	   suitable	   donors	   and	  
reduce	  transplant	  related	  mortality	  and	  thereby	  improve	  the	  outcome	  of	  transplantation.	  
The	   inherited	   paternal	   antigens	   (IPA)	   might	   also	   play	   a	   role	   in	   the	   outcome	   of	  
transplantation.	   30	   During	   pregnancy	   the	   mother	   can	   develop	   B-­‐	   and	   T-­‐cell	   immunity	  
against	  these	  antigens.	  Cord	  blood	  can	  contain	  maternal	  anti	  IPA	  cells	  that	  can	  enhance	  a	  
strong	  Graft	  versus	  Leukemia	  response	  and	  reduce	  relapse.	  Despite	   the	   large	  number	  of	  
banked	   units,	   it	   is	   difficult	   to	   find	   a	   6/6	   matched	   CB	   unit	   for	   a	   patient	   and	   further	  
matching	  for	  e.g.	  HLA-­‐C	  and	  NIMA	  provides	  an	  even	  bigger	  challenge.	  Alternative	  methods	  
are	   therefore	   being	   explored	   to	   improve	   the	   outcome	   of	   CB	   HST.	   The	   most	   obvious	  
alternative	  approaches	  are	  1)	   to	   increase	   the	  number	  of	   cells	   that	   are	   transplanted	   into	  
the	   patient	   and	   2)	   to	   enhance	   the	   engraftment	   of	   the	   CB	   cells	   by	   co-­‐transplantation	   of	  
accessory	  cells.	  	  
5	  
	  
Method	   1:	   Increasing	   the	   cell	   dose	   of	   a	   CB	   graft	   by	   improving	   the	   number	   and	  
quality	  of	  engrafting	  cells	  in	  a	  CB	  graft	  
There	   are	   three	  ways	   	   to	   increase	   the	   cell	   dose	   of	   a	   cord	   blood	   graft:	   A)	   increasing	   the	  
number	   of	   cells	   available	   for	   transplantation	   after	   thawing	   of	   the	   cord	   blood	   unit,	   B)	  
transplantation	  of	  two	  cord	  blood	  units	  and	  C)	  the	  ex	  vivo	  expansion	  of	  cord	  blood	  cells.	  
	  
A)	  Increasing	  the	  number	  of	  cells	  available	  for	  transplantation	  after	  thawing	  of	  the	  
cord	  blood	  unit:	  improving	  processing	  and	  storage	  of	  CB.	  There	  are	  a	  number	  of	  steps	  
from	  the	  collection	  of	  the	  cord	  blood	  to	  infusion	  of	  the	  final	  product	  in	  the	  patient.	  All	  of	  
these	  affect	  the	  number	  of	  cells	  that	  are	  eventually	  transplanted.	  Over	  the	  years	  progress	  
has	  been	  made	   in	  optimizing	   these	  processing	   steps.	  First	  of	   all,	   the	  volume	   that	   can	  be	  
collected	   from	   the	   umbilical	   cord	   and	   placenta	   is	   highly	   variable	   and	   dependent	   on	   the	  
method	   of	   collection.	   Intra-­‐uterine	   collection,	   i.e.	   collection	   before	   placental	   delivery,	  
significantly	  improves	  the	  volume	  of	  cells	  that	  is	  collected,	  31,32	  and	  has	  therefore	  become	  
the	   preferred	  method	   of	   collection.	   Most	   cord	   blood	   banks	   have	   therefore	   set	   minimal	  
criteria	  with	  respect	  to	  the	  volume	  and	  total	  nucleated	  cell	  (TNC)	  count	  of	  a	  CB	  unit.	  	  This	  
avoids	   the	   cost	   of	   processing	   and	  banking	   a	   cord	   blood	  unit	   that	   has	   a	   low	  potential	   of	  
successful	   engraftment.	   Secondly,	   the	   logistics	   of	   the	   banking	   process	   also	   plays	   an	  
important	  role	  in	  the	  quality	  of	  the	  CB	  unit.	  In	  the	  Netherlands,	  the	  collection	  of	  CB	  is	  done	  
in	  a	  number	  of	  peripheral	  hospitals	  after	  which	  the	  blood	  is	  transported	  to	  a	  centralized	  
processing	   facility.	   The	   time	   and	   conditions	   between	   collection	   and	   eventual	  
cryopreservation,	   however,	   strongly	   affects	   the	   viability	   of	   the	   CB	   cells.	   Processing	   and	  
freezing	  the	  CB	  between	  12-­‐24	  hours	  after	  collection	  in	  this	  respect	  significantly	  improves	  
the	   viability	   of	   the	   cells	   after	   thawing.	   33,34	   Before	   cryopreservation	   the	   red	   blood	   cell	  
(RBC)	  fraction	  and	  the	  plasma	  containing	  platelets	  are	  removed	  as	  much	  as	  possible.	  The	  
most	   important	  reason	   for	   this	   is	   to	  reduce	   the	  volume	  which	  reduces	   the	   freezer	  space	  
and	  thereby	  the	  cost	  of	  banking	  the	  unit.	  Reducing	  the	  RBC	  content	  of	  the	  graft	  also	  seems	  
to	  coincide	  with	  less	  side	  effects	  	  after	  transplantation	  by	  reducing	  high	  concentrations	  of	  
free	   hemoglobin	   released	   by	   RBC	   that	   do	   not	   survive	   the	   freezing	   and	   thawing	   process	  
which	  can	  lead	  to	  significant	  transfusion	  reactions.	  35	  	  
This	  CB	  volume	  reduction	  can	  however	  be	  realized	  with	  several	  methods.	  While	   initially	  
CB	   was	   reduced	   by	   hydoxyethyl	   starch	   sedimentation,	   36	   this	   method	   is	   now	   mostly	  
replaced	  by	  automatic	  devices	  as	  the	  SEPAX	  and	  AXP	  that	  have	  a	  higher	  TNC	  and	  CD34+	  
cell	   yield	   and	   are	   more	   compliant	   with	   GCP	   regulations.	   37	   Thirdly,	   the	   method	   of	  
cryopreservation	   of	   the	   cord	   blood	   unit	   also	   affects	   the	   post-­‐thaw	   viability.	   Important	  
factors	   in	   this	  respect	  are	   the	  use	  of	  a	  cryoprotectant	  such	  as	  dimethylsufoxide	  (DMSO),	  
the	   freezing	   rate	   and	   storage	   temperature.	   38	   Most	   CB	   banks	   therefore	   adapted	   their	  
freezing	  process	  to	  a	  widely	  accepted	  standard	  in	  which	  CB	  is	  frozen	  in	  10%	  DMSO	  in	  an	  
automated	   controlled	   rate	   freezer	   (1-­‐2ºC/min)	   and	   stored	   in	   the	   vapor	   phase	   of	   liquid	  
nitrogen	  at	  -­‐150ºC.	  36	  	  
Finally,	  after	  thawing,	  the	  cord	  blood	  unit	  the	  DMSO	  content	  can	  be	  decreased	  lowered	  by	  
washing	   the	   cells	   before	   transplantation.	   However,	   this	   post	   thaw	   wash	   step,	   besides	  
certainly	   is	  not	  being	  practical,	   leads	   to	  a	   loss	  of	   cells	   39	   and	  removal	  of	  DMSO	  does	  not	  








B)	  Transplantation	  of	  two	  cord	  blood	  units	  to	  increase	  the	  number	  of	  transplanted	  
cells.	   Although	   the	   improvement	   of	   processing	   parameters	   has	   led	   to	   a	   significant	  
increase	   in	   the	  number	  of	  cells	   in	  banked	  cord	  blood	  units,	  cell	  numbers	   in	  a	  single	  unit	  
are	  often	  still	  too	  low	  for	  adults	  or	  larger	  children.	  For	  these	  patients,	  two	  CB	  units	  can	  be	  
combined	   (double	   cord	   blood	   transplantation	   strategies).	   While	   both	   units	   initially	  
contribute	   to	   earlier	   engraftment,	   the	   eventual	   hematopoiesis	   is,	   remarkably,	   mostly	  
determined	  by	  only	  one	  of	   the	  units.	   41,42	  This	  suggests	   that	   the	   increase	  of	   the	  cell	  dose	  
provided	  by	   the	   second	  unit	   is	   only	  needed	   to	  boost	   the	   initial	   engraftment,	   but	  not	   for	  
contributing	  to	  the	  long	  term	  reconstitution	  of	  the	  hematopoietic	  cells.	  Although	  again	  cell	  
dose	   might	   play	   a	   role,	   single	   unit	   dominance,	   is	   most	   likely	   caused	   by	   immunological	  
disparities	  between	  both	  grafts.	  A	  study	  that	  analyzed	  in	  vitro	  cultures	  with	  mononuclear	  
cells	   from	  two	  cord	  blood	  units	  showed	  that	  an	  immune-­‐mediated	  dominance	  for	  one	  of	  
the	   two	  CB	  units	   could	  be	  documented	   in	  most	   combinations	   that	  were	  evaluated.	   43	  As	  
expected,	  T	   cells	   seem	   to	  play	   an	   important	   role	   in	   this	   process,	   but	   it	   is	   unclear	  which	  
subsets	  of	  T	  cells	  are	  involved.	  Analysis	  of	  the	  cells	  of	  the	  dominant	  unit	  14-­‐28	  days	  after	  
transplantation	   showed	   that	   a	   CD8+CCR7-­‐	   population	   could	   be	   responsible	   for	  
establishing	  dominance.	  44	  This	  effect	  can	  be	  seen	  earlier	  than	  14	  days	  as	  well:	  Somers	  et	  
al.	  found	  that	  CD4+	  T	  cells	  are	  most	  likely	  to	  play	  a	  role	  in	  the	  establishment	  of	  dominance,	  
42	  while	  Newell	  et	  al.	  suggest	  that	  the	  CD3	  content,	  i.e.	  all	  T	  cells,	  in	  the	  peripheral	  blood	  as	  
early	  as	  7	  days	  after	  transplantation	  can	  predict	  the	  dominant	  unit.	  45	  	  
Although	   combining	   two	   units	   has	  made	   cord	   blood	   transplantation	   available	   for	   adult	  
patients,	  the	  outcome	  of	  transplantation	  is	  still	  inferior	  to	  BM	  or	  PBSC	  grafts,	  as	  shown	  by	  
delayed	   platelet	   and	   neutrophil	   recovery.	   23,46	   Moreover,	   more	   complex	   matching	  
requirements	  not	  only	  between	  both	  CB	  units	  and	  the	  recipient	  but	  also	  between	  the	  two	  
cord	   blood	   units	   complicate	   the	   availability	   of	   acceptable	   donor	   SCT.	   Furthermore,	   a	  
higher	   risk	   of	   acute	   grade	   II-­‐	   IV	   and	   extensive	   chronic	   graft	   versus	   host	   disease	   is	  
observed	  with	  double	  cord	  blood	  transplantation.	  47,48	  	  	  
	  
C)	  Increasing	  the	  number	  of	  cells	  in	  a	  graft	  by	  ex	  vivo	  culture	  expansion	  of	  CB	  cells	  
Another	  method	   to	   increase	   the	  number	  of	   cells	   that	  are	  available	   for	   transplantation	   is	  
the	  expansion	  of	  CB	  cells	  in	  ex	  vivo	  culture	  in	  a	  defined	  medium	  that	  is	  supplemented	  with	  
cytokines	   and	   small	  molecules.	   The	   composition	   of	   the	   expansion	  medium	   has	   a	  major	  
influence	   on	   the	   number	   and	   types	   of	   cells	   that	   emerge	   after	   culture;	   Most	   expansion	  
protocols	  use	  a	  combination	  of	  Stem	  Cell	  Factor	  (SCF),	  thrombopoietin	  (TPO),	  Flt3	  ligand	  
(Flt3L),	   interleukin-­‐3	   (IL-­‐3),	   interleukin	   6	   (IL-­‐6),	   Granulocyte-­‐Macrophage	   Colony-­‐
Stimulating	   factor	   (GM-­‐CSF)	   and/or	   Granulocyte	   Colony-­‐Stimulating	   Factor	   (G-­‐CSF).	   49	  
Addition	  of	  other	  cytokines	  such	  as	  insulin	  growth	  factor	  binding	  protein	  and	  angiopoietin	  
like	  5	  can	  further	  improve	  the	  expansion	  and	  engraftment.	  50	  
More	  recently	  there	  has	  been	  a	  focus	  on	  the	  addition	  of	  small	  molecules	  to	  the	  expansion	  
medium.	  These	  small	  molecules	  can	  act	  either	  directly	  on	  signaling	  molecules	  responsible	  
for	   survival,	   proliferation	   and	   differentiation	   of	   the	   stem	   cells	   in	   CB	   or	   improve	   the	  
homing	  and	  engraftment	  of	  the	  CB	  cells	  after	  transplantation.	  Apoptosis	  of	  the	  cells	  during	  
culture	   can	   for	   instance	   be	   prevented	   by	   caspase	   and	   calpain	   inhibitors,	   51	   or	   by	   the	  
addition	   a	   copper	   chelator	   such	   as	   tetraethylenepentamine	   (TEPA)	   52.	   An	   example	   of	  
direct	  interaction	  with	  a	  signaling	  pathway	  is	  the	  addition	  of	  delta	  like	  ligand-­‐1	  (DLL-­‐1)	  to	  
the	   culture	   medium.	   53	   DLL-­‐1	   interacts	   with	   the	   Notch	   pathway,	   a	   highly	   preserved	  
signaling	   pathway	   in	   most	   multicellular	   organisms	   that	   regulates	   cell	   proliferation	   and	  
differentiation.	   54	   Other	   molecules	   such	   as	   histone	   deacetylase	   inhibitors	   55,56	   and	   DNA	  
methylases	  57	  modulate	  the	  epigenetic	  regulation	  of	  transcription.	  	  
7	  
	  
Small	  molecules	  have	  also	  been	  shown	  to	  enhance	  the	  homing	  of	  the	  stem	  cells	  to	  the	  bone	  
marrow.	   Fucosylated	   cells	   e.g.	   have	   a	   better	   ability	   to	   home	   to	   the	   BM	   than	   non-­‐
fucosylated	   cells.	   58	   Incubation	   with	   fucosyltransferase-­‐VI	   increases	   the	   number	   of	  
fucosylated	  cells	  and	  improves	  engraftment	  in	  immune	  deficient	  mice.	  Another	  method	  is	  
to	   increase	  CXCR4	  expression,	  the	  receptor	  for,	  SDF-­‐1α,	  the	  main	  chemoattractant	  of	  the	  
BM,	  for	  HSC,	  by	  incubation	  of	  the	  cells	  with	  prostaglandin	  E2.	  59-­‐61	  	  
The	  culture	  conditions	  that	  are	  used	  for	  expansion	  aim	  to	  mimic	  the	  conditions	  in	  the	  BM	  
niche	  to	  a	  certain	  extend.	  In	  this	  niche	  the	  HSC	  are	  surrounded	  by	  supporting	  cells	  such	  as	  
mesenchymal	  stromal	  cells	  (MSC),	  adipocytes	  and	  osteoblasts.	  62	  Factors	  that	  are	  secreted	  
by	   these	  cells	   regulate	   the	  self-­‐renewal,	  proliferation	  and	  differentiation	  of	   the	  HSC.	   63,64	  
Ex	   vivo	   culture	   on	   a	  monolayer	   of	   BM	   stromal	   cells	   can	   improve	  HSC	   expansion	   65	   and	  
specific	  subtypes	  of	  MSC	  66	  or	  conditioned	  medium	  of	  other	  BM	  cells	  such	  as	  adipocytes	  
67,68	  and	  osteoblasts	  69	  have	  also	  shown	  to	  improve	  the	  expansion	  of	  HSC.	  
Ex	  vivo	  expansion	  of	  cord	  blood	  cells	  has	  been	  employed	  in	  clinical	  trials.	  In	  2002,	  a	  first	  
study	  was	  published	  in	  which	  part	  of	  the	  transplanted	  cord	  blood	  unit	  was	  expanded	  with	  
SCF,	  G-­‐CSF	  and	  megakaryocyte	  growth	  and	  differentiation	  factor.	  70	  This	  study	  showed	  the	  
safety	  and	  feasibility	  of	  ex	  vivo	  expanded	  cells	  and	  since	  2002,	  a	  number	  of	  clinical	  trials	  
have	  been	  conducted.	  	  	  	  
The	  Shpall	  group	  from	  the	  MD	  Anderson	  Cancer	  Center	  has	  conducted	  two	  clinical	   trials	  
with	  different	  expansion	  strategies.	   In	  the	  first	   trial	   they	  expanded	  CB	  HSC	  with	  TEPA,	  a	  
copper	  chelator,	  71	  that,	  by	  binding	  to	  free	  copper	  ions	  can	  prevent	  the	  differentiation	  of	  
HSC	  in	  culture.	  52	  A	  proportion	  of	  a	  CB	  unit	  was	  expanded	  with	  SCF,	  Flt3-­‐L,	  IL-­‐6,	  TPO	  and	  
TEPA	  and	   infused	  with	   the	  non-­‐expanded	  part	  of	   the	  unit,	   leading	   to	  a	  median	   fold	  TNC	  
expansion	  of	  219	  and	  an	  increase	  in	  CD34+	  cells	  including	  the	  CD34+	  cells	  from	  the	  non-­‐
expanded	  part	  of	  the	  unit	  of	  six.	  In	  this	  study	  9	  out	  of	  10	  patients	  engrafted	  and	  100	  day	  
survival	  was	  90%.	  However,	  there	  was	  no	  improvement	  in	  median	  neutrophil	  and	  platelet	  
engraftment	  (median	  30	  and	  42	  days	  respectively)	  compared	  to	  results	  from	  studies	  with	  
unmanipulated	  single	  CBT.	  	  
The	   other	   strategy	   the	   Shpall	   group	   used	   was	   the	   expansion	   of	   CB	   HSC	   with	   stromal	  
support.	  72	  This	  expansion	  strategy	  led	  to	  a	  much	  lower	  fold	  TNC	  expansion	  that	  seen	  with	  
the	  TEPA	  trial,	  i.e.	  12.2	  fold,	  but	  the	  fold	  CD34+	  cells	  expansion	  was	  30.1.	  In	  this	  study	  the	  
expanded	  cells	  were	  transplanted	  with	  an	  unmanipulated	  cord	  blood	  unit	  and	  compared	  
to	   historical	   controls	   of	   dCBT	   recipients.	   The	   patients	   receiving	   expanded	   cells	   had	   a	  
clinically	  significant	  reduction	  in	  the	  number	  of	  days	  to	  neutrophil	  engraftment	  (15	  days	  
vs	  24	  days	  in	  historical	  controls)	  and	  to	  a	  lesser	  extend	  a	  reduction	  in	  the	  days	  to	  platelet	  
engraftment	   (44	   days	   vs.	   49	   days).	   These	   promising	   results	   have	   led	   to	   initiation	   of	   a	  
phase	  3	  clinical	  trial	  which	  is	  currently	  recruiting	  participants.	  73	  	  
The	  clinical	  trial	  that	  evaluated	  the	  expansion	  with	  DLL-­‐1	  also	  showed	  promising	  results	  
with	   respect	   a	   reduction	   in	   the	   time	   to	   neutrophil	   engraftment.	   74	   In	   this	   trial	   patients	  
were	  again	  transplanted	  with	  an	  expanded	  unit	  and	  an	  unmanipulated	  unit.	  The	  average	  
fold	   expansion	   was	   562	   (TNC)	   and	   164	   (CD34+).	   The	   median	   time	   to	   neutrophil	  
engraftment	  was	  reduced	  with	  10	  days	  from	  26	  days	  to	  16	  days,	  platelet	  engraftment	  was	  
not	  mentioned	  in	  the	  publication.	  Another	  molecule	  that	  interacts	  with	  the	  same	  signaling	  
pathway	   (the	   Aryl	   hydrocarbon	   receptor	   (AHR)	   pathway),	   has	   shown	   to	   be	   even	  more	  
potent	  in	  expanding	  CB.	  Ex	  vivo	  culture	  with	  Stemregenin	  1	  (SR-­‐1),	  an	  AHR	  inhibitor,	  led	  
to	   a	   328	   fold	   expansion	   CD34+	   cells,	   and	   dCBT	   recipients	   that	   received	   a	   unit	   that	  was	  
expanded	   with	   SR1	   had	   significantly	   reduced	   times	   to	   both	   neutrophil	   and	   platelet	  
engraftment.	  75	  	  
Finally,	  culture	  with	  nicotinamide,	  a	  SIRT1	  inhibitor	  has	  been	  equally	  potent	   in	  reducing	  
the	   time	   to	   neutrophil	   engraftment.	   76	   In	   the	   phase	   1	   trial	   neutrophil	   engraftment	   was	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reduced	  from	  25	  days	  to	  13	  days.	  Platelet	  engraftment	  was	  again	  only	  marginally	  reduced	  
from	  37	  to	  33	  days.	  	  
	  
CB	  expansion	  with	  TPO	  to	  improve	  platelet	  engraftment	  
Stem	  cell	  expansion	  has	  also	  been	  done	  with	  TPO	  as	  a	  single	  growth	  factor.	  Although	  the	  
fold	  expansion	  of	  the	  total	  nucleated	  cells	  and	  CD34+	  cells	   is	  considerably	   lower	  as	  seen	  
with	  the	  expansion	  of	  cells	  with	  a	  cocktail	  of	  cytokines,	  77	  this	  single	  cytokine	  strategy	  has	  
several	  advantages.	  TPO	  as	  a	  single	  growth	  factor	  might	  prevent	  the	  differentiation	  of	  HSC,	  
78	   thereby	   preserving	   the	   long	   term	   repopulating	   capacity	   of	   the	   graft.	   In	   addition,	   the	  
largest	  part	  of	  the	  differentiated	  cells	  in	  culture	  	  is	  committed	  to	  a	  megakaryocyte	  lineage,	  
79,80	   	   i.e.	   platelet	  precursors.	  These	  precursors	   can	  provide	  accelerated	  platelet	   recovery	  
after	   transplantation	   of	   such	   transplants	   and	   is	   therefore	   of	   special	   importance	   since	  
delayed	  and	  insufficient	  platelet	  recovery	  is	  one	  of	  the	  main	  persisting	  problems	  in	  CBT.	  
Even	   after	   dCBT	   platelet	   recovery	   is	   still	   delayed	   compared	   to	   PBSC	   transplantation,	  
median	  platelet	  recovery	  (>50,000	  plt/µl	  PB)	  takes	  approximately	  2-­‐4	  weeks	   longer	  and	  
only	  50-­‐75%	  of	  the	  patients	  have	  a	  normal	  platelet	  count	  in	  the	  peripheral	  blood	  6	  months	  
to	  1	  year	  after	  transplantation.	  46,81,82	  	  
A	  low	  platelet	  count	  increases	  the	  risk	  of	  hemorrhage	  and	  mortality	  and	  adequate	  levels	  of	  
platelets	   are	   therefore	   important	   for	   the	   survival	   of	   the	   patient.	   83	   Approximately	   ten	  
percent	   of	   dCBT	   recipients	   die	   of	   hemorrhage,	   compared	   to	   almost	   absent	   cases	   of	  
hemorrhage	  related	  death	  in	  patients	  transplanted	  with	  BM	  or	  PBSC	  grafts.	  46	  The	  platelet	  
count	  in	  the	  peripheral	  blood	  of	  the	  patient	  100	  days	  after	  transplantation	  is	  an	  important	  
prognostic	  factor	  for	  4-­‐year	  survival.	  84	  However,	  low	  100	  day	  platelet	  counts	  are	  mostly	  
associated	  with	  GvHD,	  infections	  or	  veno-­‐occlusive	  disease	  and	  the	  etiology	  of	  the	  causal	  
association	  of	  a	  low	  platelet	  count	  and	  mortality	  is	  difficult	  to	  determine.	  	  Finally,	  delayed	  
platelet	  recovery	  and	  the	  required	  platelet	  transfusions	  contribute	  to	  the	  already	  high	  cost	  
of	  CBT.	  Our	  group	  has	  previously	  shown	  that	  expansion	  of	  CB	  CD34+	  cells	  using	  TPO	  as	  a	  
single	  cytokine	   that	   can	   improve	  platelet	  engraftment	  after	  CB	  HST	   in	   immune	  deficient	  
mice	   models.	   The	   (pre)megakaryocytes	   in	   the	   TPO	   expanded	   	   transplants	   not	   only	  
induced	   faster	  platelet	   recovery	  compared	   to	  mice	   that	   received	  un-­‐manipulated	  CD34+	  
cells	   and	   culture	   of	   BM	   cells	   from	   these	   mice	   harvested	   7	   days	   after	   transplantation	  
generated	  higher	  numbers	  of	  megakaryocyte	  colonies,	  85	  but	  importantly,	  BM	  engraftment	  
and	   lineage	   differentiation	   of	   the	   human	   cells	   was	   also	   similar	   between	   both	   groups.	  	  
Improvement	   in	   platelet	   recovery	   therefore	  was	   not	   at	   the	   expense	   of	   BM	   engraftment.	  
After	  TPO	  expansion,	  the	  cultured	  cells	  can	  be	  divided	  into	  3	  major	  populations,	  residual	  
CD34+	   cells,	   lineage	   negative	   cells	   (Lin-­‐)	   and	   cells	   expressing	   megakaryocyte/platelet	  
markers	  CD61+	  or	  CD41+.	   86	  Remarkably,	  while	   as	   expected,	   the	   remaining	  CD34+	  cells	  
were	  responsible	   for	  stable	  BM	  engraftment	  and	  hematopoietic	  recovery,	  not	   the	  CD62+	  
cells	  but	  the	  Lin-­‐	  cells	  were	  responsible	  for	  the	  early	  platelet	  recovery.	  This	  suggests	  that,	  
repopulation	   effectivity	   always	   need	   to	   be	   confirmed	   by	   in	   vivo	   transplantation	  
experiments	  and	  cannot	  directly	  be	  related	  to	  the	  lineage	  markers	  that	  are	  found.	  	  
	  
Method	   2:	   Co-­‐transplantation	   of	   CB	   cells	   with	   accessory	   cells	   to	   improve	   the	  
engraftment	  of	  CB	  cells	  
Co-­‐transplantation	  of	  so	  called	  accessory	  cells	  is	  long	  known	  to	  improve	  engraftment	  and	  
repopulation	  of	  HSC.	  Such	  accessory	  cells	   can	  be	  mesodermal	  stem	  cells	   such	  as	  MSC,	   87	  
third	  party	  HSC,	  but	  also	  differentiated	  hematopoietic	  cells	  such	  as	  (apoptotic	  irradiated)	  
leukocytes,	   even	   when	   they	   are	   from	   xenogenic	   origin.	   88	   The	   mechanism	   behind	   the	  
improvement	  of	  engraftment	  is	  not	  fully	  known,	  but	  will	  be	  dependent	  on	  the	  type	  of	  cell	  
that	   is	   used.	   The	   cells	   e.g.	   might	   assist	   is	   the	   repair	   of	   the	   bone	   marrow	   after	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myeloablative	   conditioning,	   assist	   in	  homing	  and	  engraftment	  of	   the	  CB	  HSC	  or	  have	  an	  
immunological	  effect.	  	  Several	  co-­‐transplantation	  strategies	  can	  be	  discerned.	  	  
	  
Co-­‐transplantation	  of	  CB	  and	  third	  party	  HSC	  or	  regulatory	  T	  cells	  
As	   mentioned	   above,	   in	   double	   cord	   blood	   transplantation,	   the	   non-­‐persisting	   /	   non-­‐
dominant	  unit	   is	   thought	   to	  give	  a	  boosting	  effect	  on	   the	  engrafting	  dominant	  unit.	  This	  
can	   also	   be	   achieved	   by	   co-­‐infusion	   of	   HSC	   from	   a	   third	   party	   e.g.	   haploidentical	   adult	  
donor.	  To	  avoid	  graft	  versus	  host	  disease,	  only	  immuno-­‐adsorption-­‐isolated	  HSC,	  or	  T	  cell	  
depleted	  PBSC	  grafts	   are	   co-­‐infused	  with	   the	  CB	   cells	   89.	  Although	   this	   third	  party	  HSCs	  
will	   disappear	   with	   the	   developing	   T-­‐cell	   immunity	   of	   the	   immunocompetent	   CB	  
transplant,	   the	   increased	  number	  of	   infused	  HSC	  seems	  to	  be	  able	   to	   temporarily	  bridge	  
the	  slow	  repopulation	  of	  the	  CB.	  	  	  
Regulatory	  T	  cells	  (T-­‐regs)	  are	  a	  subset	  of	  T	  cells	  that	  play	  a	  role	  in	  the	  tolerance	  to	  self-­‐
antigens	   and	   the	   suppression	   of	   disproportionate	   immune	   responses.	   90	   These	   cells	   are	  
capable	   of	   preventing	   and/or	   suppressing	   GvHD	   in	   patients	   that	   are	   transplanted	   with	  
mismatched	  HSC,	  91	  but	  they	  do	  not	  seem	  to	  enhance	  engraftment.	  	  
	  
Co-­‐transplantation	  of	  mesenchymal	  stromal	  cells	  
MSC	  are	  multipotent	   cells	  originally	   identified	   in	   the	  bone	  marrow	  as	   cells	   that	   support	  
HSC	  maintenance	  and	  hematopoiesis.	   92,93	  MSC	  are	  able	  to	  differentiate	   into	  mesodermal	  
cells	   including	   adipocytes,	   chondrocytes	   and	   osteoblasts	   94	   and	   have	   unique	  
immunomodulatory	   properties.	   95	   Both	   these	   potentially	   marrow	   regenerative	   and	  
immune	  modulatory	  properties	  have	  been	  employed	   to	   improve	  HST,	   96-­‐103	  although	   the	  
primary	  reason	  for	  co-­‐infusion	  is	  most	  often	  the	  prevention	  or	  treatment	  of	  GvHD.	  	  
In	  animal	  models	  co-­‐transplantation	  of	  MSC	  has	  been	  shown	  to	  improve	  the	  engraftment	  
of	  HSC	  87,104-­‐108.	  However,	  the	  underlying	  mechanisms	  for	  this	  enhancement	  are	  unknown	  
and	  it	  is	  not	  clear	  whether	  the	  co-­‐transplanted	  MSC	  home	  to	  the	  bone	  marrow.	  Both	  local	  
support	   of	   engraftment	   by	   e.g.	   replacing	   the	   damaged	   stromal	   cells,	   releasing	   pro-­‐
angiogenic	  factors	  109	  or	  releasing	  growth	  factors	  110	  as	  well	  as	  more	  systemic	  mechanisms	  
such	  as	   immunomodulation	   95	  have	  been	  suggested.	  Homing	  studies	  of	  MSC	   to	   the	  bone	  
marrow,	  needed	  for	  more	  localized	  effects,	  have	  shown	  variable	  results.	  Two	  studies	  did	  
not	  find	  MSC	  in	  the	  BM	  of	  the	  mice	  after	  transplantation.	  87,107	  MSC	  were	  found	  in	  the	  lung,	  
suggesting	   sequestration	   of	   the	   MSC	   by	   a	   lung	   barrier.	   However,	   after	   intra-­‐cardiac	  
injection,	  thereby	  bypassing	  the	  pulmonary	  circulation,	  MSC	  could	  not	  be	  demonstrated	  in	  
the	  BM	  either.	  This	  general	  entrapment	  of	  MSC	  in	  the	  lungs	  is	  corroborated	  by	  a	  study	  by	  
Schrepfer	  et	  al,	   that	  used	  in	  vivo	  imaging	  and	  found	  	  most	  MSC	  in	  the	  lungs	  five	  minutes	  
after	  transplantation	  111	  but	  another	  study	  did	  find	  MSC	  co-­‐localized	  with	  CB	  CD34+	  cells	  
in	  the	  pelvis	  of	  the	  mice	  after	  intravenous	  transplantation.	  105	  Strong	  evidence	  for	  a	  local	  
or	   direct	   effect	   of	   the	  MSC	  on	   engraftment,	   however,	   is	   lacking.	  As	  mentioned	   above,	   in	  
double	   cord	   blood	   transplantation,	   single	   unit	   dominance	   is	   most	   likely	   caused	   by	   a	  
systemic	   immunological	   effect.	   In	   a	   murine	   double	   CB	   transplantation	   study	   co-­‐
transplantation	   of	   MSC	   led	   alleviation	   of	   single	   unit	   dominance,	   105	   showing	   that	   the	  
engraftment	  of	  the	  non-­‐dominant	  unit	  can	  be	  enhanced	  by	  the	  co-­‐transplantation	  of	  MSC.	  
Another	   study	   in	  which	   CB	  MNC	   cells	  were	   transplanted,	   has	   shown	   that	   both	  MSC	   co-­‐
transplantation	  and	  lineage	  depletion	  of	  the	  MNC	  alleviated	  single	  donor	  dominance	  and	  
improved	  overall	  engraftment.	  107	  	  
Clinical	   studies	   in	   which	   MSC	   were	   co-­‐transplanted	   to	   enhance	   engraftment	   are	   so	   far	  
hard	   to	   interpret	   since	   these	   studies	   were	   either	   safety	   or	   feasibility	   studies,	   112,113	   or	  
studies	  that	  compared	  neutrophil	  and	  platelet	  recovery	  with	  historical	  controls.	  114,115	  The	  
study	  of	  Ball	  et	  al.	  did	  however	  show	  an	  improvement	  in	  leukocyte	  recovery	  and	  less	  graft	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failure.	   114	  Recent	  pilot	  studies	   in	  which	  MSC	  were	  co-­‐transplanted	  with	  cord	  blood	  HSC	  
showed	   an	   improvement	   in	   platelet	   engraftment	  when	   compared	   to	   controls	   that	  were	  
transplanted	   with	   CB	   HSC	   alone.	   116,117	   Wu	   et	   al.	   found	   a	   median	   time	   to	   platelet	  
engraftment	  of	  32	  days	  (69	  days	  in	  the	  control	  group)	  and	  Lee	  et	  al.	  a	  median	  time	  of	  47	  
days	  (57	  days	   in	   the	  control	  group).,	  However,	   the	  median	  time	  to	  MSC	   induced	  platelet	  
engraftment	  was	  still	  delayed	  compared	  to	  the	  median	  engraftment	  time	  of	  a	  (PBSC)	  graft	  
from	  a	  matched	  unrelated	  donor.	  In	  a	  comparison	  study	  by	  Chen	  et	  al.	  in	  which	  recipients	  
of	  a	  matched	  unrelated	  donor	  graft	   (MUD)	  were	  compared	  with	  recipients	  of	  double	  CB	  
(dCB)	  transplantations,	  the	  median	  time	  to	  platelet	  engraftment	  was	  19	  days	  for	  the	  MUD	  
recipient	  versus	  42	  days	  for	  the	  dCB	  recipients.	  118	  	  	  
	  
The	  use	  of	  CB	  for	  non-­‐hematopoietic	  purposes	  
Publically	  stored	  CB	  is	  exclusively	  banked	  for	  the	  purpose	  of	  allogeneic	  HST,	  but	  CB	  also	  
contains	   cell	   populations	   with	   non-­‐hematopoietic	   regenerative	   potential.	   Private	   CB	  
banking	  initially	  also	  aimed	  for	  using	  the	  CB	  to	  treat	  (future)	  hematological	  malignancies	  
of	   the	  child	   itself	  or	  a	   family	  member,	  but	   the	  chance	  of	  using	  the	  CB	  for	   this	  purpose	   is	  
small;	   approximately	   only	   1	   in	   2700	   individuals	   would	   benefit	   from	   these	   privately	  
banked	  units.	  119	  The	  prospect	  of	  an	  alternative	  use	  of	  these	  non-­‐	  hematopoietic	  cells	  for	  
later	  in	  life	  degenerative	  conditions	  is	  therefore	  used	  to	  gain	  interest	  for	  private	  banking	  
initiatives.	   CB	   banking	   for	   anonymous	   allogeneic	   use	   is	   often	   not	   cost-­‐efficient.	   An	  
arrangement	  to	  store	  hematopoietic	  stem	  cells	  for	  the	  purpose	  of	  allogeneic	  banking	  with	  
maintenance	   of	   non-­‐hematopoietic	   regenerative	   cells	   for	   private	   autologous	   use,	   could	  
lead	   to	   a	   financial	   boost	   to	   increase	   in	   public	   anonymous	   CB	   banking.	   The	   non-­‐
hematopoietic	  capacity	  of	  CB	  was	  first	  shown	  by	  Nieda	  et	  al.	   in	  1997,	  who	  cultured	  cells	  
from	   CB	   with	   endothelial	   characteristics	   such	   as	   von	  Willibrand	   factor	   and	   PECAM.	   120	  
These	  cells	  were	  cultured	  from	  the	  CD34+	  enriched	  fraction	  which	  also	  harbors	  the	  HSCs.	  
Erices	  et	  al.	  cultured	  adherent	  cells	  from	  CB	  resulting	  in	  an	  osteoclast	  or	  mesenchymal	  cell	  
like	  phenotype	   121.	  Over	   the	  next	  decade	  a	  variety	  of	   cell	   types	  have	  been	  cultured	   from	  
CB,	  including	  endothelial	  cells	  (EC)	  122,	  mesenchymal	  stromal	  cells	  (MSC),	  123	  neural	  cells,	  
124	   island	  beta	   cells	   125	   and	   cardiomyocytes.	   126	  The	   functionality	  of	   these	   cells	  has	  been	  
shown	  on	  various	  levels,	  some	  cells	  were	  only	  characterized	  	  in	  vitro	  as	  the	  proposed	  cell	  
type,	   Some	   of	   these	   CB	   derived	   cells	  were	   	   successfully	   applied	   in	   regenerative	   cellular	  
therapy	   such	   as	   vascular	   repair	   and	   wound	   healing,	   127,128	   or	   as	   therapy	   for	   immune	  
related	  diseases.	  129-­‐131	  	  
Currently	   the	   regenerative	   potential	   of	   CB	   is	   restricted	   to	   the	   private	   setting	   and	   thus	  
excludes	   the	  use	  of	   cord	  blood	   for	  allogeneic	  HSC	  purpose.	   If	   the	   cells	   that	  generate	   the	  
non-­‐hematopoietic	  tissues	  can	  be	  separated	  from	  the	  hematopoietic	  cells,	  a	  ‘dual’	  banking	  
system	   can	   be	   established	   which	   would	   compensate	   partly	   for	   the	   cost	   for	   public	  
anonymous	  banking.	  Before	  “dual”	  public-­‐private	  banking	  can	  be	  considered	  and	  sincerely	  
offered,	   several	   conditions	  must	   be	   fulfilled.	   The	   first	   and	  main	   requirement	   is	   that	   the	  
separation	   of	   precursors	   for	   repair	   purpose	   should	   leave	   the	   hematopoietic	   potential	  
uncompromised.	   Second,	   the	   regenerative	   potential	   of	   CB	   should	   have	   an	   advantage	  
compared	   to	   other	   (adult)	   sources	   of	   regenerative	   cells.	   Third,	   the	  methods	   to	   separate	  
the	  hematopoietic	  precursors	  should	  be	  cost-­‐effective	  and	  not	  increase	  the	  cost	  of	  CB	  for	  
hematopoietic	   transplantation.	   Separation	   of	   the	   two	   fractions	   could	   be	   realized	   with	  
selective	   immuno-­‐separation	   on	   the	   basis	   of	   markers	   that	   identify	   MSC,	   EPC	   or	   the	  
hematopoietic	  cells.	  132	  Endothelial	  cells	  e.g.	  can	  be	  identified	  by	  the	  expression	  of	  vascular	  
endothelial	  growth	  factor	  receptor	  2	  (VEGF-­‐R2)	  and	  VE	  Cadherin	  (CD144)	  and	  have	  been	  
identified	   in	   fresh	   cord	   blood,	   but	   the	   frequency	   of	   these	   cells	   is	   very	   low	   and	   highly	  
variable	  between	  donors.	  133,134	  MSC	  can	  be	  identified	  by	  a	  combination	  of	  distinct	  makers	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and	  properties	  set	  by	  the	  International	  Society	  for	  Cellular	  Therapy	  (ISCT).	  135	  Besides	  the	  
ability	   to	   adhere	   to	  plastic	   and	   to	  differentiate	   into	  3	  mesodermal	   linegaes,	  MSC	   should	  
express	  CD105,	  CD73	  and	  CD90,	  and	  lack	  expression	  of	  CD45,	  CD34,	  CD14,	  CD19	  and	  HLA-­‐
DR.	  Efforts	  to	  identify	  MSC	  like	  cells	  in	  CB	  based	  on	  marker	  expression	  alone	  have	  shown	  
cell	   types	   that	   express	   certain	  markers,	   but	   confirmation	   by	   culture	   experiments	   is	   still	  
needed	   to	   confidently	   state	   that	   these	   cells	   are	   indeed	  MSC.	   136	   Both	  MSC	   and	   EPC	   are	  
derived	   from	   the	   non-­‐hematopoietic	   CD45	  negative	   fraction	   of	   CB.	   134,137	   Separating	   the	  
CD45	   negative	   cells	   from	   the	   hematopoietic	   fraction	   might	   therefore	   preserve	   the	  
possibility	  to	  culture	  both	  cell	   types.	  Selection	  of	  hematopoietic	  cells	   from	  the	  CB	  on	  the	  
basis	  of	  CD45	  expression	  might	  be	  an	  alternative	  although	  not	  all	  hematopoietic	  stem	  cells	  
need	  to	  express	  CD45+.	  	  
	  
Other	  (extra-­‐)	  embryonic	  tissues	  
Other	   fetal	   tissues	   such	   as	   bone	   marrow,	   kidney,	   liver	   and	   lungs	   as	   well	   as	   extra	  
embryonic	  tissues	  such	  as	  the	  placenta,	  the	  umbilical	  cord	  itself,	  the	  amniotic	  membrane	  
and	  amniotic	   fluid	  contain	  much	  higher	  numbers	  of	  non-­‐hematopoietic	  stem	  cells.	   138-­‐140	  
However	  the	  use	  of	  embryonic	  stem	  cells	  is	  accompanied	  with	  several	  ethical	  constraints	  
and	   is	   therefore	   not	   a	   desirable	   source.	   Extra-­‐embryonic	   tissues	   on	   the	   other	   are	  more	  
interesting	  because	  of	  their	  availability	  as	  waste	  products	  and	  the	  resulting	  lack	  of	  ethical	  
constraints.	  	  
The	  advantage	  of	  combined	  collection,	  HLA	  typing,	  screening	  for	  infections	  and	  banking	  of	  
CB	   together	  with	   (a	   selection	  of)	   these	   tissues	  or	   their	   stem	  cell	   fraction,	   is	   not	  hard	   to	  
envision	   and	   could	   in	   this	   respect	   also	   reduce	   costs.	   The	  umbilical	   cord	   as	   example	  has	  
shown	  to	  be	  a	  good	  source	  for	  MSC	  since	  the	  conditions	  for	   isolations	  are	   less	  strict	  and	  
the	  number	  of	  MSC	  that	  can	  be	  grown	  from	  a	  single	  collection	  are	  much	  higher	  than	  those	  
of	  MSC	  isolated	  from	  CB	  141	  Of	  all	  extra	  embryonic	  tissues	  the	  umbilical	  cord	  seems	  to	  be	  
the	  most	  promising	  candidate	  for	  cell	  culture	  since	  the	  collection	  of	  this	  tissue	  is	  easy	  and	  
the	   isolation	   of	   stem	   cells	   from	   this	   tissue	   is	   relatively	   straightforward.	   The	   placenta	   is	  
much	  larger	  in	  volume	  and	  partly	  consists	  of	  tissue	  that	  is	  derived	  from	  the	  mother.	  The	  
collection	   of	   the	   amnion	   and	   amniotic	   fluid	   is	   difficult	   to	   collect	   during	   delivery,	  which	  
creates	  a	  burden	  for	  the	  mother.	  	  
	  
Objective	  of	  this	  thesis	  
This	   thesis	   focuses	  on	  ways	   to	   improve	  CB	  application	   from	  both	   the	  perspective	  of	   the	  
patient	   (i.e.	   better	   engraftment)	   as	   well	   as	   from	   the	   cost	   perspective	   (i.e.	   wider	  
applicability).	   To	   this	   aim,	   we	   investigated	   (combinations	   of)	   methods	   for	   the	  
improvement	  of	  CB	  engraftment	  in	  a	  murine	  engraftment	  model	  for	  human	  hematopoietic	  
cells.	  Besides	  our	  focus	  on	  the	  PB	  recovery	  of	  platelets	  and	  CD45+	  cells,	  we	  furthermore	  
looked	   at	   practical	   aspects	   of	   the	   application	   of	   CB	   such	   as	   the	   possibility	   of	   banking	  
expanded	  cells,	  banking	  CB	  for	  other	  purposes	  than	  HST	  and	  the	  use	  of	  other	  extra-­‐fetal	  
(embryonic)	  tissues	  such	  as	  the	  umbilical	  cord.	  
Chapter	  1:	  Co-­‐transplantation	  of	  MSC	  from	  the	  Wharton’s	  Jelly	  of	  the	  umbilical	  cord.	  
MSC	  that	  are	  used	  for	  therapeutic	  purposes	  are	  usually	  derived	  from	  adult	  BM,	  142	  but	  MSC	  
can	  be	  isolated	  from	  a	  variety	  of	  other	  tissues	  as	  well	  such	  as	  adipose	  tissue,	  143	  compact	  
bone,	  144	  amniotic	  fluid,	  145	  umbilical	  cord	  blood,	  121	  placenta	  146	  or	  the	  umbilical	  cord.	  147	  
The	  harvest	  of	  MSC	  from	  the	  BM	  of	  healthy	  donors	  involves	  a	  certain	  risk	  and	  discomfort	  
for	   the	   donor	   and	   is	   therefore	   ethically	   less	   desirable.	   Instead	   we	   first	   studied	   the	  
umbilical	   cord	   blood	   as	   alternative	   MSC	   source.	   However,	   the	   number	   of	   MSC	   in	   CB	   is	  
limited	   compared	   to	   BM	   148	   and	   isolation	   is	   difficult	   compared	   to	   other	   sources.	   149	  
Furthermore,	  isolation	  of	  MSC	  from	  the	  CB	  would	  not	  allow	  the	  additional	  use	  of	  the	  unit	  
12 
	  
for	   HST.	   The	   umbilical	   cord	   (UC)	   itself	   was	   subsequently	   studied.	   UCs	   consists	   of	   an	  
umbilical	  vein	  and	  arteries	  surrounded	  by	  Wharton’s	  Jelly	  (WJ),	  which	  is	  a	  rich	  source	  of	  
MSC.	  147	  The	  already	  iterated	  advantage	  of	  the	  umbilical	  cord	  (UC)	  is	  that	  after	  birth	  it	  can	  
be	  regarded	  as	  waste.	  Therefore,	  after	  the	  collection	  of	  the	  cord	  blood	  from	  the	  placenta	  
and	  the	  UC,	  the	  UC	  itself	  can	  be	  stored	  in	  a	  sterile	  container	  and	  used	  for	  the	  isolation	  of	  
MSC.	  Furthermore,	  the	  cost	  of	  the	  collection	  of	  the	  UC	  is	  low	  while	  collection	  logistics,	  HLA	  
typing	   and	   screening	   of	   infectious	   diseases	   of	   the	   donor	   can	   be	   shared	   with	   what	   is	  
needed	  for	  the	  CB.	  	  
We	  therefore	  set	  up	  a	  collection	  system	  for	  UCs	  in	  collaboration	  with	  the	  cord	  blood	  bank	  
(Sanquin	   Navelstreng	   Bloedbank,	   NBB)	   and	   modified	   an	   existing	   protocol	   for	   the	  
expansion	   of	   MSC	   that	   does	   not	   involve	   the	   use	   of	   enzymes.	   150	   As	   definite	   proof,	   we	  
analysed	  the	  capacity	  of	  the	  WJ	  derived	  MSC	  to	  enhance	  CB	  CD34+	  cell	  mediated	  recovery	  
of	  human	  platelets	   and	  CD45+	  cells	   and	  BM	  engraftment	   in	   an	   immune	  deficient	  mouse	  
model	  and	  compared	  this	  with	  the	  enhancement	  seen	  after	  the	  co-­‐transplantation	  of	  BM	  
MSC	  together	  with	  CB	  CD34+	  cells.	  	  
	  
Chapter	   2:	   Combining	   TPO	   expansion	   of	   CB	   CD34+	   cells	   with	   double	   cord	   blood	  
transplantation.	  	  
Because	   of	   concerns	   about	   the	   long	   term	   engraftment	   capacity	   of	   expanded	   cells,	  
manipulated	   CB	   grafts	   are	   usually	   transplanted	   with	   an	   unmanipulated	   graft.	   We	  
therefore	  set	  out	  to	  analyze	  the	  influence	  of	  these	  co-­‐transplantations	  with	  respect	  to	  the	  
separate	  contributions	  to	  the	  platelet	  and	  CD45+	  cell	  recovery	  in	  the	  peripheral	  blood	  of	  
the	   mouse	   and	   the	   engraftment	   in	   the	   bone	   marrow	   after	   20	   weeks	   (long	   term	  
engraftment).	   For	   this,	   we	   used	   selected	   HLA	   mismatches	   between	   recipients	   and	   CB	  
donor	  cells	  which	  allowed	  for	  the	  detection	  of	  each	  graft	  by	  HLA	  specific	  antibodies.	  We	  
specifically	  looked	  at	  the	  contribution	  of	  the	  expanded	  cells	  or	  unmanipulated	  cells	  when	  
transplanted	  together,	  and	  compared	  this	  with	  the	  PB	  recovery	  and	  engraftment	  of	  mice	  
that	  were	  transplanted	  with	  only	  unmanipulated	  CD34+	  cells	  from	  2	  different	  CB	  units.	  	  
	  
Chapter	   3:	   TPO	   expansion	   of	   CB	   CD34+	   cells:	   should	   we	   use	   existing,	   banked	   CB	  
units	  or	  expand	  fresh	  CB	  units?	  
As	  mentioned,	   our	   lab	   previously	   developed	   a	   protocol	   for	   the	   expansion	   of	   CB	   CD34+	  
cells	  with	  only	  TPO	  as	  a	  growth	   factor.	   79,80,85,86	  Building	  on	   that	  strategy,	  cryopreserved	  
CD34+	   cells	  were	   expanded	   and	   again	   transplanted	   into	   immune	   deficient	  mice.	   In	   this	  
setting	   we	   investigated	   whether	   expansion	   before	   cryopreservation	   would	   have	   an	  
advantage	  over	  the	  expansion	  of	  cryopreserved	  cells.	  We	  therefore	  compared	  the	  quality	  
of	   expanded	   cells	   that	   were	   cultured	   from	   fresh	   CB	   CD34+	   cells	   with	   cells	   that	   were	  
expanded	   from	   cryopreserved	   CD34+	   cells.	  We	   next	   analyzed	   the	   6	  weeks	   engraftment	  
capacity	  of	  the	  cells	  in	  a	  NOD	  SCID	  model	  by	  looking	  at	  the	  difference	  in	  platelet	  recovery	  
in	  the	  peripheral	  blood	  and	  the	  general	  engraftment	  of	  human	  cells	  in	  the	  bone	  marrow,.	  
	  
Chapter	  4:	  Combining	  TPO	  expansion	  of	  CB	  CD34+	  cells	  with	  the	  co-­‐transplantation	  
of	  MSC	  
As	   mentioned	   above,	   TPO	   expanded	   cells	   can	   improve	   the	   platelet	   recovery	   in	   the	  
peripheral	   blood	  while	  MSC	   co-­‐transplantation	   improves	   the	   overall	   engraftment	   of	   CB	  
cells.	  We	   therefore	  combined	  both	  approached	  and	  studied	   the	  engraftment	  potential	  of	  





Chapter	  5:	  Dual	  use	  of	  cord	  blood	  for	  both	  hematopoietic	  stem	  cell	  transplantation	  
and	  other	  cellular	  therapies	  
So	   far	  CB	   is	  mostly	  banked	   for	   the	  purpose	  of	  HST,	  but	  as	  said,	  CB	  also	  contains	  
non	   hematopoietic	   cells	   with	   an	   additional	   potential	   for	   cellular	   therapies.	   We	  
therefore	   analyzed	   the	   possibility	   to	   separate	   the	   hematopoietic	   and	   non	  
hematopoietic	  	  (stem)	  cells,	  We	  separated	  these	  non	  hematopoietic	  cells	  from	  the	  
hematopoietic	  compartment	  of	  the	  CB	  unit	  and	  studied	  their	  function	  in	  vitro	  and	  
their	   influence	  on	   the	   engraftment	   of	   CB	  CD34+	   cells	   in	   vivo.	  This	  dual	   banking	  
could	  stimulate	  in	  the	  future	  collection	  and	  storage	  in	  parallel	  with	  private	  banks,	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Co-­‐transplantation	   of	   CD34+	   hematopoietic	   stem	   and	   progenitor	   cells	   (HSPC)	   with	  
mesenchymal	   stromal	   cells	   (MSC)	   enhances	   HSPC	   engraftment.	   For	   these	   applications,	  
MSC	  are	  mostly	  obtained	  from	  bone	  marrow.	  However,	  MSC	  can	  also	  be	  isolated	  from	  the	  
Wharton's	   jelly	   (WJ)	   of	   the	   human	   umbilical	   cord.	   This	   source,	   regarded	   to	   be	   a	   ‘waste	  
product’,	   enables	   relatively	   low	   cost	  MSC	   acquisition	  without	   any	   burden	   to	   the	   donor.	  
Here,	   we	   evaluated	   the	   ability	   of	   WJ	   MSC	   to	   enhance	   HSPC	   engraftment.	   	   First,	   we	  
compared	  cultured	  human	  WJ	  MSC	  with	  human	  bone	  marrow-­‐derived	  MSC	  (BM	  MSC)	  for	  
in	   vitro	  marker	   expression,	   immunomodulatory	   capacity	   and	   differentiation	   into	   three	  
mesenchymal	   lineages.	   Although	   we	   confirmed	   that	   WJ	   MSC	   have	   a	   more	   restricted	  
differentiation	   capacity,	   both	   WJ	   MSC	   and	   BM	   MSC	   expressed	   similar	   levels	   of	   surface	  
markers	   and	   exhibited	   similar	   immune	   inhibitory	   capacities.	   Most	   importantly,	   co-­‐
transplantation	   of	   either	  WJ	  MSC	   or	   BM	  MSC	  with	   CB	   CD34+	   cells	   into	   NOD-­‐SCID	  mice	  
showed	  similar	  enhanced	  recovery	  of	  human	  platelets	  and	  CD45+	  cells	   in	   the	  peripheral	  
blood	   and	   a	   3-­‐fold	   higher	   engraftment	   in	   the	   BM,	   blood	   and	   spleen	   six	   weeks	   after	  
transplantation	   when	   compared	   to	   transplantation	   of	   CD34+	   cells	   alone.	   Upon	   co-­‐
incubation,	  both	  MSC	  sources	   increased	   the	  expression	  of	   adhesion	  molecules	  on	  CD34+	  
cells,	  although	  SDF-­‐1-­‐induced	  migration	  of	  CD34+	  cells	  remained	  unaltered.	  Interestingly,	  
there	  was	  an	  increase	  in	  CFU-­‐GEMM	  when	  CB	  CD34+	  cells	  were	  cultured	  on	  monolayers	  of	  
WJ	  MSC	  in	  the	  presence	  of	  exogenous	  thrombopoietin,	  and	  an	  increase	  in	  BFU-­‐E	  when	  BM	  
MSC	  replaced	  WJ	  MSC	   in	  such	  cultures.	  Our	  results	  suggest	   that	  WJ	  MSC	   is	   likely	   to	  be	  a	  













































































Cord	  blood	  (CB)	  is	  used	  as	  an	  alternative	  source	  for	  hematopoietic	  stem	  -­‐and	  progenitor	  
cell	  (HSPC)	  transplantation.	  1-­‐3	  However,	  the	  successful	  outcome	  of	  CB	  transplantation	  is	  
limited	  by	  the	  relatively	  low	  number	  of	  transplantable	  HSPC	  in	  these	  grafts,	  which	  results	  
in	   delayed	   hematopoietic	   recovery	   post-­‐transplant.	   4	   Double	   CB	   transplantation	   in	   this	  
respect	   increases	   the	  number	  of	   transplantable	  HSPC,	  but	   the	   time	   to	  recovery	  of	  donor	  
neutrophils	   and	   platelets	   in	   the	   peripheral	   blood	   post-­‐transplant	   is	   still	   inferior	   to	  
transplantation	  of	  bone	  marrow	  (BM)	  or	  mobilized	  peripheral	  blood	  (mPB)	  grafts.	   5	  One	  
method	   to	   overcome	   this	   CB	   associated	   disadvantage	   is	   to	   enhance	   the	   engraftment	   of	  
HSPC	  by	  co-­‐transplantation	  of	  accessory	  cells	  such	  as	  mesenchymal	  stromal	  cells	  (MSC).	  6	  
MSC	  were	  first	   identified	  in	  BM	  as	  multipotent	  cells	  and	  characterized	  largely	  by	   in	  vitro	  
attributes.	   7	   These	   included	   their	   ability	   to	   differentiate	   into	  mesodermal	   cells,	   such	   as	  
adipocytes,	  chondrocytes	  and	  osteoblasts,	  their	  adherence	  to	  plastic	  and	  their	  expression	  
of	  specific	  cell	  surface	  markers.	  8	  In	  addition,	  MSC	  have	  the	  capacity	  to	  modulate	  immune	  
responses.	   9	   Interestingly,	   in	   animal	   models,	   co-­‐transplantation	   of	   human	   CB-­‐derived	  
CD34+	  cells	  with	  human	  MSC	  was	  shown	  to	  improve	  hematopoietic	  engraftment.	  10,11	  Both	  
local	  and	  systemic	  mechanisms	  may	  play	  a	  role	  in	  this	  latter	  process,	  for	  example,	  by	  the	  
MSC	   promoting	   homing	   to	   the	   bone	   marrow	   or	   its	   vasculature	   or	   releasing	   pro-­‐
angiogenic,	  immunomodulatory	  or	  growth	  factors	  that	  promote	  engraftment.	  9,12,13	  	  
Although	  originally	  identified	  in	  cultures	  obtained	  from	  bone	  marrow	  aspirates,	  14,15	  MSC	  
can	   also	   be	   isolated	   from	   other	   sources	   such	   as	   adipose	   tissue,	   16	   compact	   bone,	   17	  
amniotic	  fluid,	  18	  cord	  blood,19	  the	  umbilical	  cord	  20,21	  or	  the	  placenta.	  22	  
MSC	   cultured	   from	   Wharton’s	   Jelly	   (WJ	   MSC)	   of	   the	   umbilical	   cord	   display	   unique	  
characteristics	  such	  as	  a	  greater	  expansion	  capacity	  and	  faster	   in	  vitro	  growth	  compared	  
to	  BM	  MSC.	  23,24	  Moreover,	  WJ	  MSC	  have	  some	  logistical	  advantages	  over	  BM	  MSC.	  Notably,	  
the	  umbilical	  cord	  	  is	  considered	  a	  waste	  product	  and	  WJ	  MSC	  can	  therefore	  be	  obtained	  
from	   this	   source	   at	   relatively	   low	   cost	   and	  without	   burden	   to	   the	   donor.	   The	  WJ	   could	  
therefore	  be	  a	  promising	  source	  for	  the	  clinical	  application	  of	  MSC.	  25,26	  
With	   this	   in	  mind,	  we	   set	   out	   to	   compare	   the	   effect	   of	   co-­‐transplantation	  of	   human	  CB-­‐
derived	  CD34+	  cells	  with	  either	  BM	  or	  WJ	  MSC	  on	  hematopoietic	  engraftment	  in	  immune	  
deficient	   NOD-­‐SCID	   mice.	   Furthermore,	   we	   assessed	   whether	   co-­‐transplantation	   of	   WJ	  
MSC	  that	  were	  autologous	  to	  the	  CB	  CD34+	  cells	  affected	  this	  engraftment	  when	  compared	  
to	  co-­‐transplantation	  with	  allogeneic	  WJ	  MSC.	  	  
	  	  	  
Materials	  and	  methods	  
	  
Umbilical	   cord	   blood	   (CB)	   and	   umbilical	   cord	   collection.	   CB	   was	   drawn	   from	   the	  
umbilical	   vein	   at	   birth	   at	   >36	  weeks	   gestation	   after	  written	   informed	   consent	   from	   the	  
mother	   at	   hospitals	   in	   the	   Netherlands	   according	   to	   Netcord–FACT	   standards	   and	  with	  
ethical	  permission	  from	  the	  medical	  ethical	  board	  of	  the	  Leiden	  University	  Medical	  Center	  
(LUMC),	   Leiden,	   The	   Netherlands.	   Blood	   was	   collected	   by	   gravity	   drainage	   into	  
Macopharma	   collection	   bags	   containing	   21	   ml	   Citrate	   Phosphate	   Dextrose	   Adenine-­‐1	  
(Macopharma,	   Utrecht,	   The	   Netherlands).	   The	   blood	   was	   stored	   at	   4°C	   and	   processed	  
within	  48	  hours	  of	  collection.	  Umbilical	  cords	  were	  collected	  concomitantly	  with	  the	  CB	  in	  
a	   sterile	   container	   containing	   PBS	   with	   1%	   (v/v)	   antibiotic/antimycotic	   mix	   (Life	  




CD34+	   cell	   purification.	  Mononuclear	   cells	  were	   isolated	   from	  CB	  using	   a	   sterile	   Ficoll	  
density	  gradient	  (1.077	  g/cm3,	  Pharmacy	  LUMC,	  Leiden,	  The	  Netherlands).	  The	  CD34+	  cell	  
fraction	  was	   isolated	   from	   the	  mononuclear	   cell	   fraction	   by	   double	   CD34+	   cell	   selection	  
using	  immunomagnetic	  beads	  (Miltenyi	  Biotec	  GmbH,	  Bergisch	  Gladbach,	  Germany).	  The	  
purity	   of	   the	   isolated	   CD34+	   cell	   fraction	   was	   verified	   by	   flow	   cytometry	   (Beckman	  
Coulter,	   Woerden,	   The	   Netherlands)	   using	   CD45-­‐FITC	   and	   CD34-­‐PE	   antibodies	   (all	  
Beckman	  Coulter,	  ISHAGE	  protocol	  27),	  and	  was	  higher	  than	  90%	  for	  all	  CD34+	  cells	  used	  
throughout	   the	   experiments.	   Cells	  were	   cryopreserved	   in	   IMDM	  with	   10%	   (v/v)	   DMSO	  
and	  4%	  (w/v)	  human	  serum	  albumin	  (Pharmacy	  LUMC)	  and	  stored	  at	  -­‐150˚C	  until	  use.	  
	  
MSC	   isolation	   and	   culture.	   Umbilical	   cord-­‐derived	   MSC:	   MSC	   were	   isolated	   with	   an	  
explant	  method	   as	   described	   in	   DeBruyn	   et	   al.	   28	   Briefly,	   the	   cords	  were	   cut	   into	   5	   cm	  
segments	  and	  then	  longitudinally	  and	  the	  vein	  and	  arteries	  tissue	  removed.	  The	  segments	  
were	  placed	  on	  10	  cm	  culture	  dishes	  (Greiner,	  Alphen	  a/d	  Rijn,	  The	  Netherlands)	  with	  the	  
inside	   of	   the	   cord,	   i.e.	   the	   Wharton	   Jelly,	   facing	   the	   bottom	   of	   the	   plate.	   MSC	   medium	  
(DMEM	  supplemented	  with	  15%	  (v/v)	  FBS	  and	  1%	  (v/v)	  Antibiotic-­‐Antimycotic	  solution,	  
all	   Life	   Technologies)	   was	   added	   to	   the	   plate	   until	   the	   segments	   were	   submerged	   in	  
medium.	  The	   culture	  plates	  were	  placed	   in	   a	   humidified	   incubator	   at	   37˚C	   and	  5%	  CO2.	  
Medium	  was	  refreshed	  every	  3	  days.	  After	  10	  days,	  the	  segments	  were	  removed	  and	  the	  
MSC	   adhering	   to	   the	   plate	   were	   grown	   to	   confluence	   and	   passaged	   into	   culture	   flasks.	  
Since	  we	  did	  not	  separate	  the	  (sub)amnion	  an	  the	  Wharton	  Jelly,	  we	  cannot	  exclude	  that	  a	  
small	   part	   of	   the	  MSC	  derived	   from	   the	   (sub)amnion.	  However	   in	   line	  with	   the	   original	  
description	  of	   this	  method	  by	   the	  De	  Bruyn	  et	   al	   28	  we	  decided	   to	  use	   the	   cells	  WJ	  MSC	  
throughout	  the	  manuscript.	  BM-­‐derived	  MSC:	  BM	  was	  collected	  from	  patients	  undergoing	  
knee	   or	   hip	   replacement	   surgery	   at	   the	   LUMC	  with	   informed	   consent	   of	   the	   donor	   and	  
with	  ethical	  permission	   from	  the	  medical	  ethical	  board	  of	   the	  Leiden	  University	  Medical	  
Center	   (LUMC).	   Mononuclear	   cells	   were	   isolated	   from	   the	   BM	   suspensions	   by	   gradient	  
centrifugation	  with	   Ficoll	   (1.077	   g/ml,	   pharmacy	   LUMC)	   and	   loaded	   into	   culture	   flasks	  
containing	  DMEM	  with	  10%	  (v/v)	  FBS	  and	  1%	  (v/v)	  Penicillin	  and	  Streptomycin	  (all	  Life	  
Technologies).	  After	  overnight	  culture	  in	  a	  humidified	  incubator	  at	  37˚C	  and	  5%	  CO2,	  non-­‐
adhering	   cells	   were	   washed	   from	   the	   flask	   with	   PBS.	   Adherent	   cells	   were	   grown	   to	  
confluence	   and	   passaged.	   After	   3	   passages,	   cells	   were	   cryopreserved	   in	   FBS	   with	   10%	  
(v/v)	   DMSO	   (pharmacy	   LUMC).	   The	   MSC	   that	   were	   used	   throughout	   this	   study	   were	  
between	  passage	  3	  and	  6.	  
	  
Flow	   cytometry.	   Flow	   cytometry	   analysis	   for	   cell	   surface	   marker	   expression	   was	  
performed	  with	  a	  Beckman	  Coulter	  FC500	  or	  a	  BD	  FACSCalibur	  running	  CXP	  or	  CellQuest	  
Pro	  software	  respectively.	  Isolated	  CD34+	  cells	  were	  analyzed	  for	  the	  expression	  of	  CD34	  
and	   CD45	   (both	   from	   Beckman	   Coulter)	   and	   MSC	   were	   analyzed	   for	   the	   expression	   of	  
CD105,	   CD90,	   CD80,	   CD73,	   CD45,	   CD34,	   CD31,	   HLA-­‐ABC	   and	   HLA-­‐DR	   (all	   from	   BD	  
Biosciences).	  	  	  	  	  	  	  
	  
Differentiation	  of	  UC	  and	  BM	  MSC	  into	  mesodermal	  lineages.	  The	  WJ	  MSC	  and	  BM	  MSC	  
were	   analyzed	   for	   their	   ability	   to	   differentiate	   into	   adipocytes,	   chondrocytes	   and	  
osteoblasts	   as	   described	   previously.	   29,30	   In	   brief,	   MSC	   were	   cultured	   in	   specific	  
adipogenic,	   chondrogenic	   and	   osteogenic	   differentiation	   media.	   After	   21	   days,	   the	  
osteogenic	  cultures	  were	  analyzed	  for	   the	  presence	  of	  osteoblasts	  by	  staining	  of	  calcium	  
deposits	   with	   Alizarin	   red	   and	   alkaline	   phosphatase	   with	   fast	   blue.	   In	   the	   adipogenic	  
cultures,	   lipid	  droplets	  were	  visualized	  with	  Oil	   red	  O	   staining	  and,	   in	   the	   chondrogenic	  
cultures,	  cells	  were	  stained	  with	  Toluidine	  blue.	  We	  used	  an	  arbitrary	  scoring	  system	  that	  
29	  
	  
assesses	   the	  degree	  of	  differentiation	   in	   the	  cultures.	  Cultures	  showing	  no	  differentiated	  
cells	  were	  scored	  as	  0,	  a	  few	  differentiated	  cells	  as	  1,	  moderate	  differentiation	  as	  2	  and	  full	  
differentiation	  as	  3	  (Figure	  1).	  
	  
Gene	  expression	  of	  adipogenic	  and	  osteogenic	  differentiation	  cultures.	  BM	  MSC	  and	  
WJ	  MSC	  were	   cultured	   for	  2	  weeks	   in	   specific	   adipogenic	   and	  osteogenic	  differentiation	  
media	  or	  normal	  MSC	  medium	  (control);	  The	  cells	  of	  the	  cultures	  were	  lysed	  and	  RNA	  was	  
isolated	   using	   the	  DirectZol	   RNA	  miniprep	   kit	   (Zymo	  Research,	   Irvine,	   USA).	   cDNA	  was	  
subsequently	  prepared	  using	  the	  High	  Capacity	  RNA	  to	  cDNA	  kit	  (Life	  Technologies,	  Grand	  
Island,	  USA).	  Expression	  of	  osteogenic	  and	  adipogenic	  genes	  was	  analyzed	  using	  TaqMan	  
Gene	   Expression	   assays	   (see	   below)	   and	   the	   ViiA	   7	   Real-­‐Time	   PCR	   System	   (Life	  
Technologies).	   Relative	   expression	   of	   the	   genes	   was	   calculated	   with	   the	   ΔΔCt	   method	  
normalized	   to	   RPL13a.Osteogenic	   genes:	   Runt-­‐related	   transcription	   factor	   2	   (RUNX2),	  
Osterix,	   (OSX),	   Osteocalcin	   (OC),	   Bone	   Morphogenetic	   Protein	   2	   (BMP2).	   Adipogenic	  
genes:	   Peroxisome	   Proliferator-­‐Activated	   Receptor-­‐gamma	   (PPARg),	   Fatty	   Acid	   Binding	  





























Figure 1: Scoring system of the level of differentiation of WJ MSC or BM MSC into 3 mesodermal 
lineages. The amount of staining was assessed for the all different donors after differentiation 
cultures and compared to reference stains to determine the level of staining. 0=no differentiated 









Immune	  inhibition	  of	  adult	  PBMC	  and	  CB	  MNC	  by	  WJ	  MSC	  and	  BM	  MSC.	  To	  analyze	  the	  
effect	   of	   MSC	   on	   the	   proliferation	   of	   mononuclear	   cells	   obtained	   from	   adult	   peripheral	  
blood	  (PBMC),	  1x105	  PBMC	  were	  cultured	   for	  5	  days	   in	  24	  well	  plates	  with	  αCD3αCD28	  
beads	  (Life	  Technologies)	  alone	  or	  in	  combination	  with	  different	  concentrations	  of	  BM	  -­‐or	  
WJ-­‐derived	  MSC	  in	  a	  fully	  humidified	  incubator	  at	  37°C	  and	  5%	  CO2.	  Cell	  proliferation	  was	  
measured	  by	  3H-­‐thymidine	  incorporation.	  	  
	  
Co-­‐culture	  of	  MSC	  and	  CB	  CD34+	  cells	  with	  TPO.	  MSC	  obtained	  from	  BM	  and	  WJ	  were	  
thawed	  and	  plated	  into	  a	  24	  well	  plate	  at	  1.25x105	  cells/well	  and	  grown	  overnight	  in	  MSC	  
medium	  (DMEM	  with	  10%	  (v/v)	  FCS).	  After	  24h,	  the	  MSC	  were	  irradiated	  (10	  Gy)	  and	  the	  
cells	   were	   washed	   twice	   with	   PBS.	   CB	   CD34+	   cells	   were	   added	   to	   the	   wells	   at	   105	  
cells/well	  and	  cultured	  in	  expansion	  medium	  with	  Nplate	  (50ng/ml,	  TPO	  analog,	  Amgen,	  
Breda,	   the	   Netherlands)	   as	   described	   previously.	   31	   After	   10	   days	   of	   culture,	   the	  
hematopoietic	  cells	  were	  harvested	  by	  collecting	  all	  non	  adherent	  cells	  by	  aspirating	  the	  
supernatant,	   washing	   the	   plates	   with	   PBS	   and	   spinning	   down	   the	   collected	   cell	  
suspension.	  The	  cells	  were	  counted	  and	  analyzed	  for	  the	  expression	  of	  CD34-­‐PE,	  CD61-­‐PE-­‐
Cy7	  and	  CD45-­‐FITC	  (all	  Beckman	  Coulter)	  by	  flow	  cytometry.	  The	  hematopoietic	  stem	  and	  
progenitor	  cells	  (HSPC)	  that	  were	  cultured	  were	  subsequently	  analyzed	  for	  their	  capacity	  
to	  generate	  myeloid	  colonies	  in	  Methocult	  (Stemcell	  Technologies,	  Vancouver,	  Canada)	  as	  
described	  previously.	  32	  
	  
Transwell	   migration	   experiments.	   Four	   different	   cell	   suspensions	   were	   prepared.	  
These	   were	   identical	   to	   the	   in	   vivo	   experiment	   described	   below.	   After	   30	   minutes	   of	  
incubation	  of	  CB	  CD34+	  cells	  with	  MSC,	  part	  of	   the	  cell	   suspension	  was	  analyzed	   for	   the	  
expression	   of	   CD34,	   CD11a,	   CD11b,	   CD184,	   CD49e	   and	   CD49d	   (antibodies	   all	   from	  
Beckman	   Coulter)	   using	   flow	   cytometry.	   The	   remaining	   cells	   were	   used	   for	   migration	  
experiments	   in	   transwell	   plates	   (Costar,	   (VWR)	   Amsterdam,	   The	   Netherlands),	   6.5	  mm	  
diameter	  with	  5	  μm	  pore	   filters.	  The	   lower	  compartment	  of	   the	  well	  and	   the	   filter	  were	  
coated	  with	  2	  ng/ml	  fibronectin	  (Sigma,	  St	  Louis,	  USA)	  for	  15	  minutes	  at	  37°C.	  The	  lower	  
compartments	  of	  the	  plates	  were	  loaded	  with	  IMDM	  and	  100ng/ml	  SDF-­‐1α	  (R&D	  Systems,	  
Abingdon,	  UK).	  All	  cells	  were	  placed	  in	  the	  upper	  compartment	  of	  the	  plate	  and	  incubated	  
for	  5	  hours	  at	  37ºC	  and	  5%	  CO2	  in	  a	  humidified	  incubator.	  After	  incubation,	  the	  numbers	  
of	   CD34+	   cells	   that	   were	   harvested	   from	   the	   lower	   compartment	   were	   counted	   to	  
determine	  the	  proportion	  of	  cells	  that	  migrated.	  
	  
Transplantation	   in	   NOD-­‐SCID	   mice.	   Female	   5-­‐6-­‐week	   old	   NOD-­‐SCID	   mice	   (Charles	  
River,	   l’Arbresle,	   France)	  were	  kept	   in	  micro-­‐isolator	   cages	   in	   laminar	   flow	   racks	   in	   the	  
LUMC	   animal	   facilities.	   The	   animal	   ethical	   committee	   of	   the	   LUMC	   approved	   all	   animal	  
experiments.	   NOD	   SCID	   mice	   received	   3.5	   Gy	   total	   body	   irradiation	   24	   hours	   before	  
transplantation.	   Mice	  were	   transplanted	  with	   1x105	   CB-­‐derived	   CD34+	   cells	   alone	   or	   in	  
combination	  with	  1x106	  MSC	  through	  tail	  vein	   injections.	  Peripheral	  blood	  was	  collected	  
from	   the	   tail	   vein	   at	   weekly	   intervals	   starting	   3	   weeks	   after	   transplantation.	   Blood	  
collection	   and	   human	   platelet	   measurements	   were	   performed	   as	   described	   previously	  
[32].	  Briefly,	  human	  platelets	  were	  stained	  with	  a	  non-­‐cross	   reactive	  mouse-­‐anti-­‐human	  
CD41-­‐PE	   and	  mouse	   anti	   human	   CD45-­‐PC7	   (both	   Beckman	   Coulter).	   Erythrocytes	  were	  
lysed	  with	   IOTest3	   lysing	   solution	   (Beckman	  Coulter)	   for	  10	  min.	   at	   room	   temperature.	  
Flow-­‐Count™	  fluorospheres	  (Beckman	  Coulter)	  were	  added	  to	  the	  cells	  to	  enable	  analysis	  
of	   the	   absolute	   number	   of	   circulating	   human	  platelets.	   Analysis	  was	   performed	   by	   flow	  
cytometry	  (FC500,	  Beckman	  Coulter)	  using	  CXP	  software.	  Six	  weeks	  after	  transplantation,	  
mice	  were	  sacrificed	  and	  bone	  marrow	  cells	  were	  obtained	  by	  flushing	  femurs	  with	  IMDM.	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Next,	   human	   cell	   engraftment	   and	   multilineage	   chimerism	   were	   analyzed	   by	   flow	  
cytometry	  using	  goat-­‐anti-­‐mouse-­‐CD45-­‐PE	  (LCA,	  Ly-­‐5,	  30-­‐F11,	  Pharmingen,	  Erebodegem,	  
Belgium),	   mouse-­‐anti-­‐human	   CD45-­‐FITC,	   CD33-­‐FITC,	   CD34-­‐PE,	   CD19-­‐PE	   (all	   from	  
Beckman	  Coulter)	  and	  the	  appropriate	  isotype	  controls.	  Erythrocytes	  were	  lysed	  with	  IO	  
Test3	   Lysing	   solution	   (Beckman	   Coulter).	   Analysis	   was	   performed	   by	   flow	   cytometry	  
(FC500,	  Beckman	  Coulter)	  using	  CXP	  software.	  	  
	  
Statistics.	   All	   statistics	   were	   done	   using	   IBM	   SPSS	   Statistics	   (version	   20,	  
www.ibm.com/SPSS_Statistics).	   Results	   are	   presented	   as	   mean	   ±	   S.E.M.	   To	   test	   for	  
statistical	   significance,	   a	  Mann-­‐Whitney	   test	  or	  one	  way	  ANOVA	  was	  used.	  Results	  were	  





WJ-­‐derived	   MSC	   have	   similar	   marker	   expression	   but	   limited	   differentiation	  
potential	  compared	  to	  BM-­‐derived	  MSC	  
Following	   isolation	   and	   subsequent	   expansion,	   the	   phenotype	   of	   the	   WJ	   MSC	   was	  
determined	  and	  compared	  to	  BM	  MSC	  (Figure	  2A).	  Similar	  to	  BM	  MSC,	  WJ	  MSC	  expressed	  
HLA-­‐ABC,	  CD73,	  CD90	  and	  CD105	  and	  lacked	  expression	  of	  the	  pan	  hematopoietic	  marker	  
CD45	   and	   the	   endothelial/hematopoietic	   marker	   CD31.	   A	   small	   population	   of	   BM	  MSC	  
expressed	  HLA-­‐DR	  (BM	  MSC	  6.2±4.2%	  vs	  WJ	  MSC	  0.2±0.1%);	  while	  a	  small	  subset	  of	  WJ	  
MSC	  expressed	  CD34	  (WJ	  MSC	  3.8±0.3%	  vs.	  BM	  MSC	  0.6±0.4%).	  	  
We	   next	   analyzed	   the	   ability	   of	   BM	   MSC	   and	   WJ	   MSC	   to	   differentiate	   into	   adipocytes,	  
chondrocytes	  and	  osteoblasts.	  The	  majority	  of	  BM-­‐derived	  MSC	  isolates	  had	  the	  capacity	  
to	   differentiate	   into	   chondrocytes	   and	   adipocytes	   and	   half	   of	   the	   BM	   MSC	   isolates	  
differentiated	  into	  osteoblasts.	  In	  contrast,	  more	  than	  25%	  of	  the	  WJ	  MSC	  isolates	  (4	  out	  of	  
18)	  showed	  adipocytes	  generation	  and	  less	  than	  15	  %	  of	  the	  WJ	  MSC	  isolates	  (	  2	  out	  of	  18)	  
showed	  osteoblast	  differentiation	  (Figure	  2B	  and	  C).	  Moreover,	  in	  these	  respective	  4	  and	  2	  
cultures	   adipocyte	   and	   osteoblast	   differentiation	  was	   sporadic	   (grade	   1).	   Chondrogenic	  
differentiation	  occurred	   in	  half	   of	   the	  WJ	   isolates	   (9	  out	  of	  18).	  Thus,	   although	  BM	  MSC	  
and	  WJ	  MSC	  are	  phenotypically	  similar,	  WJ	  MSC	  are	  limited	  with	  respect	  to	  their	  capacity	  
to	   differentiate	   into	   mature	   mesodermal	   cell	   types	   as	   shown	   by	   their	   lower	   degree	   of	  
differentiation	  compared	  to	  BM	  MSC.	  	  
For	   one	   MSC	   donor	   of	   each	   type	   of	   MSC,	   these	   functional	   differences	   were	   also	  
investigated	   by	   the	   comparison	   of	   differentiation	   specific	   gene	   expression.	   As	   shown	  
before,	  no	  osteoblast	  or	  adipocyte	  specific	  staining	  was	  observed	   in	   the	  WJ	  MSC	  culture,	  
whereas	   positive	   staining	   for	   both	   cell	   types	   could	   be	   found	   in	   the	   BM	   MSC	   cultures	  
(Figure	   3A).	   The	   expression	   of	   the	   adipocyte	   related	   genes	   peroxisome	   proliferator-­‐
activated	   receptor-­‐γ	   (PPARG),	   fatty	  acid	  binding	  protein	  4	   (FABP4)	  and	  perilipin	   (PLIN)	  
was	  clearly	  upregulated	  in	  the	  BM	  MSC	  cultures,	  while	  WJ	  MSC	  only	  showed	  upregulation	  
of	  PPARG	  (Figure	  3B).	  For	  osteoblast	  related	  genes	  this	  method	  showed	  to	  be	  unreliable	  
since	   osteogenic	   differentiated	   BM	   MSC	   did	   not	   show	   any	   increase	   in	   osteogenic	   gene	  







Figure 2: Characterization of the Wharton’s Jelly MSC. A: Expression of cell surface markers by 
WJ MSC and BM MSC. The percentage of cells (±SEM; n=10) that express the respective markers is 
shown. B: Ability of WJ MSC (n=18 different isolates) and BM MSC (n=23 different isolates) to 
differentiate into adipocytes (Oil Red O), osteoblasts (alkaline phosphatase and calcium deposition) 
and chondrocytes (toluidine blue staining). 0=no differentiated cells, 1= <20% differentiated cells d, 2= 
<60% differentiated cells, 3= >60% differentiated cells (see also Figure S1). The bar represents the 
mean of all experiments C: Representative images of differentiation cultures after incubation with cell 
























































Figure 3: differentiation cultures of BM and WJ MSC, A: Staining of 
the differentiation cultures for cell specific markers/deposits of osteoblasts 
(alizarin red and alkaline phosphatase) and adipocytes (oil red O), B: 
Relative expression of adipogenic genes by BM MSC and WJ MSC after 
adipogenic differentiation cultures. Shown is the difference in up or down 
regulation of the genes by MSC in differentiation cultures compared to 
cultures in normal MSC medium (2^ΔΔCt, normalized to RPL13a)., C: 
Relative expression of osteogenic genes by BM MSC and WJ MSC after 
osteogenic differentiation cultures. Shown is the difference in up or down 
regulation of the genes by MSC in differentiation cultures compared to 









WJ	   MSC	   and	   BM	   MSC	   inhibit	   T	   cell	   proliferation	   of	   PBMC	   stimulated	   with	  
αCD3αCD28	  beads	  	  
Next,	  we	  compared	  in	  vitro	  immunomodulatory	  properties	  of	  WJ	  MSC	  and	  BM	  MSC	  in	  co-­‐
cultures	  with	  un-­‐stimulated	  and	  αCD3αCD28-­‐stimulated	  PBMC.	  In	  this	  setting,	  MSC	  were	  
not	   immunogenic	  themselves,	  since	  co-­‐incubation	  with	  MSC	  did	  not	   lead	  to	  proliferation	  
of	   unstimulated	   PBMC.	   Moreover,	   WJ	   MSC	   and	   BM	   MSC	   inhibited	   proliferation	   of	  
stimulated	  PBMC	  and	  this	  reduction	  was	  MSC	  dose	  dependent	  (Figure	  4,	  p<0.0001	  for	  all	  
ratios	  of	  MSC	  and	  PBMC	  compared	  to	  stimulated	  PBMC	  alone).	  Interestingly,	  co-­‐culture	  of	  
BM	  MSC	  and	  PBMC	  at	  a	  1:1	  ratio	  resulted	  in	  decreased	  inhibition	  of	  proliferation	  (43±6%)	  
as	  compared	  to	  a	  1:2	  ratio	  of	  BM	  MSC	  (70±4%,	  p<0.001).	  Additionally,	  at	  this	  1:1	  ratio,	  WJ	  
MSC	   were	   more	   inhibitory	   than	   BM-­‐MSC	   (Figure	   4;	   68±4%	   vs.	   43±6%	   inhibition	  

































Figure 4: WJ and BM MSC inhibit T cell proliferation. BM or WJ MSC were 
mixed with 1x105 PBMC at different ratios and stimulated with αCD3αCD28 beads 
for 5 days. Proliferation of the PBMC was measured by (3H) thymidine incorporation 
on day 5 and compared to a control without MSC. MSC obtained from both sources 
significantly inhibited the proliferation of the PBMC in a dose dependent manner 
(n=8, *p<0.0001 for all ratios; at a 1:1 ratio of MSC:PBMC comparing WJ MSC with 





Co-­‐transplantation	   of	  MSC	   enhances	   the	   engraftment	   of	   CB-­‐derived	   CD34+	   cells	   in	  
NOD	  SCID	  mice	  irrespective	  of	  the	  donor	  source	  
To	  evaluate	  and	  compare	  the	  effects	  of	  the	  different	  MSC	  on	  HSC	  engraftment	   in	  vivo,	  we	  
co-­‐transplanted	  human	  CB-­‐derived	  CD34+	  cells	  and	  human	  MSC	  into	  sublethally	  irradiated	  
NOD	  SCID	  mice	   (n=3	   experiments	  with	   3	   different	   donors).	   Additionally,	   autologous	  WJ	  
MSC	  (i.e.	  MSC	  generated	  from	  the	  umbilical	  cord	  of	  the	  CD34+	  cell	  donor),	  and	  allogeneic	  
WJ	  MSC	  (MSC	  generated	  from	  the	  umbilical	  cord	  of	  another	  donor)	  were	  compared	  with	  
co-­‐transplantation	  of	  allogeneic	  BM	  derived	  MSC	  and	  transplantation	  of	  CD34+	  cells	  alone.	  
Starting	  from	  3	  weeks	  after	  transplantation	  until	   the	  mice	  were	  sacrificed	  at	  week	  6,	  we	  
analyzed	  the	  peripheral	  blood	  (PB)	  of	  the	  mice	  for	  the	  presence	  of	  human	  platelets	  (Figure	  
5A)	   and	   human	   CD45+	   cells	   at	   weekly	   intervals	   (Figure	   5B).	   All	   recipient	   mice	   had	  
detectable	   levels	   of	   human	   platelets	   in	   their	   peripheral	   blood	   as	   early	   as	   week	   3.	   Co-­‐
transplantation	  of	  MSC	   from	  all	   sources	   resulted	   in	   higher	   levels	   of	   circulating	  platelets	  
compared	  to	  transplantation	  of	  CD34+	  cells	  alone	  (CD34+	  cells	  alone:	  57±31	  plt/µl	  PB	  vs.	  
with	  BM	  MSC:	  304±135	  plt/µl	  PB,	  p=0.073,	  with	  autologous	  WJ	  MSC:	  610±244	  plt/µl	  PB,	  
p<0.05	   or	   with	   allogeneic	   MSC:	   556±390	   plt/µl	   PB,	   p<0.05).	   At	   6	   weeks	   after	  
transplantation,	  platelet	   levels	  were	  on	  average	  5-­‐fold	  higher	   in	   the	  CD34+	  and	  MSC	  co-­‐
transplanted	   groups	   when	   compared	   to	   the	   platelet	   levels	   in	   recipients	   of	   CD34+	   cells	  
alone	   (CD34+	   cells	   alone:	   790±216	   plt/µl	   PB	   vs.	   BM	   MSC	   and	   CD34+	   cells:	   4146±1586	  
plt/µl	   PB,	   p<0.005,	   autologous	  WJ	  MSC	   and	   CD34+	   cells:	   4649±1203	   plt/µl	   PB,	   p<0.005	  
and	   allogeneic	   WJ	   MSC	   and	   CD34+	   cells:	   5546±1654	   plt/µl	   PB,	   p<0.05).	   Similarly,	   co-­‐	  
transplantation	  of	  WJ	  MSC	  significantly	  increased	  human	  CD45+	  cells	  in	  the	  PB	  from	  week	  
4	   onwards	   as	   compared	   to	   transplantation	   with	   CD34+	   cells	   alone	   (40.6±22.7x103	   and	  
45.1±17x103	   versus	   10.1±5.7x103	   CD45+	   cells/ml	   for	   CD34+	   cells	   with	   autologous	   and	  
allogeneic	   WJ	   MSCs	   vs	   CD34+	   cells	   alone	   respectively,	   p<0.05).	   Slower	   recovery	   of	  
circulating	  human	  leukocytes	  was	  observed	  with	  co-­‐transplanted	  BM	  MSC	  as	  compared	  to	  
co-­‐transplanted	  WJ	  MSC.	  Co-­‐transplantation	  of	  BM	  MSC	  increased	  circulating	  CD45+	  cells	  5	  
weeks	   after	   transplantation	   reaching	   levels	   similar	   to	   co-­‐transplanting	   WJ	   MSC	   at	   this	  
time	   point	   (69.7±21.9x103	   versus	   12.6±3.9x103	   CD45+	   cells/ml	   for	   CD34+	   cells	  with	  BM	  
MSC	  or	  for	  CD34+	  transplantation	  only,	  p<0.05).	  Six	  weeks	  after	  transplantation,	  the	  mice	  
were	   sacrificed	   and	   the	   bone	   marrow	   was	   analyzed	   for	   the	   presence	   of	   human	  
hematopoietic	  cells.	  Co-­‐transplantation	  of	  MSC	  obtained	  from	  both	  WJ	  and	  BM	  increased	  
the	  frequency	  of	  human	  CD45+	  cells	  in	  the	  bone	  marrow	  by	  at	  least	  2-­‐fold	  as	  compared	  to	  
transplantation	   of	   CD34+	   cells	   alone	   (Figure	   5C,	   CD34+	   cells	   alone:	   26.7±5.5%	   human	  
CD45+	  cells	  vs.	  CD34+	  cells	  with	  BM	  MSC	  61.8±7.1%,	  p<0.0005,	  with	  autologous	  WJ	  MSC:	  
67.7±4.8%,	  p<0.0001	  or	  with	  allogeneic	  WJ	  MSC	  68.9±3.6%,	  p<0.0001).	  A	  similar	  pattern	  
was	   observed	   for	   human	   CD45+	   cell	   chimerism	   in	   spleen	   and	   peripheral	   blood.	   Co-­‐
transplantation	  of	  MSC	  and	  CD34+	  cells	   increased	  chimerism	   in	   the	  spleen	  by	  at	   least	  3-­‐
fold	   compared	   to	   transplantation	   of	   CD34+	   cells	   alone	   (Figure	   5D,	   CD34+	   cells	   alone:	  
7.5±1.5%	   vs.	   co-­‐transplantation	   with	   BM	  MSC:	   23.9±4.6%,	   p<0.05,	   with	   autologous	  WJ	  
MSC:	   34.1±4.5%,	   p<0.005	   or	   with	   allogeneic	   WJ	   MSC:	   32.2±4.3%,	   p<0.001)	   and	   in	   the	  
blood	   at	   least	   5-­‐fold	   (Figure	   5E,	   CD34+	   cells	   alone:	   4.2±1.0%	  human	  CD45+	   cells	   vs.	   co-­‐
transplantation	  with	  BM	  MSC:	  21.7±5.6%,	  p<0.05,	  with	  autologous	  WJ	  MSC:	  24.7±4.5%	  or	  
with	  allogeneic	  WJ	  MSC:	  26.5±6.6%,	  p<0.005).	  BM	  cells	  harvested	  from	  the	  femurs	  of	  the	  
mice	  expressed	  similar	  percentages	  of	   the	  common	  myeloid	  marker	  CD33,	   the	   lymphoid	  
markers	  CD19	  and	  CD3	  and	  the	  stem/progenitor	  cell	  marker	  CD34	  irrespective	  of	  the	  co-­‐
transplantation	   of	   MSC	   (Figure	   5F).	   In	   our	   model,	   autologous	   and	   allogeneic	   WJ	   MSCs	  














Co-­‐culture	   of	  WJ	  MSC	   and	  CB	  CD34+	   cells	  with	  TPO	   enhances	   CFU-­‐GEM	   formation,	  
while	  BM	  MSC	  enhances	  BFU-­‐E	  formation	  	  
Several	   functional	   characteristics	   of	   MSC	   might	   play	   a	   role	   in	   their	   observed	   ability	   to	  
facilitate	  engraftment.	  MSC	  have	  been	  shown	  previously	  to	  support	  the	  growth	  of	  human	  
CB	  CD34+	  cells.	   33-­‐37	  Furthermore,	  we	  have	  shown	  that	   transplantation	  of	  TPO	  expanded	  
CB	  CD34+	  enhanced	  early	  platelet	   repopulation	  while	   retaining	   long	   term	  hematopoietic	  
engraftment	   capacity	   in	   NOD-­‐SCID	   mice.	   31,32	   Combining	   these	   2	   potential	   engraftment	  
enhancing	  strategies,	  we	  compared	  the	  capacity	  of	  human	  WJ	  MSC	  and	  BM	  MSC	  to	  support	  
differentiation	   and	   expansion	   of	   human	   CB-­‐derived	   CD34+	   cells	   in	   the	   presence	   of	  
exogenous	  TPO.	  To	  this	  end,	  CD34+	  cells	  were	  cultured	  for	  10	  days	  on	  monolayers	  of	  MSC	  
obtained	   from	   different	   sources	   in	   the	   presence	   of	   exogenous	   TPO	   and	   analyzed	   for	  
expansion	  of	  total	  MNC	  and	  CFU	  formation	  of	  the	  cultured	  CD34+	  cells.	  	  
Cultures	  of	  CD34+	  cells	  on	  either	  BM	  MSC	  or	  WJ	  MSC	  monolayers	  did	  not	  enhance	  the	  TPO	  
induced	  expansion	  of	  total	  nucleated	  cells	  (Figure	  6A,	  WJ	  MSC	  4.8±0.9	  fold	  expansion	  and	  
BM	  MSC	  4.1±1.5	  fold	  expansion	  vs.	  no	  stromal	  support	  4.0±0.8	  fold	  expansion)	  over	  this	  
time	   period.	   	   Additionally,	   the	   ratio	   between	   the	   3	   main	   cell	   subpopulations	   that	   are	  
typically	   formed	   when	   CB	   CD34+	   are	   cultured	   with	   TPO,	   namely	   residual	   CD34+	   cells	  
(rCD34+),	   CD34-­‐-­‐	   CD61-­‐	   cells	   (Lin-­‐)	   and	   CD34-­‐61+	   cells	   (CD61+),	   38	  were	   similar	   between	  
cultures	  without	   stromal	   support	  and	   those	  on	  MSC	  mono-­‐layers	   from	  different	   sources	  
(Figure	   6B).	   To	   investigate	   the	   differentiation	   potential	   of	   the	   remaining	   hematopoietic	  
stem	   and	   progenitor	   cells	   (HSPC)	   in	   the	   TPO	   induced	   cultures,	   we	   next	   analyzed	   their	  
colony-­‐forming	   capacity	   in	  CFU	  assays.	  To	   this	   end,	  HSPC	  were	   first	   separated	   from	   the	  
MSC	  after	  co-­‐culture	  and	  subsequently	  cultured	  in	  semi-­‐solid	  cultures	   in	  the	  presence	  of	  
cytokines.	  	  Interestingly,	  HSPC	  derived	  from	  cultures	  on	  BM	  MSC	  monolayers	  exhibited	  an	  
increased	   capacity	   to	   form	   BFU-­‐E	   colonies	   (Figure	   6C,	   BM	  MSC	   42.8±10.2	   BFU-­‐E/1000	  
rCD34+	   cells	   compared	   to	   no	   MSC	   14.5±6.1	   BFU-­‐E/1000	   rCD34+	   cells,	   p<0.05).	   HSPC	  
cultured	  in	  the	  presence	  of	  WJ	  MSC	  gave	  rise	  to	  higher	  numbers	  of	  CFU-­‐GEMM	  (35.8±9.9	  
colonies/1000	  CD34+	  cells	  vs.	  20.6±6.3/1000	  CD34+	  without	  stromal	  support;	  Figure	  6C,	  












Figure 5: Co-transplantation of MSC and CD34+ cells enhances peripheral blood recovery and bone 
marrow engraftment in NOD SCID mice , A: Human platelet recovery in the PB of the mice after 
transplantation. B: Human CD45+ cell recovery in the PB of the mice after transplantation. C: Percentage of 
human CD45+ cells in the BM of the mice 6 weeks after transplantation D: Percentage of human CD45+ cells 
in the spleen of the mice 6 weeks after transplantation. E: Percentage of human CD45+ cells in the blood of 
the mice 6 weeks after transplantation. Bars represent the mean of all mice F: Lineage differentiation of the 
human CD45+ cells in the BM 6 weeks after transplantation. The total number of human CD45+ cells in the 
femurs off all mice was analyzed for the expression of lymphoid markers CD19 and CD3, myeloid marker 






Figure 6: Co-culture of BM or WJ MSC with CB CD34+ cells supports the expansion of CB CD34+ cells 
in the presence of TPO. CB CD34+ cells obtained from different donors (n=5) were cultured with TPO for 10 
days in the presence or absence of MSC obtained from different sources. Next, the composition of the 
expanded cells was analyzed using flow cytometry and the capacity to form myeloid colonies was analyzed 
with CFU assays. A: Fold expansion (depicted as the total number of hematopoietic nucleated cells after 
culture divided by the number of input cells) in the absence or presence of stromal cells B: Percentage of the 
3 major populations of the total hematopoietic cells observed after expansion in the absence or presence of 
stromal support from MSC from different sources; rCD34+ = residual CD34 cells, Lin- = CD34-CD61-Lineage- 
cells, and CD61+ = CD34-CD61+ cells. C: Colony-forming capacity of TPO expanded CD34+ cells after 

















Incubation	   of	   CB-­‐derived	   CD34+	   cells	   with	   MSC	   does	   not	   significantly	   alter	   their	  
migration	  towards	  CXCL12,	  but	  increases	  the	  expression	  of	  adhesion	  markers	  	  
Hematopoietic	  stem	  cell	  homing	  to	  the	  marrow	  is	  the	  primary	  step	  for	  their	  engraftment	  
and	   relies	   on	   their	   adhesive	   and	   migratory	   capacities.	   	   We	   investigated	   whether	   MSC	  
change	   the	   migratory	   characteristics	   of	   CB	   CD34+	   cells	   towards	   CXCL12	   in	   transwell	  
migration	   studies.	   To	   this	   end,	   CB	  CD34+	   cells	   and	  MSC	  were	   incubated	   together	   for	   30	  
minutes	  to mimic	  the	  time	  that	  CD34+	  cells	  and	  MSC	  are	  in	  the	  same	  tube	  prior	  to	  infusion.	  
Aliquots	   of	   the	   cell	   suspensions	   were	   placed	   in	   transwell	   	   plates	   	   while	   others	   were	  
analyzed	   in	   parallel	   for	   adhesion	   marker	   expression.	   Additionally,	   the	   effect	   of	   the	  
presence	  of	  either	  autologous	  or	  allogeneic	  WJ	  MSC	  on	  the	  migration	  of	  CD34+	  cells	  was	  
tested	   (Figure	   7A). Autologous	   WJ	   MSC	   tended	   to	   increase	   CD34+	   migration	   when	  
compared	   to	   the	   migration	   of	   CD34+	   cells	   alone;	   this	   difference	   however,	   was	   not	  
significant	  (11.3±5.2%	  vs	  6.8±2.2%	  for	  CD34+	  cell	  migration	  with	  or	  without	  autologous	  
WJ	  MSC).	  Next,	  we	  investigated	  the	  expression	  of	  several	  adhesion	  markers	  known	  to	  be	  
involved	   in	   homing	   to	   the	   BM.	   39	   In	   this	   respect,	  we	   analyzed	   the	   expression	   of	   CD11a,	  
CD11b,	  CD49d,	  CD49e	  and	   the	  CXCL12	  receptor	  CD184	  (CXCR4)	  on	  CD34+	  cells	  after	  30	  
minutes	  incubation	  with	  MSC	  (Figure	  7B).	  	  Regardless	  of	  the	  MSC	  source,	  incubation	  of	  CB	  
CD34+	  cells	  with	  MSC	  seemed	  to	  induce	  a	  general	  increase	  in	  marker	  expression.	  However,	  
even	   between	   MSC	   from	   the	   same	   source,	   expression	   levels	   varied	   considerably.	  
Therefore,	  only	  CD49d	  and	  CD49e	  expression	  was	  significantly	  increased	  after	  incubation	  






Figure 7: In vitro homing characteristics of and adhesion molecule expression of CD34+ in the 
presence of MSC obtained from different sources. A: Migration of CD34+ cells towards SDF-1α in the 
presence of MSC obtained from WJ or BM. B: Expression of adhesion markers and CXCR4 on CB-derived 







In	  the	  present	  study,	  we	  compared	  the	  effect	  of	  human	  MSC	  obtained	  from	  WJ	  and	  BM	  on	  
the	   engraftment	   of	   CB-­‐derived	   CD34+	   cells	   in	   an	   immune-­‐deficient	   murine	   transplant	  
model.	  The	  recovery	  of	  human	  platelets	  and	  CD45+	  cells	   in	  the	  peripheral	  blood	  of	  these	  
mice	   was	   significantly	   enhanced	   by	   co-­‐transpantation	   of	   either	   WJ	   or	   BM	   MSC	   from	   3	  
weeks	  onwards.	  At	  6	  weeks	  post-­‐transplantation,	  the	  percentage	  of	  human	  CD45+	  cells	  in	  
the	   BM,	   spleen	   and	   peripheral	   blood	   was	   at	   least	   3-­‐fold	   higher	   when	   MSC	   were	   co-­‐
transplanted	   with	   CD34+	   cells	   compared	   to	   transplantation	   of	   CD34+	   cells	   alone.	   MSC	  
obtained	  from	  BM	  and	  WJ	  were	  comparable	  in	  their	  capacity	  to	  enhance	  the	  engraftment	  
of	  CB-­‐derived	  CD34+	  cells.	  	  
Although	   the	  mechanism	   is	   so	   far	  not	  determined,	  MSC	   induced	  CD34+	   cell	   engraftment	  
has	  been	   suggested	   to	  be	   associated	  with	   their	   immune-­‐modulatory	   capacity.	  MSC	   from	  
different	   tissues	   including	  WJ	   are	   known	   to	   modulate	   immunological	   responses.	   9,40	   At	  
high	  levels	  of	  IFN-­‐γ	  and	  TNF-­‐α,	  MSC	  have	  an	  anti-­‐inflammatory	  effect	  for	  which	  secreted	  
indoleamine	  2,3-­‐dioxygenase	  (IDO)	   is	  one	  of	  the	  proposed	  mediators.	  41,42	  Conversely,	   in	  
steady	   state	   conditions	   at	   low	   levels	   of	   IFN-­‐γ	   and	   TNF-­‐α,	   allogeneic	   MSC	   are	   able	   to	  
stimulate	  an	  immunological	  response.	  9	  The	  absence	  of	  inflammatory	  signals	  directly	  after	  
transplantation	  could	  therefore	  not	  only	  diminish	  the	  immunosuppressive	  effect	  of	  the	  co-­‐
transplanted	   MSC	   but	   may	   even	   have	   an	   immune	   activating	   effect.	   The	  
immunosuppressive	  properties	  of	  MSC,	  however,	   are	  most	   likely	   to	  mediate	  a	  beneficial	  
effect	  on	  the	  outcome	  of	  HCT	  e.g.	  by	  exhibiting	  a	  prophylactic	  effect	  on	  the	  occurrence	  or	  
severity	  of	  Graft	  versus	  Host	  Disease	  or	  host	  mediated	  graft	  rejection.	  43,44	  In	  agreement,	  a	  
study	   in	  which	  mononuclear	  cells	   (MNC)	  obtained	   from	  two	  CB	  units	  were	   transplanted	  
demonstrated	   that	  either	  removal	  of	   the	   immune	  competent	  cells	   from	  the	  graft	  or	  MSC	  
co-­‐transplantation	   alleviated	   single	   CB	   donor	   dominance	   and	   improved	   overall	  
engraftment.	  10	  In	  our	  in	  vitro	  experiments	  MSC	  from	  the	  BM	  and	  WJ	  were	  equally	  potent	  
in	   inhibiting	   the	   proliferation	   of	   αCD3αCD28	   stimulated	   PBMC.	   However,	   as	   we	   use	  
immune	   deficient	   NOD	   SCID	   mice	   for	   our	   in	   vivo	   transplantation	   experiments	   and	  
transplants	  without	  any	  immune	  competent	  cells,	   these	  immune	  modulating	  qualities	  do	  
not	   seem	   to	   be	   instrumental	   for	   the	   similar	   engraftment	   enhancing	   effect	   of	   both	   MSC	  
sources	   since.	   Alloimmunization	   between	   the	   recipient	   and	   the	   transplanted	   cells	   or	  
between	   the	   CD34+	   cell	   purified	   HSC	   graft	   and	   the	   co-­‐transplanted	   allogeneic	   MSC	   are	  
therefore	  not	   likely	   to	  occur.	   	   In	  agreement,	  no	  difference	   in	   the	  engraftment	  enhancing	  
capacity	   of	   autologous	   and	   allogeneic	   WJ	   MSC	   was	   found.	   Since	   immune	   related	  
components	  cannot	  be	  assessed	   in	  our	  model,	   the	  marked	   increase	  of	  engraftment	  must	  
therefore	  be	  caused	  by	  other	  MSC-­‐derived	  factors.	  	  
Alternatively,	  MSC	  may	  play	  a	  direct	  role	  in	  regenerating	  the	  bone	  marrow	  niche,	  first	  by	  
homing	  to	  the	  marrow	  and	  differentiating	  into	  stromal	  tissues	  and	  second	  by	  inducing	  the	  
proliferation	  and	  differentiation	  of	  HSC.	  Concerning	  the	  first	  option,	  our	  studies	  show	  that	  
the	  differentiation	  capacity	  of	  WJ	  MSC	  is	  variable	  and	  limited	  and	  thus	  unlikely	  to	  be	  the	  
cause	  for	  their	  engraftment	  stimulating	  effect.	  Corroborated	  by	  a	  study	  from	  Bosch	  et	  al.,	  
45	   this	   also	  makes	  WJ	  MSC	   less	   interesting	   candidates	   for	   therapeutic	   bone	   or	   cartilage	  
regeneration.	   Concerning	   the	   second	   option,	   WJ	   MSC	   have	   been	   shown	   to	   support	   the	  
growth	   of	   CB-­‐derived	   CD34+	   cells	   ex	   vivo.	   33-­‐37	   As	   we	   previously	   showed	   that	   TPO	  
expanded	   CB	   CD34+	   cells	   contributed	   to	   both	   improved	   platelet	   recovery	   and	   BM	  
engraftment,	  31	  we	  combined	  these	  2	  different	  mechanisms	  in	  an	  in	  vitro	  experiment	  and	  
investigated	  whether	  MSC	  could	  further	  enhance	  TPO-­‐induced	  effects	  on	  CD34+	  cultures.	  
In	   this	   regard	   additional	   presence	   of	   MSC	   did	   not	   change	   TPO	   induced	   expansion	   and	  
neither	  was	   the	  composition	  of	   the	   formed	  subpopulations	  changed.	  CFU	  cultures	  of	   the	  
41	  
	  
expanded	  cells	  did	  however	  show	  that	  the	  MSC	  have	  a	  different	  effect	  on	  the	  types	  of	  cells	  
that	   are	   formed	  after	   expansion.	   Cultures	   of	  HSPC	  on	  BM	  MSC	  monolayers	   exhibited	   an	  
increased	  capacity	  to	  form	  BFU-­‐E	  colonies	  while	  HSPC	  cultured	  in	  the	  presence	  of	  WJ	  MSC	  
gave	   rise	   to	   higher	   numbers	   of	   CFU-­‐GEMM.	   These	   observations	  might	   be	   of	   conceptual	  
importance	   since	   CFU-­‐GEMM	   are	   correlated	   with	   the	   presence	   of	   more	   primitive	   stem	  
cells.	  46	  Hence,	  WJ	  MSC	  in	  this	  respect	  might	  have	  a	  better	  potential	  to	  preserve	  the	  more	  
immature	  CD34+	  cells	   in	  culture	  with	  TPO	  than	  BM	  MSC.	  Other	  studies	  have	  shown	  that	  
the	   co-­‐culture	   of	   MSC,	   including	  WJ	  MSC,	   can	   enhance	   the	   fold	   expansion	   of	   both	   total	  
nucleated	  cells	  and	  CD34+	  cells.	  33,35,37	  These	  studies	  used	  a	  cocktail	  of	  cytokines	  including	  
SCF,	   Flt3L	   and	   TPO	   in	   their	   culture	   protocol.	   Adding	   SCF	   and	   Flt3L	   to	   the	   expansion	  
medium	   can	   significantly	   enhance	   the	   fold	   expansion	   of	   the	   cells,	   47	   and	   the	   absence	   of	  
these	  cytokines	  could	  therefore	  explain	  the	  lack	  of	  TNC	  and	  CD34+	  cell	  expansion	  in	  our	  
experiments.	  	  
However,	   for	  both	   the	  MSC	   induced	  marrow	  niche	   regenerating	  mechanisms	   to	  become	  
relevant,	  homing	  of	  MSC	  with	  the	  HSPCs	  to	  the	  bone	  marrow	  is	  necessary.	  This	  has	  so	  far	  
not	  been	  convincingly	  shown.	  11,48,49	  Although	  co-­‐localization	  of	  MSC	  and	  CD34+	  cells	  in	  the	  
pelvis	  has	  been	  reported	  [49],	  48	  MSC	  are	  more	  often	  detected	  in	  various	  organs,	  but	  not	  in	  
the	   BM	   11	   and	   entrapment	   of	   MSC	   in	   the	   lungs	   has	   been	   described	   as	   a	   possible	  
explanation	  for	  the	  lack	  of	  homing	  of	  the	  MSC.	  49	  
MSC-­‐induced	   homing	   of	   CD34+	   cells	   to	   the	  HSC	   niche	  might	   be	   another	   explanation	   for	  
increased	  engraftment	  by	  local	  (e.g.	  by	  cell	  to	  cell	  contact	  in	  the	  marrow)	  or	  systemic	  (e.g.	  
by	   paracrine	   factors	   production)	   support.	   Our	   in	   vitro	   studies,	   with	   brief	   exposure	   of	  
CD34+	   cells	   to	   MSC	   could	   not	   consistently	   show	   enhanced	   migration	   of	   CD34+	   cells	  
towards	   CXCL12.	   However,	   in	   the	   presence	   of	   MSC,	   CD34+	   cells	   upregulate	   surface	  
markers	   that	   are	   associated	   with	   their	   homing	   to	   or	   retention	   in	   the	   BM	  marrow	   (e.g.	  
CD11a,	  CD11b,	  CD184,	  CD49e	  and	  CD49d).	  39,50,51	  
In	   conclusion,	   our	   data	   support	   the	   use	   of	   human	  WJ	   MSC	   as	   an	   alternative	   source	   to	  
enhance	  the	  engraftment	  of	  human	  CB-­‐derived	  CD34+	  cells.	  Although	  MSC	  induced	  homing	  
of	   HPSC	   to	   the	   BM,	   seems	   an	   interesting	   explanation	   from	   our	   studies,	   for	   a	   real	   life	  
estimate	   of	   MSC	   role	   in	   engraftment	   support	   other	   mechanisms	   also	   need	   to	   be	  
considered.	  Engraftment	  in	  this	  regard	  is	  likely	  dependent	  on	  (interacting)	  factors	  like	  the	  
immune	   status	   of	   the	   recipient	   and	   hematopoietic	   immune	   (activating)	   cells	   in	   the	  
transplants.	  However,	   the	   immune-­‐deficient	  recipient	  mice	  and	  the	  CD34+	   isolated	  stem	  
cell	  transplant	  that	  were	  used	  in	  our	  studies,	  makes	  MSC	  induced	  immunomodulation	  an	  
unlikely	   explanation	   for	   the	   observed	   enhanced	   engraftment	   in	   vivo.	   Our	   in	   vitro	  
experiments,	  however,	  do	  suggest	  that	  WJ	  MSC	  may	  serve	  as	  an	  alternative	  source	  to	  BM	  
MSC	   for	   immunomodulatory	   applications.	   A	   general	   advantage	   of	   WJ	   MSC	   is	   that	   the	  
umbilical	   cord	   can	   be	   regarded	   as	   a	   waste	   product,	   and	   that	  WJ	  MSC	   can	   therefore	   be	  
obtained	  at	  relatively	  low	  cost	  without	  harm	  or	  risk	  for	  the	  donor.	  	  
Since	  co-­‐transplantation	  of	  allogeneic	  MSC	  did	  not	  show	  particular	  disadvantages,	  52-­‐54	  and	  
while	   co-­‐transplantation	   of	   autologous	  MSC	  with	   donor	   hematopoietic	   stem	   cells	  might	  
even	  inhibit	  engraftment,	  55	  our	  study	  does	  not	  support	  the	  paired	  use	  and	  banking	  of	  CB	  
CD34+	  cells	  and	  WJ	  MSC	  of	  the	  same	  umbilical	  cord.	  However,	  concurrent	  collection	  of	  the	  
umbilical	   cord	   with	   CB	   collection	   enables	   sharing	   the	   logistics,	   tissue	   typing	   and	  
virological	   testing	   for	   two	  products	   from	  only	  one	  donor	  with	  additional	   saving	  of	   costs	  
and	   effort	   to	   obtain	  MSC	   from	  BM.	  This	   new	  CB	   cord	   strategy	  would	   therefore	   create	   a	  
relative	  cheap,	  off	  the	  shelf	  MSC	  product	  that	  can	  be	  provided	  by	  tissue	  banks	  to	  hospitals.	  
The	  value	  of	  such	  an	  approach	  however	  will	  eventually	  depend	  on	  the	  therapeutic	  efficacy	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Thrombopoietin	  treatment	  of	  one	  graft	  in	  
a	  double	  cord	  blood	  transplant	  provides	  
early	  platelet	  recovery	  while	  contributing	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Human	  cord	  blood	  (CB)	  hematopoietic	  stem	  (HSC)	  cell	   transplants	  demonstrate	  delayed	  
early	   neutrophil	   and	   platelet	   recovery	   and	   delayed	   longer	   term	   immune	   reconstitution	  
compared	  to	  bone	  marrow	  and	  mobilized	  peripheral	  blood	  transplants.	  	  Despite	  advances	  
in	   enhancing	   early	   neutrophil	   engraftment,	   platelet	   recovery	   after	   CB	   transplantation	   is	  
not	   significantly	   altered	   when	   compared	   to	   contemporaneous	   controls.	   Recent	   studies	  
have	  identified	  a	  platelet	  biased	  murine	  HSC	  subset,	  maintained	  by	  thrombopoietin	  (TPO)	  
which	   has	   enhanced	   capacity	   for	   short	   and	   long	   term	   platelet	   reconstitution,	   can	   self-­‐
renew,	   and	   can	   give	   rise	   to	  myeloid	   and	   lymphoid	  biased	  HSCs.	   In	  previous	   studies,	  we	  
have	  shown	  that	  transplantation	  of	  human	  CB	  CD34+	  cells	  pre-­‐cultured	  in	  TPO	  as	  a	  single	  
graft	   accelerates	   early	   platelet	   recovery	   as	   well	   as	   yielding	   long	   term	   repopulation	   in	  
immune	  deficient	  mice.	  Here,	  using	  a	  double	  CB	  murine	  transplant	  model,	  we	  investigated	  
whether	   TPO	   cultured	   human	   CB	   CD34+	   cells	   have	   a	   competitive	   advantage	   or	  
disadvantage	  over	  untreated	  human	  CB	  CD34+	  cells	   in	   terms	  of	   i)	  short	  and	   longer	   term	  
platelet	   recovery	   and	   ii)	   longer	   term	   hematological	   recovery.	   Our	   studies	   demonstrate	  
that	  the	  TPO	  treated	  graft	  shows	  accelerated	  early	  platelet	  recovery	  without	  impairing	  the	  
platelet	  engraftment	  of	  untreated	  CD34+	  cells.	  Notably,	   this	  was	   followed	  by	  a	  dominant	  
contribution	   to	   platelet	   production	   via	   the	   untreated	   CD34+	   cell	   graft	   over	   the	  
intermediate	  to	   longer	  term.	   	  Furthermore,	  although	  the	  contribution	  of	  the	  TPO	  treated	  
graft	  to	  long	  term	  hematological	  engraftment	  was	  reduced,	  the	  TPO	  treated	  and	  untreated	  
grafts	  both	  contributed	  significantly	  to	  long	  term	  chimerism	  in	  vivo.	  
	  
	  

























































Cord	  blood	  (CB)	   transplantation	   is	  used	  as	  an	  alternative	   for	  bone	  marrow	  or	  mobilized	  
peripheral	  blood	  grafts,	  particularly	  when	  no	  HLA	  matched	  related	  or	  unrelated	  donor	  can	  
be	   found.	   1-­‐4	   However,	   in	   contrast	   to	   the	   other	   cell	   sources,	   un-­‐manipulated	   CB	  
hematopoietic	   stem	   and	   progenitor	   cells	   (HSPCs)	   demonstrate	   defective	   CXCL12-­‐
mediated	   homing	   and	   adhesion	   to	   endothelium	   and	   delayed	   hematological	   engraftment	  
and	   reconstitution.	   5-­‐7	   Higher	   HSPC	   dosages,	   measured	   in	   terms	   of	   CFU	   content	   and	  	  
>1.8x105	   viable	   CD34+	   cells	   transplanted	   per	   kg	   recipient	   body	   weight	   in	   this	   respect,	  
seem	   needed	   to	   improve	   the	  median	   time	   to	   and	   probability	   of	   neutrophil	   and	   platelet	  
engraftment,	  factors	  essential	  for	  reducing	  transplant	  related	  morbidity	  and	  mortality.	  8-­‐17	  
The	  restricted	  number	  of	  CD34+	  HSPCs	  in	  one	  cord	  blood	  unit,	  however,	  is	  often	  a	  hurdle	  
to	   treat	   adults.	   To	   overcome	   this	   limitation,	   adults	   and	   large	   children	   are	   generally	  
considered	   for	   double	   CB	   (dCB)	   transplantation,	   18-­‐21	   with	   both	   improved	   Non	   Relapse	  
Mortality	   (NRM)	   and	   increased	   relapse-­‐free	   survival	   (RFS)	   reported	   using	   this	   dCB	  
approach.	  18-­‐21	  The	  relapse	  mediated	  advantages	  of	  dCB	  transplants	  are	  still	  partly	  offset	  
by	  NRM	  as	  a	  result	  of	  increased	  infectious	  complications	  and	  bleeding	  caused	  by	  delayed	  
neutrophil	   and	   platelet	   recovery	   when	   compared	   to	   matched	   related	   or	   unrelated	  
mobilized	   peripheral	   blood	   and	   bone	   marrow	   grafts.	   18	   One	   solution	   to	   this	   delayed	  
hematological	  engraftment	  is	  to	  expand	  the	  numbers	  of	  HSPCs	  in	  the	  graft	  leading	  to	  long	  
term	  repopulating	  cells	  most	  preferably	  in	  combination	  with	  expansion	  of	  neutrophil	  and	  
platelet	   progenitors	   to	   enable	   early	   hematological	   repopulation	   as	   well.	   Unfortunately	  
most	  ex	  vivo	  manipulations	  seem	  to	  be	  associated	  with	  the	  loss	  of	  long	  term	  repopulation	  
and/or	  the	  skewing	  of	  progenitors	  towards	  neutrophil	  differentiation.	  	  
Although	  substantially	  higher	  CD34+	  cell	  numbers	  have	  been	  generated	  by	  ex	  vivo	  culture	  
with	   cytokines	   and	   small	  molecules	   or	   the	   homing/engraftment	   of	   these	   cells	   has	   been	  
enhanced	   with	   small	   molecules	   in	   the	   attempts	   reported	   so	   far,	   22-­‐32	   the	   co-­‐
transplantation	  of	  an	  un-­‐manipulated	  CB	  unit	  with	  an	  ex	  vivo	  expanded	  CB	  unit	  or	  part	  of	  
a	   unit	   has	   been	   regarded	   as	   a	   sensible	   precaution	   as	   the	   long	   term	   repopulating	   HSCs	  
often	  originate	  from	  the	  non-­‐expanded	  CB	  unit.	  	  Importantly,	  the	  first	  cautious	  attempts	  to	  
expand	  one	  of	  the	  grafts	  prior	  to	  dCB	  transplantation	  have	  significantly	  reduced	  the	  time	  
to	   neutrophil	   recovery,	   24,26-­‐28,30	   although	   platelet	   recovery	   has	   	   remained	   substantially	  
delayed	  when	  compared	  to	  current	  rather	  than	  historical	  transplant	  outcomes.	  33	  
Thrombopoietin	   (TPO)	   is	   known	   to	   be	   critical	   for	   both	   HSC	   maintenance	   and	   platelet	  
production.	   34-­‐40	   Sanjuan-­‐Pla	   et	   al.	   41	   have	   recently	   identified,	   in	   the	   mouse,	   a	   TPO-­‐
dependent	  platelet	  biased	  HSC	  expressing	  Sca-­‐1,	  c-­‐kit,	  CD150	  and	  vWF	  which	  exists	  at	  the	  
apex	  of	  the	  hematopoietic	  hierarchy	  and	  which	  not	  only	  generates	  platelets	  over	  the	  short	  
and	   longer	   term	  but	   also	   can	  give	   rise	   to	  both	  myeloid	   and	   lymphoid	  biased	  HSCs.	  This	  
corresponding	   TPO	   dependent	   platelet	   biased	   subset	   has	   not	   been	   identified	   in	   the	  
human,	  principally	  because	  in	  the	  mouse	  a	  vWF-­‐eGFP	  reporter	  is	  used.	  	  However,	  previous	  
studies	   from	   our	   group	   and	   others	   have	   demonstrated	   that	   culturing	   human	   CB	   CD34+	  
cells	  for	  7-­‐9	  days	  	  with	  thrombopoietin	  (TPO)	  can	  lead	  to	  improved	  early	  platelet	  recovery	  
in	   immune-­‐deficient	   mice	   when	   compared	   to	   transplantation	   with	   untreated	   CB	   CD34+	  
cells	   in	   the	   single	   CB	   transplant	   setting,	   without	   apparently	   compromising	   longer	   term	  
hematological	   reconstitution.	   42-­‐44	   Since	   thrombocytopenia	   is	   a	   common	   complication	   of	  
both	  single	  and	  double	  CB	  HSC	  transplants,	  it	  has	  been	  proposed	  from	  these	  studies	  that	  
TPO	  treatment	  ex	  vivo	  of	  one	  or	  part	  of	  one	  CB	  unit	  in	  a	  dCB	  transplant	  setting	  might	  be	  
especially	   useful	   in	   preventing	   delays	   in	   platelet	   recovery	   post-­‐transplant	   and	   hence	   in	  
improving	  overall	  patient	  survival.	   1,45	  Although	  purified	  and	  ex	  vivo	  manipulated	  CD34+	  
are	  most	  likely	  to	  be	  combined	  with	  an	  un-­‐manipulated	  CB	  unit	  in	  the	  transplant	  setting,	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the	  influence	  of	  ex	  vivo	  manipulation	  on	  hematological	  reconstitution	  should	  be	  compared	  
first	  for	  a	  fixed	  number	  of	  CD34+	  cells	  in	  surrogate	  models	  of	  dCB	  transplantation	  ahead	  
of	   assessing	   other	   immunologic	   and	   matching	   dependent	   effects	   of	   the	   graft	   on	  
repopulation	  and	  final	  chimerism.	  
In	  this	  paper,	  we	  therefore	  used	  a	  dCB	  transplant	  model	  in	  NSG	  mice	  and	  isolated	  CD34+	  
cells	   from	   three	  different	  CB	  donor	  pairs	   to	   first	  determine	   if	  TPO	   treated	  CD34+	  HSPCs	  
from	  one	  CB	  unit	  when	  combined	  with	  untreated	  CD34+	  cells	  from	  another	  CB	  unit	  could	  
both	   improve	   and	   sustain	   platelet	   recovery	   when	   compared	   with	   a	   dCB	   transplant	   of	  
untreated	  CD34+	  cells	  of	  both	  donors.	   	  Secondly,	  we	  assessed	  if	  untreated	  CB	  CD34+	  cells	  
from	  one	  donor	  had	  a	  competitive	  advantage	  or	  disadvantage	  when	  co-­‐transplanted	  with	  
the	   same	   number	   of	   TPO-­‐treated	   vs	   untreated	   CB	   CD34+	   cells	   from	   a	   second	   donor	   in	  
terms	   of	   short	   or	   longer	   term	   platelet	   recovery	   and	   longer	   term	   hematological	  
reconstitution.	  Interestingly,	  the	  TPO	  cultured	  CD34+	  cells	  were	  responsible	  for	  improved	  
early	  platelet	   recovery	  and	  contributed	   substantially	   to	   longer	   term	  platelet	   recovery	   in	  
the	  dCB	  transplant	  setting,	  although	  the	  dominant	  contribution	  to	  platelet	  recovery	  in	  the	  
intermediate	  to	  longer	  term	  arose	  from	  the	  untreated	  CD34+	  cells.	  Furthermore,	  although	  
there	   was	   less	   contribution	   from	   the	   TPO-­‐treated	   CD34+	   cell	   graft,	   long	   term	  
hematological	   cell	   reconstitution	   was	   dependent	   on	   both	   the	   TPO	   treated	   and	   the	  
untreated	  grafts.	  Finally,	   the	  hematopoietic	  potential	  of	   the	  untreated	  CB	  cells	  units	  was	  
not	  negatively	  influenced	  by	  the	  co-­‐transplantation	  of	  TPO	  treated	  cells.	  	  	  
	  
Materials	  and	  Methods	  
	  
Umbilical	  cord	  blood	  (CB)	  collection.	  CB	  was	  drawn	  from	  the	  umbilical	  vein	  at	  birth	  at	  
>36	   weeks	   gestation	   after	   written	   informed	   consent	   from	   the	   mother	   at	   peripheral	  
hospitals	   in	   the	   Netherlands	   according	   to	   Netcord–FACT	   standards	   and	   with	   ethical	  
permission	   from	   the	   medical	   ethical	   board	   of	   the	   Leiden	   University	   Medical	   Center	  
(LUMC),	   Leiden,	   The	   Netherlands.	   Blood	   was	   collected	   by	   gravity	   drainage	   into	  
Macopharma	   collection	   bags	   containing	   21	   ml	   Citrate	   Phosphate	   Dextrose	   Adenine-­‐1	  
(Macopharma,	   Utrecht,	   The	   Netherlands).	   The	   blood	   was	   stored	   at	   4°C	   and	   processed	  
within	  48	  hours	  of	  collection.	  	  
	  
CD34+	   cell	   purification.	  Mononuclear	   cells	  were	   isolated	   from	  CB	  using	   a	   sterile	   Ficoll	  
density	   gradient	   (1.077	   g/cm3,	   Pharmacy	   LUMC).	   The	   CD34+	   cell	   fraction	   was	   isolated	  
from	  the	  mononuclear	  cell	  fraction	  by	  double	  CD34+	  cell	  selection	  using	  immunomagnetic	  
beads	   (Miltenyi	   Biotec	   GmbH,	   Bergisch	   Gladbach,	   Germany).	   The	   purity	   of	   the	   isolated	  
CD34+	   cell	   fraction	   was	   verified	   by	   flow	   cytometry	   (Beckman	   Coulter,	   Woerden,	   The	  
Netherlands)	   using	   CD45-­‐FITC	   and	   CD34-­‐PE	   antibodies	   (Beckman	   Coulter)	   and	   the	  
ISHAGE	   protocol.46	   Cells	   were	   cryopreserved	   in	   10%	   (v/v)	   DMSO	   in	   4%	   (w/v)	   human	  
serum	  albumin;	  (Pharmacy	  LUMC)	  in	  IMDM	  and	  stored	  at	  -­‐150˚C	  until	  use.	  
	  
Cultures.	   CD34+	   cells	   were	   cultured	   in	   24	   well	   sterile	   tissue	   culture	   plates,	   at	   a	  
concentration	  of	  1x105	  cells/ml,	   in	  Iscove’s	  modified	  Dulbecco’s	  medium	  (IMDM)	  (Gibco,	  
Breda,	  The	  Netherlands)	  supplemented	  with	  20%	  (v/v)	  AB	  heparinized	  plasma	  (Sanquin	  
Blood	   Supply	   Foundation,	   Rotterdam,	   The	   Netherlands),	   0.5	   mg/ml	   human	   transferrin	  
saturated	   with	   FeCl3.H20	   (Sigma,	   Zwijndrecht,	   The	   Netherlands),	   0.34%	   (v/v)	   human	  
serum	  albumin	  (20%	  (w/v)	  stock;	  Cealb®	  CLB,	  Amsterdam,	  The	  Netherlands),	  1%	  (v/v)	  
penicillin/streptomycin	   (PenStrep;	   Bio-­‐Whittaker,	   Verviers,	   Belgium),	   0.05	   mM	   β-­‐
mercapto-­‐ethanol	  (Sigma),	  and	  50	  ng/ml	  mpl-­‐ligand	  (Nplate)	  or	   thrombopoietin	  (TPO,	  a	  
kind	  gift	  from	  KIRIN	  Brewery	  Ltd.,	  Tokyo,	  Japan).	  At	  day	  7,	  the	  medium	  was	  refreshed	  by	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demi-­‐dilution,	  with	  medium	  containing	  50	  ng/ml	  TPO	  or	  Nplate.	  At	  day	  9,	  the	  cells	  were	  
split	  into	  two	  new	  wells	  and	  diluted	  1:1	  with	  medium	  without	  TPO	  and	  harvested	  on	  	  day	  
10.	   	   The	   total	   viable	   cell	   number	  was	   counted	   using	   flow	   cytometry	   and	   the	   degree	   of	  
expansion	   calculated.	   	   The	   composition	   of	   the	   cultured	   cells	   was	   analysed	   by	   flow	  
cytometry	   using	   mouse-­‐anti-­‐human	   CD45,	   CD61,	   CD34,	   CD3	   and	   CD56	   antibodies	   (all	  
from	  Beckman	  Coulter).	  It	  should	  be	  noted	  that	  previous	  comparisons	  of	  TPO	  with	  Nplate	  
in	   parallel	   cultures	   of	   CD34+	   cells	   from	   5	   donors	   gave	   similar	   expansion	   rates	   and	  
percentages	   of	   the	   predominant	   populations	   during	   culture.	   However,	   because	   of	  
accessibility	   to	   reagents,	  TPO	  was	   changed	   to	  Nplate	   in	   the	   last	   experiment.	   	   Cells	  were	  
analysed	   for	   HLA	   epitope	   expression	   before	   and	   after	   expansion	  with	   custom-­‐made,	   in	  
house	  human	  HLA	  epitope	  specific	  monoclonal	  antibodies.	  47-­‐49	  
	  
Transplantation	  in	  NSG	  mice.	  Female	  5-­‐6	  week	  old	  NSG	  mice	  (Charles	  River,	  l’Arbresle,	  
France)	   were	   kept	   in	   micro-­‐isolator	   cages	   in	   laminar	   flow	   racks	   in	   the	   LUMC	   animal	  
facilities.	   The	   animal	   ethical	   committee	   of	   the	   LUMC	   approved	   all	   animal	   experiments.	  
NSG	  mice	   received	  2.85	  Gy	   total	   body	   irradiation	  24	  hours	  before	   transplantation.	  Mice	  
were	   transplanted	   i.v.	   with	   cells	   (Fig.	   1)	   using	   4	   mice	   per	   group.	   Three	   dCB	  
transplantation	  experiments	  were	  performed	  with	  one	  CB	  donor	  pair	  for	  each	  experiment,	  
each	  experiment	  consisting	  of	  three	  groups	  of	  four	  mice	  within	  each	  group.	  Mice	  received	  
one	  of	  the	  following	  combinations	  of	  cells	   in	  their	  transplants	  (Fig.	  1):	  Group	  1)	  the	  first	  
donor	  CB	  TPO	   treated	  CD34+	   cells	   (X1)	   and	   the	   second	  donor	  CB	  untreated	  CD34+	   cells	  
(N2);	  Group	  2)	  the	  second	  donor	  CB	  TPO	  treated	  CD34+	  cells	  (X2)	  and	  the	  first	  donor	  CB	  
untreated	  CD34+	  cells	  (N1);	  and	  Group	  3)	  both	  CB	  donor	  cells	  infused	  as	  untreated	  CD34+	  
cells	  (N1	  and	  N2).	  For	  the	  analysis	  of	  the	  data,	  all	  mice	  that	  received	  one	  TPO	  treated	  graft	  
and	  one	  untreated	  graft	  (groups	  1	  and	  2)	  were	  compared	  with	  the	  mice	  that	  received	  two	  
untreated	   grafts	   (group	   3).	   The	   number	   of	   cells	   that	   each	   of	   the	   mice	   received	   are	  







Figure 1: Schematic representation of the experimental strategy. Isolated CD34+ cells from 6 human CB 
donors were divided into 3 donor pairs. The cells from each donor were then split into two parts and 
cryopreserved. One part was cultured with TPO for 9 days, the other part was thawed before transplantation. 
After TPO based culture, cells were combined with untreated cells from the other donor of the donor pair 
creating 6 groups with TPO treated cells and untreated cells (N+X group), and the untreated cells of both 
donors of the donor pairs were combined creating 3 groups with untreated cells from two donors. Cells from 
each group were transplanted in 4 NSG mice. 
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Analysis	  of	  peripheral	  blood	  after	   transplantation.	  Blood	  was	   collected	   from	   the	   tail	  
vein	   twice	   weekly	   during	   the	   first	   3	   weeks	   after	   transplantation	   and	   once	   weekly	  
thereafter.	   Blood	   collection	   and	   human	   platelet	   measurements	   were	   performed	   as	  
described	  previously.	   49-­‐51	  Briefly,	  human	  platelets	  were	   stained	  with	  non-­‐cross	   reactive	  
mouse-­‐anti-­‐human	  CD41-­‐PE	  and	  human	  CD45	  cells	  were	  stained	  with	  mouse	  anti	  human	  
CD45-­‐PC7	   (both	   Beckman	   Coulter).	   To	   determine	   donor	   origin	   HLA	   epitope	   specific	  
monoclonal	   antibodies	   conjugated	   with	   Alexa	   488	   or	   PE-­‐Dy647	   were	   used.	   47,49	  
Erythrocytes	  were	   lysed	  with	   IOTest3	   lysing	   solution	   (Beckman	   Coulter)	   for	   10	  min.	   at	  
room	   temperature.	   All	   cells	   were	   fixed	   with	   a	   0.1%	   (w/v)	   formaldehyde	   solution	  
(Pharmacy	  LUMC).	  Flow-­‐Count™	  fluorospheres	  (Beckman	  Coulter)	  were	  added	  to	  the	  cells	  
to	   enable	   the	   measurement	   of	   the	   absolute	   number	   of	   circulating	   human	   platelets.	  
Analysis	  was	  performed	  by	  flow	  cytometry	  (FC500,	  Beckman	  Coulter)	  using	  CXP	  software.	  
	  
Analysis	  of	   the	  bone	  marrow,	  spleen	  and	  blood	  after	  20	  weeks.	  Twenty	  weeks	  after	  
transplantation,	  mice	  were	  sacrificed	  and	  the	  bone	  marrow	  recovered	  from	  the	  femurs	  by	  
flushing	  with	   IMDM	   containing	   1%	   (v/v)	   PenStrep	   (Life	   Technologies)	   and	   10U/ml	  Na-­‐
heparin	   (Pharmacy	   LUMC).	   Single	   cell	   suspensions	  were	   prepared	   from	   the	   spleen	   that	  
were	  washed	  with	   IMDM	  with	   1%	   (v/v)	   PenStrep	   (Life	   Technologies)	   and	   10U/ml	   Na-­‐
heparin	  (Pharmacy	  LUMC)	  and	  the	  blood	  was	  collected	  via	  cardiac	  puncture.	  Evaluation	  of	  
human	  cell	  engraftment	  and	  the	  relative	  lineage	  distribution	  of	  the	  engrafted	  human	  cells	  
in	  the	  bone	  marrow,	  spleen	  and	  blood	  were	  performed	  with	  flow	  cytometry	  analysis.	  Cells	  
were	   labelled	   with	   rat-­‐anti-­‐mouse-­‐CD45-­‐PE	   (BD	   Biosciences,	   Breda,	   The	   Netherlands),	  
mouse-­‐anti-­‐human	   CD45-­‐FITC,	   CD33-­‐PE,	   CD34-­‐PE,	   CD19-­‐PE	   and	   CD3-­‐ECD	   (all	   from	  
Beckman	  Coulter),	  and	  the	  appropriate	  isotype	  controls.	  Subsequently,	  erythrocytes	  were	  
lysed	  with	  IO	  Test3	  lysing	  solution	  (Beckman	  Coulter)	  for	  10	  mins.	  at	  room	  temperature	  
and	   fixed	  with	   a	  0.1%	   (w/v)	   formaldehyde	   solution.	  Chimerism	  was	  analysed	  with	  HLA	  
specific	   antibodies.	   47-­‐49	   Analysis	   was	   performed	   by	   flow	   cytometry	   (FC500)	   using	   CXP	  
software	  (Beckman	  Coulter).	  
	  
Hematopoietic	   progenitor	   cell	   assays.	   To	   investigate	   whether	   bone	   marrow	   cells	  
harvested	   20	   weeks	   after	   transplantation	   contained	   human	   hematopoietic	   progenitor	  
cells	  (HPC),	  3	  different	  in	  vitro	  assays	  were	  used;	  HALO	  cultures,	  myeloid	  CFU	  cultures	  and	  
cobblestone	   area	   forming	   cell	   (CAFC)	   assays.	   The	   HALO	   assay	   (HemoGenix,	   Colorado	  
Springs,	   USA)	   was	   used	   to	   enumerate	   the	   number	   of	   colony	   forming	   cells.	   In	   short,	  
1.25x104	   human	   CD45+	   cells	   from	   the	   bone	  marrow	   of	   each	  mouse	  were	   suspended	   in	  
HALO	  master	  mix	  (containing	  EPO,	  GM-­‐CSF,	  IL-­‐2,	  IL-­‐3,	  Il-­‐6,	  IL-­‐7,	  SCF,	  TPO	  and	  Flt3-­‐L)	  and	  
incubated	  in	  a	  96	  well	  plate	  for	  6	  days	  at	  37˚C	  and	  5%	  CO2	  in	  a	  humidified	  incubator.	  After	  
6	  days,	  the	  cells	  were	  harvested	  from	  the	  wells	  and	  lysed,	  after	  which	  the	  ATP	  content	  was	  
measured	  with	  a	   luciferase/luciferin	  assay	  using	  a	  standard	  ATP	  curve	   to	  determine	  the	  
ATP	   concentration.	  Methocult	   CFU	   assays	   (H4434	   Classic,	   Stemcell,	   Vancouver,	   Canada)	  
were	  used	  to	  determine	  the	  capacity	  to	  differentiate	  into	  different	  myeloid	  lineages.	  	  Here,	  
2x104	  cells	  were	  suspended	  in	  classic	  Methocult	  medium	  and	  cultured	  for	  2	  weeks	  at	  37˚C	  
and	  5%	  CO2	   in	  a	  humidified	   incubator	  after	  which	  different	  differentiated	  colonies	  were	  
counted	  with	  an	   inverted	  microscope.	  CAFC	  assays	  were	  used	  to	  determine	  whether	   the	  
cells	   were	   primitive	   hematopoietic	   progenitor	   cells	   50,52.	   In	   short,	   6.4x104	   cells	   from	   1	  
representative	  mouse	  of	  each	  group	  for	  each	  experiment	  were	  seeded	  onto	  an	  irradiated	  
NIH3T3	   monolayer,	   growing	   on	   a	   collagen	   coated	   24	   well	   plate	   in	   CAFC	   medium	  
containing	  3%	  (v/v)	  FCS,	  3%	  (v/v)	  horse	  serum,	  glutamine,	  PenStrep,	  hydrocortisone	  and	  
β-­‐mercaptoethanol.	   Five	  wells/mouse	  were	   seeded	  with	   bone	  marrow	   cells.	   Cells	   were	  
55	  
	  
cultured	   for	   5	  weeks	   at	   37˚C	   and	   5%	   CO2	   in	   a	   humidified	   incubator	   and	   colonies	  were	  
counted	  at	  week	  4	  and	  week	  5	  with	  an	  inverted	  microscope.	  
	  
Statistics.	  All	  statistics	  were	  done	  using	  IBM	  SPSS	  Statistics	  20.	  Unless	  stated	  otherwise,	  
significance	  was	  determined	  with	  unpaired	  two	  tailed	  Student’s	  T	  tests	  or	  Mann	  Whitney	  






Culturing	  CD34+	  cells	  with	  thrombopoietin	  
The	  CD34+	   cell	  purity	  before	  TPO	  culture	  or	   transplant	  was	  92-­‐98%.	  After	   culturing	   the	  
human	  CB	  CD34+	  cells	  with	  TPO,	  the	  expression	  of	  CD61	  (ITGB3,	  GPIIIa	  or	  beta3	  integrin)	  
which	  forms	  part	  of	  the	  GPIIb/IIIa	  (CD41/CD61)	  complex	  that	  binds	  to	  vWF,	  fibronectin,	  
finrinogen	   and	   vitronectin	   36,43,50	   was	   measured.	   Three	   broad	   cell	   populations	   were	  
detected:	   1)	   total	   CD34+	   cells	   (both	   CD34+CD61+	   and	   CD34+CD61-­‐),	   2)	   CD34-­‐CD61-­‐	   cells	  
and	  3)	  CD34-­‐CD61+	  cells.	  As	  observed	  previously,43,44,50	  TPO	  induced	  differentiation	  from	  
CB	  CD34+	  cells	  first	  to	  the	  double	  negative	  CD34-­‐CD61-­‐	  population	  and	  then	  to	  a	  strongly	  
expanded	  CD34-­‐CD61+	  population	  (Figure	  2).	  With	  the	  relatively	  short	  TPO	  exposure,	  we	  
aimed	   to	   and	   succeeded	   in	   generating	   approximately	   as	   many	   CD34-­‐CD61-­‐	   cells	   as	   the	  
CD34+	   starting	   population.	   This	   double	   negative	   population	   has	   been	   shown	   to	   be	  
responsible	   for	   the	   earlier	   platelet	   recovery	   in	   in	   vivo	   models	   50.	   With	   the	   expected	  
significant	  inter-­‐experimental	  and	  inter-­‐donor	  variation,	  TPO	  exposure,	  however,	  also	  led	  
to	   a	   variable	   and	   sometimes	   higher	   reduction	   in	   absolute	   CD34+	   cell	   numbers	   for	   some	  
donors.	  However,	  both	  CD34+CD61-­‐	  and	  CD34+CD61+	  cells	  remained	  present	   in	   the	  graft	  







Figure 2: Number of cells and composition of 
the TPO treated graft of the 6 different donor 
grafts transplanted into the mice that received 
a TPO treated graft and an untreated graft.  
The transplanted cell number was based on 
equivalent CD34+ cell numbers in the original 
graft before culturing with TPO and in the 
untreated CB unit. Thus, the total number of cells 
in the dCB transplant was variable between all 
donors that received one TPO treated graft. 
Although all transplants included a fixed number 
of CD34+ cells from the untreated donor graft, the 
cell numbers that were culture derived from the 
same number of CD34+ cells of the other donor 
graft varied between 2.6x105 and 24.0x105 cells. 
Moreover, the composition of the grafts was also 
variable, although all grafts contained high 
numbers of expanded megakaryocytic cells, 
ranging from 2.0x105 to 17.3x105 cells and 












Table 1: Graft compositions after TPO expansion of CD34+ cells from the 6 
different donors used in the 3 different transplantation experiments. Shown are 
the results of each population after CD34 and CD61 analysis with flow cytometry; 
(graft 1,2 graft 3,4 and graft 5, 6 were respectively combined in the different 
experiments). Nr=number of. 
 
	  	  
CD34+CD61- nr CD34+ d0 nr CD34+ d10 fold expansion from CD34+ 
graft 1 188,520 78,732 0.42 
graft 2 195,260 249,080 1.28 
graft 3 92,420 12,164 0.13 
graft 4 96,890 50,922 0.53 
graft 5 97,450 31,715 0.33 
graft 6 93,200 9,846 0.11 
CD34+CD61+ nr CD34+ d0 nr CD34+CD61+ d10 fold expansion from CD34+ 
graft 1 188,520 12,636 0.07 
graft 2 195,260 91,010 0.47 
graft 3 92,420 4,871 0.05 
graft 4 96,890 7,424 0.08 
graft 5 97,450 14,030 0.14 
graft 6 93,200 35,373 0.38 
CD34-CD61- TNC d0 nr CD34-CD61- d10 fold expansion from TNC 
graft 1 200,000 377,136 1.89 
graft 2 200,000 318,535 1.59 
graft 3 100,000 34,629 0.35 
graft 4 100,000 82,276 0.82 
graft 5 100,000 141,126 1.41 
graft 6 100,000 64,592 0.65 
CD34-CD61+ TNC d0 nr CD34-CD61+ d10 fold expansion from TNC 
graft 1 200,000 503,496 2.52 
graft 2 200,000 1,736,375 8.68 
graft 3 100,000 203,337 2.03 
graft 4 100,000 135,378 1.35 
graft 5 100,000 992,129 9.92 










Total	   platelet	   and	   leukocyte	   recovery	   in	   the	   peripheral	   blood	   (PB)	   of	   NSG	   mice	  
receiving	  TPO-­‐treated	  and	  untreated	  CD34+	  cell	  grafts	  
At	  day	  4	  and	  onwards	  after	  transplantation	  of	  TPO	  treated	  and/or	  untreated	  CB	  cells	  into	  
NSG	  mice,	   human	   platelets	   were	   observed	   in	   the	   peripheral	   blood	   (PB).	   A	   significantly	  
higher	   number	   and	  more	   rapid	   increase	   of	   human	  platelets	   in	   the	  PB	  of	  mice	  was	   seen	  
when	  mice	  were	   transplanted	  with	   CD34+	   cells	  where	   those	   from	   one	   donor	  were	   first	  
cultured	  with	  TPO	  (Figure	  3A).	  Ten	  days	  after	  transplantation,	  however,	  a	  rapid	  increase	  
in	   platelet	   numbers	   was	   observed	   in	  mice	   that	   received	   two	   untreated	   and	   uncultured	  
grafts	  (N+N	  group).	  With	  a	  notable	  transient	  peak	  at	  2.5	  weeks	  post	  transplantation,	  the	  
platelet	   concentration	   in	   the	   N+N	  mice	   even	   exceeded	   the	   numbers	   found	   in	  mice	   that	  
received	  one	  TPO	  treated	  graft	  together	  with	  one	  untreated	  graft	  (N+X	  group)	  for	  up	  to	  6	  
weeks.	  	  From	  that	  time	  on,	  the	  differences,	  although	  still	  present	  between	  the	  two	  groups,	  
were	  no	  longer	  significant	  with	  platelet	  numbers	  gradually	  increasing	  in	  both	  groups	  up	  to	  
18	  weeks	  after	  transplantation	  (Figure	  3B).	  	  
The	   human	  CD45+	   cell	   concentrations	   in	   PB	   (signifying	   total	   human	   leukocytes)	   for	   the	  
different	   groups	   are	   shown	   in	   Figure	   4,	  with	   all	  mice	   showing	   a	   gradual	   increase	   in	   PB	  
human	  CD45+	  cells,	  which	  began	  to	  plateau	  for	  the	  N+N	  group	  at	  6	  weeks	  post-­‐transplant	  
and	  for	  the	  N+X	  group	  at	  week	  12	  post-­‐transplant	  (Figure	  3C).	  A	  trend	  towards	  a	  slightly	  
higher	   total	   human	   CD45+	   cell	   recovery	   was	   observed	   in	   mice	   from	   the	   N+N	   group	  
between	  2	   to10	  weeks	  post-­‐transplant,	  but	   the	  difference	   from	   the	  N+X	  group	  was	  only	  
statistically	  significant	  at	  week	  6	  after	  transplantation	  (p<0.05).	   
	  
Overall	   long	   term	   engraftment	   in	   bone	   marrow,	   spleen	   and	   peripheral	   blood	  
comparing	  the	  TPO	  treated	  and	  untreated	  grafts	  with	  the	  double	  untreated	  grafts	  
Twenty	   weeks	   after	   transplantation,	   the	   mice	   were	   sacrificed	   and	   their	   blood,	   bone	  
marrow	  and	  spleens	  showed	  that	  72-­‐89%	  of	  the	  CD45+	  cell	  population	  was	  derived	  from	  
human	   as	   opposed	   to	   murine	   leukocytes	   (Table	   2).	   Additionally,	   both	   myeloid	   and	  
lymphoid	   lineages	  were	  detected.	   In	   the	   lymphoid	   lineage,	  CD19+	  B	  cells	   far	  outweighed	  
the	  concentration	  of	  CD3+	  T	  cells	  (Table	  2).	  The	  percentage	  of	  human	  CD34+	  cells	  based	  on	  
the	  total	  human	  CD45+	  cell	  fraction	  in	  the	  bone	  marrow	  was	  greater	  than	  0.5%	  in	  all	  mice	  
at	  20	  weeks,	  with	  the	  variation	  observed	  between	  the	  3	  experiments	  being	  2.91±0.42	  %,	  
6.39±1.16	  %	  and	  0.80±1.11	  %	  for	  experiments	  1,	  2	  and	  3	  respectively.	  Between	  the	  N+N	  
and	  N+X	  groups,	  no	  significant	  differences	  in	  the	  percentages	  of	  lineage	  specific	  and	  CD34+	  
























Table 2. Mean Percentage (±SEM) of CD45+, 
CD34+, CD19+, and CD3+ cells of the total 
human CD45+ cells in the bone marrow (BM) and 
spleen of the mice that received a TPO cultured 
graft and an untreated graft and the mice that 
received two untreated grafts. The number of 
CD45+ cells in the different hematopoietic organs 
was approximately similar for the N+N and the N+X 
group. There were differences between the 
percentages of the different lineages, but these were 


































Fig. 3: Mean human platelet or leukocyte concentration (per µl PB, ±SEM) in the peripheral blood 
(PB) of the mice after transplantation. (♦, dashed line) one of the CB donor grafts was TPO cultured (X), 
(■, straight line) both CB donor grafts were untreated (N). A: first 5 weeks after transplantation, **p<0.05, 
*p<0.02. B: week 1-18 after transplantation. Cells from the N+X group had earlier platelet recovery in the first 
week after transplantation. In contrast, cells from the N+N group had higher platelet numbers 2 weeks after 
transplantation after which the platelet numbers of both groups both gradually increase towards a plateau. 





  BM 
 
one unit TPO treated Both units 
  other unit untreated  untreated 
CD45 88.7 (±2.2) 86.1 (±2.8) 
CD34 3.7 (±0.7) 2.7 (±0.8) 
CD19 57.2 (±4.1) 52.2 (±7.0) 
CD33 21.7 (±2.8) 20.8 (±4.5) 




one unit TPO treated Both units 
  other unit untreated  untreated 
CD45 71.9 (±3.2) 77.9 (±4.9) 
CD34 n.d. n.d. 
CD19 31.8 (±6.0) 46.1 (±9.5) 
CD33 5.9 (±2.2) 2.7 (±0.8) 




one unit TPO treated Both units 
  other unit untreated  untreated 
CD45 78.7 (±2.0) 73.9 (±3.7) 
CD34 n.d. n.d. 
CD19 n.d. n.d. 
CD33 n.d. n.d. 
CD3 3.0 (±1.1) 6.9 (±3.1) 
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In	  vitro	  assays	  of	  the	  engrafted	  bone	  marrow	  cells	  
Three	  assays	  were	  carried	  out	   to	  assess	   the	  human	  progenitor	  cell	  potential	  of	   the	  bone	  
marrow	  (BM)	  cells	  20	  weeks	  post-­‐transplant.	   	  We	  verified	  that	  colonies	  were	  not	  mouse	  
derived	  by	  performing	  similar	  cultures	  of	  the	  BM	  cell	  suspension	  from	  mice	  not	  receiving	  
human	  dCB	   transplants	   and	  none	  of	   these	   yielded	   colonies.	   First,	   using	   the	  HALO	  assay	  
where	   the	   mean	   concentration	   of	   ATP	   produced	   is	   a	   measure	   of	   proliferating	   cells,	   no	  
significant	  difference	  was	  observed	  between	  human	  cells	  derived	  from	  the	  bone	  marrow	  
from	   the	   N+X	   or	   N+N	   groups	   of	   mice	   (Figure	   4A).	   Secondly,	   to	   study	   whether	   the	  
engrafted	  human	  cells	  were	  capable	  of	  differentiating	  into	  different	  myeloid	  lineages,	  CFU	  
assays	   were	   performed	  with	   the	   same	  marrow	   samples.	   In	   both	   the	   N+N	   and	   the	   N+X	  
group,	   lineage	  forming	  potential	  was	  shown	  (Figure	  4B)	  by	  the	  generation	  of	  colonies	  of	  
all	   different	   myeloid	   lineages:	   Burst	   Forming	   Unit	   Erythroid	   (BFU-­‐E)	   colonies	  
(mean=9.1±3.7	  colonies	   for	   the	  mice	   from	  the	  N+X	  group	  and	  9.7±5.1	   for	   the	  N+N	  mice,	  
the	  Granulocyte/Macrophage	  colonies	  (CFU-­‐GM,	  mean=63.2±10.9	  for	  the	  mice	  of	  the	  N+X	  
group	  and	  94.0±39.9	   for	   the	  mice	  of	   the	  N+N	  group)	  and	  the	  Granulocyte/	  Erythrocyte/	  
Macrophage/	  Megakaryocyte	  colonies	  (CFU-­‐GEMM,	  8.8±3.2	  for	  the	  mice	  of	  the	  N+X	  group	  
graft	  and	  13.0±9.2	   for	   the	  mice	  of	   the	  N+N	  group).	  Although	  bone	  marrow	  from	  mice	  of	  
the	  N+N	  group	  on	  average	  formed	  more	  colonies	  of	  all	  different	  myeloid	  lineages,	  none	  of	  






























Figure 4, A: Mean (±S.E.M.) ATP levels produced by expanded cells harvested from the 
bone marrow of the mice 20 weeks after transplantation. Shown is the mean ATP 
concentration/well of all mice of the groups that received one TPO treated graft and an 
untreated graft (black bar) and the mice that received two untreated grafts (white bar). There 
was no difference in ATP production after HALO culture between the N+X and the N+N group. 
B: Mean number of different myeloid colonies formed by the engrafted bone marrow 
cells of a mouse of each representative group of each experiment after 2 weeks of 
culture in Methocult. Cells from the N+N group produced more colonies than cells from the 
N+X group, but this difference was not significant. 
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Finally,	  we	  used	  the	  in	  vitro	  CAFC	  assay	  to	  show	  that	  the	  harvested	  bone	  marrow	  from	  the	  
transplanted	   mice	   still	   contained	   primitive	   cells,	   since	   the	   CAFC	   assay	   is	   used	   as	   a	  
surrogate	  assay	  for	  predicting	   long	  term	  engraftment	  potential	  52.	   	  Although	  cells	   from	  a	  
representative	  mouse	  of	  each	  group	  were	  capable	  of	  generating	  CAFC	  colonies	  in	  at	  least	  2	  
of	   the	   five	  wells	   (results	   not	   shown),	   less	   CAFC	   colonies	   could	  be	   grown	   from	   the	  bone	  
marrow	  cells	  of	  the	  mice	  that	  received	  mixed	  transplants.	  These	  culture	  results	  of	  all	  bone	  
marrow	  cells	  were	  followed	  up	  by	  in	  vivo	  analysis	  of	  donor	  specific	  cell	  counts	  both	  in	  the	  
PB	  and	  in	  the	  marrow.	  
	  
Platelet	  and	  leukocyte	  recovery	  in	  the	  peripheral	  blood	  comparing	  the	  TPO	  treated	  
and	  the	  untreated	  donor	  grafts	  	  
To	   analyze	   how	   much	   the	   TPO	   treated	   and	   the	   untreated	   donor	   grafts	   contribute	   to	  
platelet	  production,	  PB	  samples	  were	  stained	  with	  present	  on	  one	  and	  not	   the	  other	  co-­‐
transplanted	  graft.	  Since	  the	  HLA	  staining	  of	  platelet	  is	  not	  absolute,	  we	  could	  analyze	  the	  
donor	  contribution	  in	  two	  donor	  pairs	  only	  (n=12	  mice).	  Figure	  5A	  show	  that	  the	  platelets	  
produced	  in	  the	  first	  week	  after	  transplantation	  were	  indeed	  derived	  from	  the	  CD34+	  cells	  
that	   had	   been	   TPO	   treated.	   In	   contrast,	   when	   the	   graft	   was	   not	   TPO	   treated,	   platelet	  
production	   commenced	   after	   week	   one	   only.	   However,	   from	   two	   weeks,	   the	   untreated	  
CD34+	   cells	   produced	   higher	   platelet	   numbers	   and	   this	   progressed	   throughout	   the	  
remainder	   of	   the	   experiment.	   Total	   CD45+	   leukocyte	   production	   from	   the	   TPO	   treated	  
CD34+	  cells	  was	  significantly	   impaired.	  Although	  detectable	  CD45+	   leukocyte	   levels	  were	  
observed	   after	   1.5	   weeks	   from	   both	   the	   TPO	   cultured	   unit	   and	   the	   untreated	   unit,	   the	  
increase	  in	  leukocytes	  was	  more	  rapid	  when	  the	  unit	  from	  a	  non	  TPO	  cultured	  graft	  and	  
the	   total	   leukocyte	   production	   from	   this	   untreated	   graft	   was	   higher	   throughout	   the	  
experiment	   (Figure	   5B).	   Leukocyte	   production	   from	   the	   TPO	   cultured	   graft,	   however,	  
remained	   present	   and	   constant	   although	   at	   a	   lower	   level	   than	   leukocytes	   from	   the	  
untreated	  graft.	  	  
	  
Bone	   marrow	   chimerism	   in	   mice	   co-­‐transplanted	   with	   one	   TPO	   treated	   and	   one	  
untreated	  graft	  
In	   agreement	   with	   the	   results	   in	   peripheral	   blood,	   human	   hematopoiesis	   (i.e.	   human	  
CD45+	   cells)	   in	   the	   bone	   marrow	   of	   mice	   from	   the	   N+X	   group	   20	   weeks	   after	  
transplantation	   on	   average	   demonstrated	   increased	   human	   hematopoiesis	   from	   the	  
untreated	   graft	   compared	   to	   the	   TPO	   treated	   graft	   (66±4%	   vs.	   34±4%	   mean+SEM).	  
Assuming	   that	   the	   untreated	   donor	   grafts	   would	   theoretically	   contribute	   equally	   to	  
engraftment	   (i.e.	   the	   contribution	   of	   each	   graft	   is	   50%),	   the	   skewing	   in	   favor	   of	   the	  
untreated	   donor	   graft	   was	   highly	   significant	   (p<0.001).	   This	   skewed	   chimerism	   in	   the	  
bone	  marrow	  for	  human	  CD45+	  cells	  (Table	  3)	  was	  also	  observed	  for	  CD34+	  cells	  (p<0.01)	  
and	   B	   lymphoid	   cells	   (CD19+,	   p<0.01),	   while	   the	   dominance	   was	   less	   clear	   for	   T	   cells	  
(CD3+,	  p=0.555)	  and	  myeloid	  cells	  (CD33+,	  p=0.314).	  Indeed,	  in	  the	  N+N	  group,	  chimerism	  
as	  expected	  was	  equal	  between	  the	  two	  donors.	  These	  combined	  results	  indicate	  that	  both	  
the	  untreated	  graft	  and	   the	  TPO	  cultured	  graft	   can	  provide	   long	   term	  reconstitution	  but	  
that	   the	   initial	  difference	   in	  stem	  cell	  numbers	  between	  the	  TPO	  cultured	  and	  untreated	  











Figure 5: Mean (±SEM) platelet (A) 
and leukocyte (B) concentrations in 
the PB of one of the donor grafts in 
experiments 1 and 2 when the donor 
graft was untreated (♦, straight line) 
or TPO cultured (■, dashed line). Cells 
from the TPO cultured donor graft had 
earlier platelet recovery in the first week 
after transplantation. In contrast, cells 
from the N+N group had higher platelet 
numbers from 2 weeks after 
transplantation up to the end of the 
experiment. Leukocyte numbers were 
higher for the untreated donor graft 

































Table 3. Mean (±SEM) contribution to 
the BM cells of the TPO cultured graft 
and the untreated graft in the mice 
receiving cells from a TPO treated 
graft and an untreated graft (N+X 
Group). On average dominance came 








Fraction TPO treated unit 
 Untreated 
unit 
CD45 34.2 (±4.3) 65.8 (±4.3) 
CD34 35.0 (±4.9) 65.0 (±4.9) 
CD19 35.7 (±4.8) 64.3 (±4.8) 
CD33 43.8 (±6.0) 56.2 (±6.0) 
CD3 45.2 (±8.0) 54.4 (±8.0) 
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Platelet	   and	   leukocyte	   recovery	   in	   the	   peripheral	   blood	   and	   long	   term	   bone	  
marrow,	  spleen	  and	  blood	  chimerism	  mediated	  by	  the	  untreated	  donor	  graft	  when	  
it	  is	  transplanted	  with	  a	  TPO	  treated	  or	  a	  untreated	  donor	  graft	  
Using	  the	  same	  donor	  specific	  HLA	  antibodies	  used	  for	  the	  analysis	  of	  the	  contribution	  of	  
each	   donor	   graft	   in	   the	   N+X	   group,	   we	   next	   studied	   if	   the	   engraftment	   efficacy	   of	   the	  
untreated	  CD34+	  cells	  from	  one	  donor	  could	  be	  changed	  by	  the	  presence	  of	  TPO	  treated	  or	  
of	   untreated	   cells	   of	   another	   donor.	   During	   the	   experiment,	   human	   platelet	   numbers	  
originating	   from	   the	   untreated	   donor	   CD34+	   cells	   were	   not	   significantly	   different	  
regardless	   of	   whether	   they	   were	   co-­‐transplanted	   with	   TPO	   cultured	   cells	   or	   untreated	  
CD34+	   from	   another	   donor	   (Figure	   6A,	   n=16).	   On	   the	   contrary,	   a	   temporarily	   higher	  
number	  of	  total	  human	  CD45+	  leukocytes	  originated	  from	  the	  untreated	  graft	  when	  it	  was	  
co-­‐transplanted	  with	  a	  TPO	  cultured	  graft.	  This	  difference	  became	  clear	  at	  week	  2	  and	  was	  
significant	  at	  week	  4	  and	  5	  after	  transplantation	  (Figure	  6B,	  p<0.05	  for	  both).	  The	  longer	  
term	   human	   CD45+	   repopulation	   in	   the	   PB	   was	   not	   significantly	   changed	   by	   the	  










Figure 6: Human platelet (A) and 
leukocyte (B) concentrations of one 
of the donors in experiments 1 and 2 
when an untreated graft was co-
transplanted with either another 
untreated graft (♦, straight line) or a 
TPO cultured graft (■, dashed line). 
*p<0.05. Platelet production was 
approximately equal throughout the 
experiment, regardless of co-
transplantation with TPO treated or 
untreated cells. Leukocyte production 
was slightly faster when untreated cells 
were co-transplanted with TPO treated 
cells as compared to co-transplantation 




















Thrombocytopenia	   is	   a	   common	   complication	   of	   allogeneic	   HSC	   transplantation,	   with	  
platelet	   recovery	   being	   particularly	   delayed	   after	   CB	   HSC	   transplants1,2,4,53.	   Transplant	  
patients	   may	   also	   present	   with	   secondary	   failure	   of	   platelet	   recovery54.	  
Thrombocytopenia	  at	  day	  +100	  and	  secondary	  failure	  of	  platelet	  recovery	  post	  allogeneic	  
HSC	   transplant	   have	   been	   associated	   with	   poorer	   survival.	   45,54	   Current	   expansion	  
protocols	   for	   one	   CB	   unit	   in	   a	   dCB	   transplant	   setting	   still	   do	   not	   show	   substantial	  
improvements	  in	  platelet	  recovery	  when	  transplant	  outcomes	  are	  compared	  with	  current	  
rather	   than	   with	   historical	   outcome	   data	   27,28,30.	   Furthermore,	   given	   that	   their	  
administration	   can	   induce	   reticulin	   formation	   in	   the	   bone	   marrow	   and	   possibly	   bone	  
marrow	   fibrosis	   and	   that	   TPO	   in	   the	  myeloablative	   	   ransplant	   setting	   failed	   to	   improve	  
platelet	   recovery,	   the	   use	   of	   thrombopoietin	   receptor	   agonists	   to	   promote	   platelet	  
recovery	   post-­‐transplant	   still	   requires	   additional	   safety	   and	   efficacy	   studies.	  
35Interestingly,	  platelet	  primed	  or	  biased	  HSCs	  have	  been	   identified	   in	  mice.	   41,55,56	  Their	  
phenotypic	   profiles	   have	   not	   yet	   been	   analyzed	   in	   a	   single	   study	   from	   one	   group	   and	  
further	   subset	   analysis	   is	   needed.	   thrombopoietin	   receptor	   agonists	   to	  promote	  platelet	  
recovery	  post-­‐transplant	  still	  requires	  additional	  safety	  and	  efficacy	  studies.	   35	  However,	  
current	   combined	   results	   from	   three	   groups	   suggest	   that	   they	   are	   c-­‐kithi+	   and	   CD41+,	  
dependent	  on	  TPO,	  capable	  of	  generating	  long	  term	  myeloid	  and	  lymphoid	  biased	  HSCs	  as	  
well	  as	  generating	  in	  vitro	  CD41+CD61+	  megakaryocytes,	  and	  are	  responsible	  for	  early	  and	  
longer	  term	  platelet	  recovery.	  41,55,56	  The	  therapeutic	  importance	  of	  such	  specialized	  HSC	  
subsets	  in	  human	  HSC	  transplantation	  remains	  to	  be	  defined.	  In	  this	  paper,	  we	  show	  that	  
TPO	   treated	  human	  CD34+	  grafts	   from	  one	  CB	  donor	  can	  successfully	  be	  combined	  with	  
untreated	  CD34+	  cells	  from	  another	  donor	  to	  a)	  improve	  short	  term	  platelet	  engraftment	  
from	  the	  TPO	  treated	  cell	  graft	  and	  to	  b)	  generate	  long	  term	  hematological	  reconstitution	  
in	  an	  immune	  deficient	  mouse	  model	  of	  dCB	  transplantation,	  while	  c)	  the	  untreated	  CD34+	  
HSCs	   that	   are	   co-­‐transplanted	   as	   a	   safety	   net	   are	   not	   hampered	   in	   their	   engraftment	  
potential	   by	   the	   CD34+	   cell	  manipulation	  with	  TPO	   in	   the	   other	   cord	   blood	   graft.	   These	  
observations	   are	   important	   in	   two	   respects.	   The	   first	   is	   because	   delayed	   platelet	  
engraftment	   in	   the	   weeks	   following	   dCB	   transplantation	   remains	   a	   significant	  
problem,1,2,4,53	  which	   has	   not	   yet	   been	   substantially	   addressed	   in	   the	   clinical	   transplant	  
setting.	  The	  second	  is	   that,	   if	  a	  platelet	  primed	  HSC	  exists	   in	  the	  human	  as	   it	  does	   in	  the	  
mouse,	  we	  now	  have	  developed	  a	  validated	   in	   vivo	   dCB	   transplant	  model	  with	  which	   to	  
identify	  and	  study	  the	  efficacy	  of	  the	  putative	  human	  TPO	  dependent	  platelet	  biased	  HSC,	  
and	   to	   define	   its	   lineage	   relationships	   in	   the	   context	   of	   other	   identified	   human	   HSPC	  
subsets	  and	  following	  their	  interactions	  with	  specific	  factors,	  agonists	  or	  antagonists.	  57,58	  
The	   studies	   presented	   here	   build	   on	   our	   previous	   short	   term	   (6	   week)	   engraftment	  
studies	  with	  single	  CB	  transplants	   in	   immune	  deficient	  mice,	  where	  we	  have	  shown	  that	  
TPO	   treatment	   can	   improve	   early	   platelet	   recovery	   and	   that	   this	   recovery	   is	   mostly	  
dependent	  on	   the	  TPO	  mediated	  generation	  of	  CD34-­‐CD61-­‐	   cells.	   44,50	   Importantly	   in	  our	  
current	  studies,	  by	  analyzing	  engraftment	  using	  donor	  specific	  HLA	  antibodies	  in	  the	  dCB	  
transplant	  setting,	  we	  could	  further	  demonstrate	  that	  this	  improved	   in	  vivo	  early	  platelet	  
recovery	  (around	  day	  7)	  was	  indeed	  originating	  from	  TPO	  treated	  CD34+	  cell	  graft,	  while	  
the	  untreated	  CD34+	  cells	  formed	  platelets	  at	  later	  time	  points	  (significantly	  from	  around	  
week	  2)	  and	  dominated	  over	  the	  TPO	  cultured	  cells.	  	  
We	  limited	  the	  number	  of	  variables	  in	  our	  experiments	  because	  we	  wanted	  to	  specifically	  
investigate	   if	   residual	  CD34+	  HSPCs	  after	  TPO	  mediated	  culture	  could	  contribute	   to	   long	  
term	   hematological	   reconstitution	   and	   if	   the	   TPO	   treated	   graft	   could	   influence	   the	  
engraftment	   of	   untreated	   CD34+	   HSPCs	   in	   a	   double	   cord	   blood	   setting.	   When	   we	   co-­‐
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transplanted	  untreated	  CD34+	  cells	   from	  one	  donor	  graft	  with	  TPO-­‐treated	  or	  untreated	  
CD34+	   cells	   from	   a	   second	   donor	   graft,	   we	   could	   show,	   by	   using	   donor	   specific	   HLA	  
antibodies,	   that	   TPO	   treated	   CD34+	   cells	   generated	   fewer	   CD45+	   cells	   in	   the	   peripheral	  
blood	   of	   NSG	  mice	   than	   the	   same	   graft	   which	   had	   not	   been	   cultured	   in	   TPO	  when	   co-­‐
transplanted	  with	  a	  non	  expanded	  graft.	  This	  could	  be	  attributed	  to	  an	  absolute	  loss	  of	  a	  
proportion	  of	  CD34+	  HSPCs	  or	  platelet	  biased	  HSCs,	  during	  the	  TPO	  based	  culture	  because	  
of	  their	  redirection	  towards	  platelet	  production.	  Thus,	  although	  its	  contribution	  was	  lower	  
when	   compared	   to	   grafting	   untreated	   CB	   CD34+	   cells,	   we	   could	   show	   that	   the	   TPO	  
cultured	  CD34+	  graft	  provided	  a	  stable	  and	  substantial	  contribution	  to	  longer	  term	  platelet	  
recovery	   and	   hematological	   reconstitution	   in	   in	   vivo	   dCB	   transplants,	   indicating	   that	   a	  
significant	  proportion	  of	  platelet	  biased	  HSCs	  might	  also	  be	  maintained	  in	  short	  term	  TPO	  
mediated	   cultures,	   as	   shown	   before.	   50	   This	   finding	  was	   corroborated	   by	   our	   CAFC	   and	  
CFU	  assays,	  which	  are	  reported	  to	  correlate	  with	  hematopoietic	  stem	  cell	  engraftment.	  In	  
bone	  marrow	  of	  all	  mice,	  the	  long	  term	  culture	  initiating	  (CAFC)	  cells	  were	  maintained	  but	  
again	   fewer	  of	   these	  cells	  were	   found	   in	  bone	  marrow	  from	  mice	   that	  received	  one	  TPO	  
cultured	  CD34+	  graft.	   	  Similarly,	  bone	  marrow	  cells	   from	  mice	  receiving	  two	  non	  treated	  
CB	  CD34+	  grafts	  formed	  on	  average	  a	  greater	  number	  of	  myeloid	  colonies	  than	  those	  from	  
mice	  receiving	  one	  untreated	  and	  one	  TPO	  cultured	  CB	  graft;	  however,	  in	  both	  groups	  all	  
types	  of	  colonies	  were	  present.	  Our	  combined	  results	  therefore	  show	  a	  consistent	  ,	  clearly	  
lower	   number	   of	   HSPCs	   in	   the	   bone	  marrow	   of	   combined	   untreated	   and	   TPO-­‐cultured	  
graft	  (N+X)	  transplanted	  mice,	  which	  is	  in	  agreement	  with	  the	  decreased	  CD34+	  HSPC	  and	  
possibly	  platelet	  biased	  HSC	  content	  in	  these	  combined	  grafts.	  Notwithstanding	  this,	  there	  
was	  no	  difference	   in	   the	  combined	  hematopoietic	  repopulation	  quality	  between	  the	  N+X	  
and	   N+N	   group.	   While	   the	   percentage	   of	   human	   chimerism	   in	   the	   bone	   marrow	   was	  
higher	  than	  80%	  in	  both	  groups	  reflecting	  the	  use	  of	  an	  optimal	  transplanted	  CD34+	  cell	  
dose	   in	  our	  experiments,	  a	  smaller	  number	  of	   transplanted	  untreated	  CD34+	  cells	   in	  one	  
graft	   might	   not	   be	   able	   to	   compensate	   for	   the	   TPO	   induced	   CD34+	   HSPC	   loss	   in	   the	  
cultured	  graft	  and	  might	  thus	  eventually	  compromise	  the	  combined	  engraftment	  in	  mice.	  
This	  requires	  further	  study	  using	  defined	  subsets	  of	  HSPCs.	  Complementing	  these	  studies,	  
we	   found	   that	   the	   untreated	   CD34+	   cells	   produced	   more	   CD45+	   leukocytes	   when	   co-­‐
transplanted	   with	   a	   TPO	   cultured	   graft	   than	   when	   co-­‐transplanted	   with	   a	   graft	   of	  
uncultured	   CD34+	   cells.	   This	   stimulatory	   effect	   needs	   to	   be	   confirmed	   and	   further	  
investigated.	   Importantly	   however,	   the	   hematopoietic	   repopulation	   capacity	   of	   un-­‐
manipulated	   CD34+	   cells	   as	   safety	   back	   up	   for	   manipulated	   CB	   transplantations	   is	   not	  
hampered	  by	  co-­‐transplantation	  of	  TPO	  manipulated	  CD34+	  cells.	  	  	  	  
In	   conclusion,	   we	   have	   developed	   an	   in	   vivo	   transplant	  model	   with	  which	   to	   study	   the	  
relative	   contribution	   to	   short	   and	   longer	   term	   platelet	   recovery	   and	   longer	   term	  
hematological	  reconstitution	  of	  and	  competition	  between	  human	  CB	  grafts	  from	  different	  
donors	  or	  lineage	  biased	  HSC	  subsets	  from	  these	  grafts.	  Furthermore,	  our	  studies	  allow	  us	  
to	  also	  analyze	  the	  effects	  of	  exogenous	  factors	  on	  expanding	  the	  content	  of	  or	  enhancing	  
the	   differentiation	   of	   such	   cell	   subsets	   prior	   to	   transplant.	   Such	   approaches	   will	  
undoubtedly	   provide	   us	  with	   strategies	   to	   enhance	   both	   short	   and	   longer	   term	  platelet	  
recovery	   as	   well	   as	   to	   manipulate	   the	   HSC	   and	   HSPC	   subset	   content	   of	   such	   grafts	   for	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BACKGROUND:	  Expansion	  of	  human	  cord	  blood	  CD34+	  cells	  with	  thrombopoietin	  (TPO)	  
can	  accelerate	  delayed	  platelet	   recovery	   following	   transplantation	   into	   immunodeficient	  
mice.	  Clinical	   implementation,	  however,	  will	  depend	  on	  practical	  and	  effective	  protocols.	  
The	   best	   timing	   of	   TPO-­‐	   expansion	   in	   relation	   to	   cryopreservation	   in	   this	   respect	   is	  
unknown.	  	  	  
	  
STUDY	   DESIGN	   AND	   METHODS:	   In	   this	   study,	   we	   evaluated	   whether	   the	   order	   of	  
cryopreservation	   and	   TPO	   expansion	   affected	   the	   expansion	   rate	   and	   numbers	   of	  
clonogenic	   hematopoietic	   progenitor	   cells	   in	   vitro	   or	   platelet	   and	   longer	   term	  
hematopoietic	  repopulation	  in	  NOD	  SCID	  mice	  in	  vivo.	  
	  
RESULTS:	  Our	  results	  demonstrate	  higher	  expansion	  rates	  and	   the	  generation	  of	  higher	  
numbers	   of	  multi-­‐lineage	   and	  megakaryocytic	   progenitors	   (CFU-­‐GEMM	   and	   CFU-­‐Mk)	   in	  
vitro	  when	   freshly	   isolated	   cord	  blood	  CD34+	   cells	   are	   first	   cultured	  with	  TPO	  and	   then	  
cryopreserved	   and	   thawed	   as	   compared	   to	   TPO	   expansion	   post	   CD34+	   cell	  
cryopreservation.	   In	   contrast,	   the	   cells	  produced	  with	   the	   latter	   strategy	   showed	  higher	  
expression	  of	  CD62L	  and	  a	  superior	  SDF-­‐1α	  mediated	  migration.	  This	  might	  play	  a	  role	  in	  
an	  also	  observed	  superior	  early	  platelet	  recovery	  after	  transplantation	  of	  these	  cells	  into	  
NOD	   SCID	   mice.	   The	   hematopoietic	   engraftment	   in	   the	   bone	   marrow	   six	   weeks	   after	  
transplantation	  was	  not	  different	  between	  the	  two	  strategies.	  
	  
CONCLUSION:	   Although	   TPO	   expansion	   before	   cryopreservation	   would	   yield	   higher	  
nucleated	  cell	  and	  clonogenic	  myeloid	  and	  megakaryocyte	  cell	  numbers	  and	  enable	  earlier	  
availability,	   cord	   blood	   TPO	   expansion	   after	   cryopreservation	   is	   likely	   to	   be	   clinically	  
more	  effective,	  despite	  the	  lower	  number	  of	  cells	  obtained	  after	  expansion.	  Moreover,	  the	  






































































Allogeneic	  cord	  blood	  (CB)	  transplantation	   is	  used	  as	  an	  alternative	   for	  bone	  marrow	  or	  
mobilized	   peripheral	   blood	   grafts	   when	   no	   suitable	   HLA	   matched	   related	   or	   unrelated	  
donor	   is	   available.1,2	   CB,	   however,	   contains	   a	   limited	   number	   of	   hematopoietic	  
stem/progenitor	   cells	   and	   is,	   compared	   to	   other	   graft	   sources,	   associated	   with	   longer	  
intervals	   to	   reach	   safe	   neutrophil	   and	   platelet	   levels.	   Double	   CB	   transplantation	   can	  
increase	  the	  cell	  content,	  but	  is	  associated	  with	  poorer	  platelet	  recovery	  and	  a	  higher	  risk	  
of	   grade	   II	   and	   IV	   acute	   and	   extensive	   chronic	   graft	   versus	   host	   disease.3	   Moreover,	  
delayed	  immune	  reconstitution	  is	  observed	  after	  both	  single	  and	  double	  CB	  transplants.1-­‐3	  	  	  
One	  strategy	  to	  overcome	  this	  problem	  is	  to	  expand	  (the	  whole	  or	  part	  of)	  a	  single	  CB	  unit	  
in	   such	   a	   way	   that	   long	   term	   hematological	   reconstitution	   is	   preserved	   while	   early	  
neutrophil	   and	   platelet	   engraftment	   is	   enhanced.	   Another	   strategy	   is	   to	   combine	   an	  
expanded	   CB	   graft	   to	   bridge	   the	   engraftment	   delay	  with	   an	   un-­‐manipulated	   CB	   graft	   to	  
safeguard	   long-­‐term	   hematological	   reconstitution.4	   In	   this	   regard,	   substantial	  
improvements	  in	  early	  neutrophil	  recovery	  have	  been	  demonstrated	  in	  clinical	  trials	  that	  
combined	   post	   cryopreservation	   expanded	   CD34+	   cells	   from	   a	   single	   CB	   unit	   with	   an	  
unmanipulated	  CB	  unit.5-­‐7	  	  	  
We	   have	   previously	   developed	   a	   10	   day	   thrombopoietin	   (TPO)	   protocol	   for	   expansion/	  
differentiation	   of	   human	   CB	   CD34+	   cells	   which	   has	   shown	   to	   improve	   early	   platelet	  
recovery	   in	   immunodeficient	  mice	  when	  compared	   to	   transplantation	  with	  unexpanded,	  
cryopreserved	   CB	   CD34+	   cells.	  With	   this	   protocol,	   the	   engraftment	   capacity	   in	   the	   bone	  
marrow	   was	   maintained.8-­‐11	   However,	   engraftment	   and	   longer-­‐term	   hematological	  
reconstitution	  is	  influenced	  not	  only	  by	  hematopoietic	  stem	  and	  progenitor	  cell	  numbers,	  
but	   also	   by	   the	   viability	   and	   functionality	   of	   these	   cells.12	   The	   time	   and	   the	   storage	  
temperature	   prior	   to	   cryopreservation	   of	   CB	   units	   are	   well	   recognized	   as	   important	  
determinants	   affecting	   in	   vitro	   characteristics	   such	   as	   post	   thaw	   viability,	   recovery	   and	  
hematological	   engraftment	   post-­‐transplant	   in	   human	   recipients.13-­‐16	   The	   effect	   of	  
cryopreservation	  on	   the	  outcome	  of	  ex	  vivo	  expansion	   is	  however	   indistinct	  and	  mainly	  
compared	  by	  in	  vitro	  yields	  and	  viability	  parameters	  and	  less	  often	  in	  clinical	  studies.17-­‐20	  
Although	  adequate	  proliferation	  and	  differentiation	  ability	  of	  CD34+	  cells	   in	  culture	  with	  
TPO	  has	  been	  observed	  after	  thawing	  of	  CB	  CD34+	  cells,9,11	  several	  studies	  have	  reported	  a	  
decrease	   in	   various	   colony	   formation	   assays	   after	   cryopreservation	   and	   thawing	   of	  
expanded	  megakaryocyte	  progenitor	  cells14,21.	  Moreover,	  this	  resulted	  in	  a	  high	  cell	  death	  
and	  a	  dramatic	  loss	  of	  post-­‐thaw	  CFU-­‐GEMM	  and	  CFU-­‐Mk	  progenitors.19	  
Since	  the	  effect	  of	  cryopreservation	  on	  ex	  vivo	  expansion	  and	  subsequent	  transplantation	  
of	  UCB	  CD34+	  cells	  is	  equivocal,	  expansion	  protocols	  require	  validation.	  	  
In	   this	   study,	   we	   evaluated	   and	   compared	   whether	   the	   order	   of	   expansion	   and	  
cryopreservation,	   i.e.	   expansion	   before	   or	   after	   cryopreservation,	   affects	   the	   expansion	  
capacity	   and	   differentiation	   ability	   in	   vitro,	   and	   the	   platelet	   recovery	   and	   engraftment	  
capacity	  in	  NOD	  SCID	  mice.	  To	  investigate	  this,	  we	  compared	  isolated	  CB	  CD34+	  cells	  from	  
the	  same	  UCB	  unit	  and	  expanded	  these	  cells	  in	  parallel	  pre-­‐	  and	  post-­‐cryopreservation.	  To	  
achieve	   this,	  one	  half	  of	   the	   freshly	   isolated	  CD34+	  cells	  was	   immediately	  TPO	  expanded	  
and	   subsequently	   cryopreserved	   and	   thawed	   (Expanded/Cryopreserved/Thawed:	   ECT	  
pathway)	  while	   the	   other	   half	  was	   cryopreserved	   directly	   after	   isolation	   and	   expanded	  
after	  thawing	  (Cryopreserved/	  Thawed/Expanded:	  CTE	  pathway).	  In	  vitro	  characteristics	  
-­‐	   fold	   expansion,	   differentiation	   and	   migratory	   capacity	   -­‐	   and	   in	   vivo	   characteristics	   -­‐	  
platelet	   recovery	  and	  6-­‐week	  hematological	   engraftment	   capacity	   in	   a	  NOD	  SCID	  mouse	  




Materials	  and	  Methods	  
	  
Thrombopoietin	  expansion	  of	  cord	  blood	  CD34+	  cells.	  Umbilical	  cord	  blood	  (CB)	  (>36	  
weeks	  gestation)	  was	  obtained	  after	  written	  informed	  consent	  from	  the	  mother	  collected	  
into	  25	  ml	  Citrate	  Phosphate	  Dextrose	  Adenine-­‐1	  and	  stored	  for	  a	  maximum	  of	  48	  hours	  at	  
4°C	  until	  processed.	  The	  protocol	  was	  approved	  by	  the	  LUMC	  Medical	  Ethical	  Committee.	  
Mononuclear	   cells	  were	   isolated	   on	   Ficoll	   (<1.077	   g/cm3,	   Pharmacy	   LUMC,	   Leiden,	   The	  
Netherlands).	   CD34+	   cells	   were	   then	   isolated	   by	   CD34+	   magnetic	   cell	   sorting	   (Miltenyi	  
Biotec	  GmbH,	  Bergisch	  Gladbach,	  Germany).	  The	  purity	  of	  the	  isolated	  CD34+	  cell	  fraction	  
was	  verified	  by	  flow	  cytometry	  with	  CD45-­‐FITC	  and	  CD34-­‐PE	  (all	  from	  Beckman	  Coulter,	  
Mijdrecht,	   The	   Netherlands).7-­‐9	   5x104	   CD34+	   cells/ml	   were	   cultured	   in	   24	   well	   tissue	  
culture	  plates	  in	  IMDM	  medium	  (Gibco,	  Breda,	  The	  Netherlands)	  supplemented	  with	  20%	  
(v/v)	   AB	   heparinized	   plasma	   (Sanquin	   Blood	   Bank,	   Rotterdam,	   The	   Netherlands),	   0.5	  
mg/ml	   human	   transferrin	   saturated	   with	   FeCl3.H20	   (Sigma,	   Zwijndrecht,	   The	  
Netherlands),	   0.34%	   (v/v)	   human	   serum	   albumin	   (Cealb®	   Sanquin,	   Amsterdam,	   The	  
Netherlands),	  1%	  (v/v)	  penicillin/	  streptomycin	  (Bio-­‐Whittaker,	  Verviers,	  Belgium),	  0.05	  
mM	  β-­‐mercapto-­‐ethanol	  (Sigma,	  St	  Louis,	  MISS.,	  USA)	  for	  10	  days	  at	  37°C	  and	  5%	  CO2	  in	  a	  
humidified	  atmosphere	  with	  50	  ng/ml	  TPO	  (a	  kind	  gift	  from	  KIRIN	  Brewery	  Ltd.,	   Japan),	  
and	  media	  containing	  50	  ng/ml	  TPO	  refreshed	  at	  day	  7	  by	  semi-­‐dilution.	  At	  day	  9,	  the	  cells	  
were	  split	   into	   two	  new	  wells	  and	  diluted	  1:1	   in	  medium	  without	  TPO	  and	  harvested	  at	  
day	  10.8,9	  The	  total	  cell	  expansion	  was	  calculated	  and	  the	  composition	  of	  the	  cultured	  cells	  
analyzed	   by	   flow	   cytometry	   using	   mouse-­‐anti-­‐human	   CD45,	   CD61	   and	   CD34	  
antibodies.8,9,11	   For	   the	  migration	   experiments,	   the	   cells	   were	   expanded	  with	   50	   ng/ml	  
Nplate	   (Amgen,	   Thousand	   Oaks,	   USA),	   a	   fusion	   protein	   homolog	   of	   TPO,	   of	   which	   fold	  
expansion	  and	  characteristics	  of	  expanded	  cells	  were	  similar	   in	  paired	  experiments	  with	  
CB	  CD34+	  cells	  from	  6	  different	  donors.10	  
	  
Cryopreservation	   and	   thawing	   of	   the	   cells	   Before	   cryopreservation,	   the	   fresh	   or	  
cultured	   CD34+	   cells	  were	   resuspended	   in	   IMDM	  with	   2%	   (v/v)	   human	   serum	   albumin	  
(HSA	  Cealb	  Sanquin),	   stored	  on	   ice	   for	  at	   least	  15	  minutes	  and	  diluted	  1:1	  with	   ice-­‐cold	  
cryopreservation	   medium	   (60%	   (v/v)	   IMDM	  medium	   (Gibco)	   supplemented	   with	   20%	  
(v/v)	   HSA	   Cealb®)	   and	   20%	   (v/v)	   DMSO	   (Pharmacy	   LUMC)).	   The	   cells	   were	  
cryopreserved	  in	  a	  controlled	  rate	  freezer	  at	  a	  1°C-­‐reduction	  per	  minute	  to	  –80°C	  before	  
being	  stored	  in	  liquid	  nitrogen.	  Thawing	  was	  performed	  quickly	  in	  a	  37°C	  water	  bath	  and	  
cells	   were	   resuspended	   gently	   on	   ice	   in	   IMDM	   medium	   containing	   2.5%	   HSA	   (v/v),	  
10U/ml	   heparin	   (Pharmacy	   LUMC)	   and	   1%	   (v/v)	   penicillin/streptomycin.	   Cell	   viability	  
was	  assessed	  with	  7AAD.	  	  
	  
Transplantation	  in	  NOD	  SCID	  mice.	  Female	  5-­‐6	  week	  old	  NOD	  SCID	  mice	  (Charles	  River,	  
France)	   were	   kept	   in	   micro-­‐isolator	   cages	   in	   laminar	   flow	   racks	   in	   the	   LUMC	   animal	  
facilities.	  Mice	  were	  given	  autoclaved	  acidified	  water	  containing	  0.07	  mg/ml	  Polymixin-­‐B	  
(Bufa	   B.V.,	   Uitgeest,	   The	   Netherlands),	   0.09	  mg/ml	   ciproxin	   (Bayer	   B.V.,	   Mijdrecht,	   The	  
Netherlands)	   and	   0.1	   mg/ml	   Fungizone	   (Bristol-­‐Myers-­‐Squibb,	   Woerden,	   The	  
Netherlands).	   All	   animal	   experiments	   were	   approved	   by	   the	   LUMC	   animal	   ethical	  
committee.	  NOD	  SCID	  mice	  were	  sub	  lethally	  irradiated	  (3.5Gy)	  up	  to	  24	  hours	  before	  i.v.	  
infusion	  with	   the	   expanded	   cells.	   Blood	   collection	   via	   tail	   incision	  was	   performed	   twice	  
weekly	   during	   the	   first	   3	   weeks	   after	   transplantation	   and	   once	   weekly	   thereafter.	   The	  
human	   platelets	   concentration	   in	   the	   blood	   was	   analyzed	   with	   flow	   cytometry	   as	  
described	  before22,	  using	  mouse-­‐anti-­‐human	  CD41-­‐PE	  and	  Flow-­‐Count	  fluorspheres™	  (all	  
from	  Beckman	  Coulter).	   Six	  weeks	   after	   transplantation,	  mice	  were	   sacrificed,	   and	   their	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bone	   marrow	   was	   analyzed	   for	   human	   cell	   engraftment	   and	   the	   relative	   lineage	  
distribution	  with	  flow	  cytometry	  analysis	  using	  goat-­‐anti-­‐mouse-­‐CD45-­‐PE	  (LCA,	  Ly-­‐5,	  30-­‐
F11,	   Pharmingen,	   Alphen	   a/d	   Rijn,	   The	   Netherlands),	   mouse-­‐anti-­‐human	   CD45-­‐FITC,	  
CD33-­‐FITC,	  CD34-­‐PE,	  CD19-­‐PE	  and	  CD3-­‐ECD	  (all	   from	  Beckman	  Coulter)	  or	  appropriate	  
isotype	  controls.	  
	  
Clonogenic	   assays.	   To	   determine	   the	   clonogenic	   capacity	   of	   the	   cells,	   progenitor	   cell	  
(CFU-­‐GEMM)	  and	  megakaryocyte	  colony	   forming	  unit	   (CFU-­‐Mk)	  assays	  were	  performed.	  
The	  CFU-­‐GEMM	  assay	  was	  performed	  as	  described	  by	  the	  manufacturer.	  In	  short,	  2.7x104	  
BM-­‐WBC	  (bone	  marrow-­‐white	  blood	  cells),	  0.32x104	  CD34+	  or	  TPO	  expanded	  cells	  were	  
added	  to	  Methocult™	  (StemCell	  Technologies	  Inc.)	  in	  a	  final	  volume	  of	  1.5	  ml.	  1.1	  ml	  of	  the	  
Methocult™	  cell	  suspension	  was	  dispensed	  in	  35	  mm	  dishes	  (Greiner,	  Alphen	  a/d	  Rijn,	  The	  
Netherlands)	   and	   cultured	   for	   14	   days	   at	   37°C,	   5%	   CO2	   in	   a	   humidified	   atmosphere	  
(>95%).	  Each	  sample	  was	   tested	   in	  duplicate.	  After	  14	  days,	   the	  number	  of	  granulocyte,	  
erythroid	  and	  monocyte	  colonies	  in	  the	  culture	  dishes	  was	  counted	  manually.	  The	  CFU-­‐Mk	  
assay	   was	   performed	   in	   MegaCult™-­‐C	   medium	   with	   cytokines	   (StemCell	   Technologies	  
Inc.).	  The	  assay	  was	  performed	  as	  described	  by	  the	  manufacturer.	  In	  short,	  2x105	  BM-­‐WBC	  
cells	  or	  0.25x104	  CD34+	  or	  TPO	  expanded	  cells	  per	  3.3	  ml	  were	  cultured	  in	  a	  chamber	  slide	  
(StemCell	   Technologies	   Inc.)	   for	   10	   days	   at	   37°C,	   5%	   CO2	   in	   a	   humidified	   atmosphere	  
(>95%).	  After	  10	  days,	  the	  number	  of	  megakaryocyte	  colonies	  in	  each	  well	  of	  the	  chamber	  
slide	  was	  counted	  manually.	  	  
	  
Expression	   of	   adhesion	  markers	   and	  migration	   of	   the	   cells	   cryopreserved	   before	  
and	   after	   expansion.	   Expression	   of	   adhesion	  markers	   (CD11a-­‐b,	   CD49d-­‐e,	   CD62L)	   and	  
the	  stem	  cell	  homing	  marker	  CD184	  (CXCR4)	  on	  the	  three	  subpopulations	  was	  determined	  
by	  flow	  cytometry	  in	  combination	  with	  CD61-­‐PC7	  and	  CD34-­‐PC5	  antibodies	  (all	  Beckman	  
Coulter).	  Migration	  experiments	  were	  performed	  in	  transwell	  plates	  (Costar,	  Amsterdam,	  
the	   Netherlands),	   with	   5	   μm	   pore	   filters.	   Before	   adding	   the	   cell	   suspensions,	   the	   lower	  
compartment	  of	  the	  well	  and	  the	  bottom	  of	  the	  filter	  were	  coated	  for	  15	  minutes	  at	  37°C	  
with	   2	   ng/ml	   fibronectin	   (Sigma).	   	   1x105	   TPO	   expanded	   cells	  were	   added	   to	   the	   upper	  
compartment.	   The	   lower	   chamber	   contained	   media	   with	   or	   without	   human	   rCXCL12	  
(SDF-­‐1α,	  100	  ng/ml;	  Sigma).	  Plates	  were	  incubated	  for	  5	  hours	  at	  37ºC	  and	  5%	  CO2	  in	  a	  
humidified	   incubator,	   before	   harvesting	   the	   migrated	   cells	   from	   the	   lower	   chamber.	  
Before	  and	  after	  incubation,	  all	  cells	  were	  analyzed	  by	  flow	  cytometry	  for	  the	  expression	  
of	  CD45,	  CD34	  and	  CD61	  and	  cell	  number	  calculated	  in	  the	  presence	  of	  flow	  count	  beads	  
(all	  from	  Beckman	  Coulter).	  The	  percentage	  of	  migrating	  cells	  was	  calculated	  by	  dividing	  
the	  number	  of	  cells	  from	  the	  lower	  compartment	  by	  the	  number	  of	  cells	  that	  were	  added	  
to	  the	  upper	  compartment.	  
	  
Statistics.	   All	   statistics	   were	   done	   using	   IBM	   SPSS	   Statistics	   (version	   20,	  
www.ibm.com/SPSS_Statistics).	   Results	   are	   presented	   as	   mean	   ±	   S.E.M.	   For	   the	  
comparison	   of	   fold	   expansion,	   clonogenic	   potential	   platelet	   recovery,	   bone	   marrow	  
engraftment	   and	   migration	   potential,	   significance	   was	   determined	   with	   Student’s	   two	  
tailed	  t	  test.	  Correlation	  between	  fold	  expansion	  and	  clonogenic	  potential	  was	  done	  with	  
Spearman’s	   Rank	   Correlation	   Coefficient.	   Differences	   between	   the	   different	  
subpopulations	   after	   expansion	  were	   determined	  with	   a	   one	  way	  ANOVA.	   Results	  were	  








Thrombopoietin	  expansion	  of	  CD34+	  cells	  pre-­‐	  and	  post-­‐cryopreservation	  
CD34+	   cells	   isolated	   from	   fresh	  CB	  were	   split	   in	   two	   fractions.	  One	  part	  of	   the	   cells	  was	  
directly	   expanded	   with	   TPO	   for	   10	   days	   and	   cryopreserved	   thereafter	   (pathway	   ECT,	  
Expansion/	  Cryopreservation/Thawing).	  The	  other	  half	  was	  cryopreserved	  directly	  after	  
isolation	   and	   expanded	   with	   TPO	   after	   thawing	   (pathway	   CTE,	  
Cryopreservation/Thawing/	  Expansion)	  (Figure	  1).	  Overall,	   the	  results	  demonstrate	  that	  
the	  fold	  total	  nucleated	  cell	  expansion	  was	  significantly	  higher	  (p<0.05)	  when	  the	  CD34+	  
cells	  were	  TPO	  expanded	  before	  cryopreservation	  (Table	  1,	  Figure	  2,	  ECT	  =	  17.8±4.3	  fold,	  
n=10,	  versus	  CTE	  =10.0±2.2	  fold,	  n=10).	  After	  TPO	  expansion,	  three	  major	  populations	  of	  





Figure 1: Flow chart of the experimental design. Human CD34+ cells were isolated from fresh CB and 
split in two fractions. The CD34+ cells were either directly expanded with TPO for 10 days and cryopreserved 
(ECT pathway), or the CD34+ cells were cryopreserved directly after isolation and TPO expanded after 






We	   previously	   showed	   that	   CD34+CD61-­‐	   cells	   (hereafter	   called	   residual	   CD34+	   cells,	  
rCD34+),	   correlate	   in	   the	  mouse	  with	   sustained	   engraftment,	   while	   CD34-­‐CD61-­‐Lineage-­‐	  
(hereafter	   called	  Lin-­‐	   cells)	   accelerated	  platelet	   recovery.	  Remarkably,	  CD34-­‐CD61+	   cells	  
(hereafter	   called	   CD61+	   cells)	   appear	   not	   to	   contribute	   to	   platelet	   production	   nor	   to	  
hematopoietic	   engraftment.8	   Post-­‐thaw	   viability	   of	   the	   TPO	   expanded	   cells	   in	   the	   ECT	  
pathway	  after	  cryopreservation	  and	  thawing	  was	  83.8±5.7%,	  90.5±16.4%	  and	  79.9±2.3%	  
for	   the	   rCD34,	   Lin-­‐	   and	   CD61+	   populations	   respectively.	   	   Notably,	   we	   did	   not	   observe	  
major	  differences	  in	  viability	  between	  cells	  that	  were	  derived	  from	  the	  either	  the	  ECT	  or	  
CTE	  pathway	  (for	  5	  donors;	  Table	  1).	  The	  CTE	  pathway	  yielded	  less	  Lin-­‐	  cells	  (16.6±3.8	  vs	  
ECT	   21.7±1.4%;	   p=0.590)	   and	   more	   rCD34+	   cells	   (CTE	   14.0±3.1%	   vs	   ECT	   11.2±2.1%;	  







Table 1: Subset distribution of TPO expanded cells In vitro characteristics of the 
cells after completion of the ECT or CTE pathway. Values are mean (± SEM, 
*p≤0.05).  
	  
pathway ECT CTE 
fold expansion 17.8 (±4.3) 10.0 (±2.2)* 
proportion subpopulation rCD34+ 11.2 (±2.1) 14.0 (±3.1) 
(% of total cells) Lin- 21.7 (±1.4) 16.6 (±3.8) 
 
CD61+ 61.4 (±1.9) 63.8 (±4.3) 
post thaw viability rCD34+ 83.8(±5.7) 74.2 (±3.5) 
(% of viable cells) Lin- 90.5 (±16.4) n.a 
 
CD61+ 79.9 (±2.3) n.a. 
total nr of CFU-GEMM/1000 cultured cells 2272 (±522)* 1444 (±300)* 







Figure 2: Fold total nucleated cell 
expansion comparing the ECT and 
CTE strategies. Human CB CD34+ 
cells were isolated and ex vivo 
expanded for 10 days with TPO 
directly (ECT) or after 
cryopreservation (CTE) (n=10). Fold 
expansion after 10 days. Although 
variation in the fold expansion was 
observed between donors, expansion 
CD34+ cells via the ECT pathway 
resulted in a higher number of cells 
than expansion via the CTE pathway 
(*p<0.05; paired Student’s two tailed 






Clonogenic	  progenitor	  content	  of	  TPO	  expanded	  cells	  
Next,	  the	  TPO	  expanded	  cells	  from	  the	  ECT	  and	  the	  CTE	  pathways	  were	  examined	  for	  their	  
CFU-­‐GEMM	  and	  CFU-­‐Mk	  content.	   	  For	  each	  1,000	  CD34+	  cells	  plated,	  the	  number	  of	  CFU-­‐
GEMM	   after	   TPO	   expansion	   was	   higher	   in	   the	   CTE	   pathway	   than	   in	   the	   ECT	   pathway	  
(300±43	   vs.	   241±46	   per	   103	   CD34+	   cells	   plated	   respectively,	   mean+SEM,	   n=5;	   p<0.05;	  
Figure	   3A),	  while	   the	   number	   of	   CFU-­‐Mk	  was	   higher	   for	   the	   ECT	   compared	   to	   the	   CTE	  
pathway	  (26.9±6.2	  vs.	  21.3±5.1	  per	  103	  CD34+	  cells	  plated	  respectively,	  mean±SEM,	  n=6;	  
p<0.05;	  Figure	  3B).	  When	  the	  absolute	  numbers	  of	  clonogenic	  cells	  were	  calculated	  on	  the	  
basis	  of	  CD34+	  cells	  present	  in	  the	  final	  products,	  CFU-­‐GEMM	  and	  CFU-­‐Mk	  numbers	  were	  
on	   average	  1.6	   and	  1.8-­‐fold	   higher	   respectively	   in	   the	  ECT	  protocol	   as	   compared	   to	   the	  
CTE	  protocol	  (ECT	  vs.	  CTE:	  2,272±522	  vs.	  1,444±300	  CFU-­‐GEMM	  and	  196±34	  vs.	  107±28	  
CFU-­‐Mk;	   n=5	   and	   n=6	   independent	   experiments	   respectively;	   Figures	   3C	   and	   3D).	   As	  
indicated	  in	  Figure	  3,	  there	  was	  a	  significant	  and	  strong	  positive	  correlation	  between	  the	  
absolute	  numbers	  of	  CFU-­‐GEMM	  and	  CFU-­‐Mk	  in	  the	  TPO	  expanded	  products	  and	  the	  fold	  
80 
	  
nucleated	   cell	   expansion	   regardless	   of	   whether	   the	   CTE	   and	   ECT	   protocols	   were	   used	  
(Figure	   4A	   and	   4B,	   Spearman’s	   rank	   correlation	   r=0.721	   and	   0.806	   respectively	   and	  
p<0.05	  and	  p<0.01	   respectively).	  The	  number	  of	  GFU-­‐GEMM	  and	  CFU-­‐Mk	  were	   strongly	  












































Figure 3: CFU-GEMM and CFU-Mk cultures from cells generated by 
the ECT vs. the CTE strategy. Fresh human CB CD34+ cells were TPO 
expanded and subsequently cryopreserved and then thawed (ECT), or 
were first cryopreserved and then expanded with TPO after thawing 
(CTE). Shown is the number of CFU-GEMM (A) and CFU-Mk (B) grown 
from 1000 CD34+ cells. Cells expanded with the CTE pathway showed 
lower CFU-GEMM numbers than when grown from the ECT pathway. In 
contrast, CD34+ cells generated via this pathway showed higher CFU-Mk 
numbers than CD34+ cells derived from the CTE pathway (*p<0.05). 
When calculated as the absolute number of colonies formed from the total 
expansion product, the ECT pathway generated more CFU-GEMM (C) 




























Figure 4. Correlation between fold expansion 
and formation of CFU-GEMM and CFU-Mk 
colonies from cells generated by the ECT vs. 
the CTE strategy. The absolute number of CFU-
GEMM (A) and CFU-Mk (B) in the total expansion 
product correlated significantly with the fold 
expansion in the presence of TPO (Spearman rank 
correlation 0.721 and 0.806, p-values <0.05 and 
<0.01 respectively). (C) The absolute number of 
CFU-Mk correlated with the absolute number of 
CFU-GEMM in the total TPO expansion product 








Platelet	   recovery	   in	   the	   peripheral	   blood	   and	   engraftment	   in	   the	   bone	   marrow,	  
blood	  and	  spleen	  of	  NOD	  SCID	  mice	  
The	  CD34+	  cells	  of	  three	  different	  CB	  units	  were	  expanded	  via	  the	  ECT	  and	  CTE	  pathway	  
and	  subsequently	  transplanted	  into	  NOD	  SCID	  mice	  (n=3	  mice	  per	  group).	  Since	  the	  ECT	  
pathway	   yields	   higher	   expansion	   numbers	   than	   the	   CTE	   pathway,	   the	   absolute	   cell	  
numbers	   transplanted	   in	  NOD	  SCID	  mice	  were	  higher	   for	   the	  ECT	  protocol	   than	   for	   the	  
CTE	   protocol	   	   (on	   average	   12.5±6.0x106	   cells/mouse	   for	   the	   ECT	   pathway	   vs.	  
5.5±3.1x106cells/mouse	   for	   the	   CTE	   pathway).	   At	   day	   5	   after	   transplantation,	   human	  
platelets	   could	  be	  measured	   in	  all	  mice,	  however,	   the	  human	  platelet	   concentration	  was	  
higher	   in	  mice	   that	   received	   cells	   expanded	  with	   the	   CTE	  pathway	   (Figure	   5A,	   p<0.05).	  
Platelet	   recovery	  was	  measured	   in	   the	   peripheral	   blood	   from	  day	   5	   until	   6	  weeks	   after	  
transplantation.	  From	  day	  12	  onwards,	   the	  kinetics	  and	  extent	  of	  platelet	  recovery	  were	  
comparable	   and	   not	   statistically	   different	   between	   the	   CTE	   and	   ECT	   pathway,	   although	  
transplantation	   of	   cells	   from	   the	   ECT	   pathway	   generally	   resulted	   in	   lower	   peripheral	  
blood	  platelet	  numbers	  (Figure	  5B).	  At	  6	  weeks	  after	  transplantation	  mice	  were	  sacrificed	  
to	  evaluate	  engraftment	  of	  human	  cells	  in	  the	  bone	  marrow,	  peripheral	  blood	  and	  spleen.	  
The	   percentage	   of	   human	   CD45+	   cells	   within	   the	   total	   CD45+	   population	   (mouse	   plus	  
human	  CD45+	  cells)	   tended	  to	  be	  higher	   in	   the	  mice	   that	  received	  cells	  prepared	  via	   the	  
CTE	   pathway,	   but	   this	   difference	  was	   not	   significant	   (Figure	   5C)	  Moreover,	   the	   lineage	  
differentiation	  of	  the	  human	  cells	  in	  the	  bone	  marrow,	  as	  determined	  by	  the	  percentage	  of	  
CD34+,	  CD33+	  and	  CD19+	  cells,	  was	  similar	  (Figure	  5D).	  	  
	  
Adhesion	  marker	  expression	  and	  migratory	  capacity	  of	  cells	  expanded	  via	  the	  ECT	  
or	  the	  CTE	  pathway	  	  
Because	  of	  the	  difference	  in	  initial	  platelet	  recovery	  shortly	  after	  transplantation	  between	  
the	  ECT	  and	  CTE	   strategies,	   the	   expression	  of	   adhesion	   and	  homing	  markers	   (CD11a/b,	  
CD49d/e,	  CD62L,	  CD184/CXCR4)	  and	  the	  migratory	  capacity	  of	  the	  subpopulations	  of	  the	  
expanded	  cells	  were	  measured	  for	  both	  the	  ECT	  and	  CTE	  expansion	  methods.	   	  A	  marked	  
increase	  in	  mean	  fluorescence	  intensity	  of	  the	  CD62L	  expression	  was	  found	  in	  the	  rCD34+	  
and	   Lin-­‐	   population	   after	   expansion	   via	   the	   CTE	   pathway	   (Table	   2)	   (rCD34+:	   3.2-­‐fold	  












Figure 5: Engraftment of human cells expanded with the ECT or CTE pathway in an NOD SCID model. 
CB CD34+ cells were cryopreserved and expanded according to either the ECT pathway or the CTE pathway 
and subsequently transplanted in NOD SCID mice (n=9 mice/pathway). (A): Human platelet recovery, 
defined as the concentration of human platelets/µl PB, for each individual mouse at day 5 after 
transplantation, showing a significant advantage on platelet recovery in the mice that received cell expanded 
via the CTE pathway, p<0.05 (B): Mean human platelet concentration of all mice of each group throughout 
the experiment (*p<0.05) (C): Percentage of human cell CD45+chimerism in bone marrow, spleen and PB 
six weeks after transplantation, measured as a percentage of total murine and human CD45+ cells. Mice 
receiving CTE expanded cells had on average higher percentages of human cells in all organs tested, 
although not significant. (D): Similar average distribution of different hematopoietic subsets was observed in 
the human CD45+ marrow cells 
83	  
	  
Moreover,	   the	   relative	   percentage	   of	   CD62L	   co-­‐expression	   was	   significantly	   higher	   in	  
these	  sub-­‐populations	  when	  cells	  were	  cultured	  via	  the	  CTE	  pathway	  as	  compared	  to	  the	  
ECT	  pathway	  (Figure	  6A,	  rCD34+:	  91.9±2.4%	  vs.	  58.3±18.3%,	  1.6-­‐fold	  difference;	  p=0.011;	  
Lin-­‐:	  44.9±3.6%	  vs.	  10.3±4.3%,	  4.4-­‐fold	  difference;	  p=0.00016).	  In	  migration	  experiments,	  
the	  CD62L+	   cells	  migrated	   significantly	  better	   than	  CD62L-­‐	   cells,	  which	  was	  unrelated	   to	  
the	   expansion	   pathway	   (Figure	   6B).	   	   Interestingly	   however,	   cells	   of	   the	   CTE	   pathway	  
migrated	  better	  towards	  an	  SDF-­‐1a	  gradient	  (the	  CXCR-­‐4	  ligand)	  than	  cells	  from	  the	  ECT	  
pathway	  (Figure	  6B;	  p<0.05),	  despite	  the	  observation	  that	  CD184	  (CXCR4)	  expression	  for	  










































Table 2: Difference in mean fluorescence intensity (±SD) of adhesion markers 
on TPO expanded cells after expansion by the two different methods. CD34+ 
cells were cultured following the ECT pathway (TPO expansion of fresh CD34+ cells 
and cryopreservation of TPO expanded cells) or the CTE pathway (TPO expansion of 
cryopreserved CD34+ cells) and adhesion and migration marker expression was 
examined on the sub-populations obtained after thawing of the TPO expanded cells 
(ECT) of directly after TPO expansion (CTE). *p<0.05, §p<0.01 
 
  subpopulation 
 
CD34+ Lin- CD61+ 
  ECT CTE ECT CTE ECT CTE 
CD11a 7.4 (±1.5) 6.9 (±2.1) 7.4 (±4.4) 5.8 (±1.3) 2.2 (±0.6) 1.7 (±0.5) 
CD11b 0.4 (±0.0) 0.6 (±0.3) 0.6 (±0.2) 0.8 (±0.3) 0.8 (±0.2) 0.8 (±0.1) 
CD49d 4.1 (±0.5) 4.5 (±0.5) 5.4 (±1.2) 5.5 (±0.8) 4.7 (±0.7) 4.5 (±0.4) 
CD49e 1.0 (±0.2) 0.8 (±0.3) 1.2 (±0.1) 1.0 (±0.4) 4.0 (±0.9) 4.1 (±0.2) 
CD62L 3.0 (±0.6) 9.4 (±0.6)* 0.7 (±0.1) 2.9 (±0.1)§ 1.1 (±0.4) 1.1 (±0.3) 






























Figure 6: CD62L expression of the expanded cells (A) and 
percentage of cells that migrated towards an SDF-1α gradient in 
a trans-well plate (B). A: Percentage of cells that express CD62L of 
the cell population responsible for bone marrow engraftment 
(rCD34+) and the population responsible for early platelet 
engraftment (Lin-) after expansion via the ECT pathway (black bars) 
or the CTE pathway (grey bars). Higher CD62L expression was found 
for both populations after expansion with the CTE pathway. (**p≤0.01, 
*p<0.05). B: Cells expressing CD62L pathway showed better 
migration towards the SDF-1α gradient regardless of the expansion 
pathway and cells expanded with the CTE pathway showed better 







Expansion	   of	   CB	   CD34+	   cells	   with	   TPO	   accelerates	   platelet	   recovery	   in	   vivo	   without	  
hampering	   bone	   marrow	   engraftment	   at	   6	   weeks	   in	   immunodeficient	   mice.8-­‐11,23.	  
Anticipating	   clinical	   application,	   pre-­‐	   or	   post-­‐cryopreservation	   TPO	   expansion	   of	  
hematopoietic	  stem/progenitor	  cells	  might	  influence	  subsequent	  in	  vivo	  platelet	  recovery	  
and	   hematological	   reconstitution,	   an	   issue	   that	   has	   not	   been	   investigated	   so	   far.	   We	  
compared	   the	   effect	   of	   TPO-­‐expansion	   pre-­‐	   versus	   post-­‐cryopreservation	   of	   CB	   CD34+	  
cells	  in	  vitro	  and	  in	  the	  NOD	  SCID	  mice	  model.	  	  
The	   results	   show	   that	   TNC	   (total	   nucleated	   cell)	   expansion	   with	   TPO	   is	   higher	   when	  
freshly	  isolated	  CB	  CD34+	  cells	  are	  cultured	  for	  10	  days	  and	  subsequently	  cryopreserved	  
(ECT),	  as	  compared	  to	  CD34+	  cells	  from	  the	  same	  donor	  expanded	  after	  cryopreservation	  
and	  thawing	  (CTE).	  Although	  the	  absolute	  number	  of	  rCD34+	  cells	  on	  average	  was	  higher	  
after	  the	  CTE	  protocol,	   the	  Lin-­‐	  cell	  subset,	  which	  has	  been	  shown	  to	  correlate	  best	  with	  
early	   platelet	   recovery	   in	   vivo	   in	   NOD	   SCID	   mice8	   was	   more	   abundant	   using	   the	   ECT	  
protocol.	   Surprisingly,	   and	   in	   contrast	   to	   the	   higher	   expansion	   and	   the	   higher	   putative	  
platelet	  precursor	  numbers	  observed	  after	  the	  ECT	  protocol,	  mice	  that	  received	  CTE	  cells	  
had	  a	  significantly	  higher	  number	  of	  platelets	  early	  after	  transplantation.	  This	  was	  not	  at	  
the	  expense	  of	  bone	  marrow	  engraftment,	  which	   tended	  also	   to	  be	  higher	  with	   the	  CTE;	  
albeit	  engraftment	  as	  well	  as	  the	  lineage	  differentiation	  of	  the	  engrafted	  human	  cells	  in	  the	  
mouse	   bone	   marrow	   at	   six	   weeks	   after	   transplantation	   in	   this	   respect	   was	   not	  
significantly	   different	   between	   the	   two	   strategies.	   As	  mentioned,	   compromised	   viability	  
after	   thawing	   of	   ECT	   cells	   is	   an	   unlikely	   explanation	   for	   the	   results	   as	   viability	   of	   all	  
subsets,	  including	  the	  Lin-­‐	  cell	  recovery,	  exceeded	  75%.	  
However,	   CD34+	   cells	   are	   heterogeneous24	   and	   more	   extensive	   studies	   are	   required	   to	  
identify	  phenotypically	   the	  rCD34+	  cells	  after	  TPO	  expansion	   from	  the	  non-­‐TPO	  exposed	  
CD34+	  cells	  with	  respect	  to	  their	  sensitivity	  to	  cryopreservation.	  	  
An	   alternative	   explanation	   for	   the	   discrepancy	   between	   the	   quantitative	   in	   vitro	   and	  
qualitative	  in	  vivo	  results	  between	  the	  two	  protocols	  might	  be	  found	  in	  the	  capacity	  of	  the	  
cells	  to	  home	  to	  and	  engraft	  in	  specific	  bone	  marrow	  niches.	  Migration	  towards	  an	  SDF-­‐1a	  
gradient	  is	  a	  surrogate	  marker	  for	  this	  process.	  Additionally,	  recent	  studies	  by	  Niswander	  
et	   al.25,26	   demonstrate	   an	   additive	   effect	   of	   SDF-­‐1	   after	   TPO	   treatment	   in	   vivo	   and	  
implicate	   the	   SDF-­‐1α	   in	   the	  movement	   of	   platelet	   progenitor	   cells	   to	   the	   bone	  marrow	  
vasculature,	   where	   they	   can	   then	   promote	   a	   resulting	   increase	   in	   circulating	   platelet	  
numbers.	   Indeed,	  we	   observed	   that	   a	   higher	   percentage	   of	   cells	   from	   the	   CTE	   pathway	  
migrated	   towards	   SDF-­‐1α.	   The	   higher	   CD62L	   expression,	   an	   important	   migration	   and	  
homing	  receptor	  27-­‐29	  on	  both	  rCD34+	  and	  Lin-­‐	  cells	  from	  the	  CTE	  pathway,	  may	  play	  a	  role	  
in	   this.	   Indeed,	   CD62L	   expression	   has	   been	   correlated	   to	   speed	   of	   hematopoietic	  
recovery,30	  and	  in	  particular	  with	  platelet	  recovery.31	  	  In	  this	  regard,	  the	  lower	  migration	  
towards	  an	  SDF-­‐1α	  gradient	  of	  the	  CD62L-­‐	  population	  we	  observed	  seems	  compatible	  with	  
previous	   reports.	   The	   lower	   number	   of	   CD62L	   expressing	   cells	   derived	   from	   the	   ECT	  
pathway	  might	   in	   this	  regard	  explain	  why	   fewer	  cells	   from	  the	  ECT	  pathway	  are	  able	   to	  
migrate	   towards	   or	  within	   the	   bone	  marrow.	  However,	   admittedly	   CD62L	   expression	   is	  
unlikely	   to	  be	   the	  only	   explanation	   for	   the	  difference	   in	   the	   in	   vivo	   results	   between	   the	  
ECT	   and	   the	   CTE	   pathway.	   Migration	   of	   CD62L+	   cells	   derived	   from	   the	   CTE	   pathway,	  
whether	   rCD34+	   or	   Lin-­‐	   was	   higher	   when	   compared	   to	   cells	   derived	   from	   the	   ECT	  
pathway,	   indicating	   that	   other	   factors	  play	   a	   role	   in	   the	  migration	   as	  well.	   Important	   in	  
this	   respect,	   no	   significant	   differences	   could	   be	   found	   in	   the	   expression	   of	   the	   SDF-­‐1α	  
receptor,	  CXCR4	  (CD184),	  which	  was	  used	  as	  the	  chemo-­‐attractant	  in	  these	  experiments,	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although	   there	  was	   higher	   expression	   of	   CXCR4	   on	   the	   CD34-­‐CD61-­‐	   platelet	   progenitors	  
than	  on	  the	  CD34+	  progenitors	  post	  TPO	  expansion.	  	  	  
In	   terms	   of	   CB	   transplant	   logistics,	   expansion	   of	   fresh	   CD34+	   cells	   followed	   by	  
cryopreservation	   would	   be	   virtually	   impossible	   from	   a	   feasibility	   point	   of	   view	   with	  
respect	  to	  the	  low	  volume	  to	  be	  cryopreserved,	  the	  high	  costs	  for	  the	  purification	  and	  the	  
low	   efficiency	   as	   only	   a	   small	   proportion	   of	   UCB	   (~1%)	   are	   used	   for	   allogeneic	  
transplantation.	   Expansion	  of	   cryopreserved	  CB	  units	   that	   are	   selected	   for	   an	  unrelated	  
allogeneic	   transplantation	   therefore	   is	  much	  more	  practical	   in	   the	  clinical	  setting.	   	  From	  
our	  comparison	  in	  which	  we	  started	  with	  equal	  CD34+	  cell	  numbers,	  we	  have	  shown	  that	  
10	   days	   of	   TPO	   expansion	   both	   before	   and	   post	   cryopreservation	   did	   lead	   to	   similar	  
improved	  platelet	  recovery	  and	  to	  similar	  longer	  term	  hematological	  recoveries.	  	  	  
In	   conclusion,	  our	  study	  shows	   that	  CB	  CD34+	  cells	   can	  be	  TPO-­‐expanded	  both	  pre-­‐	  and	  
post-­‐cryopreservation.	   The	   choice	   between	   cytokine	   expansion	   of	   CB	   before	   or	   after	  
cryopreservation	   is	   essentially	   a	   trade-­‐off	   between	   different	   advantages	   and	  
disadvantages	  with	  respect	   to	   feasibility,	  costs	  and	  available	  UCB	  products,	  and	  whether	  
the	   cells	   are	   to	   be	   used	   for	   specific	   autologous	   or	   allogeneic	   transplants.	   Pre-­‐
cryopreservation	  expansion	  allows	  quality	   control	  analyses	  on	   the	  expansion,	   as	  well	   as	  
immediate	  availability	  of	  an	  expanded	  graft	  together	  with	  higher	  levels	  of	  expansion.	  For	  
unrelated	   allografts,	   pre-­‐cryopreservation	   expansion	   however	   introduces	   a	   logistical	  
stalemate	  because	  it	  is	  not	  possible	  to	  predict	  which	  CB	  units	  will	  be	  required	  and	  which	  
ones	   should	   be	   expanded	   before	   cryopreservation.	   Post-­‐cryopreservation	   expansion	  
allows	  a	  careful	  choice	  for	  this	  purpose	  of	  the	  presently	  banked	  units.	  In	  the	  case	  of	  TPO	  
mediated	  expansion,	  better	  early	  platelet	  recovery	  and	  similar	  long	  term	  engraftment	  for	  
unrelated	   allografts	   remains.	   The	   10	   day	   culture	   delay	   before	   such	   a	   transplant	   is	  
available	  in	  this	  respect	  seems	  a	  minor	  disadvantage.	  We	  therefore	  conclude	  that	  from	  a	  
logistical,	   financial	   and	   clinical	   standpoint,	   expansion	   is	   better	   performed	   after	  
cryopreservation	   for	   CB	   allotransplants	   and	   that	   the	   expansion	   protocol	   needs	   to	   be	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After	   cord	   blood	   transplantation,	   early	   platelet	   recovery	   in	   immune	   deficient	   mice	   is	  
obtained	  by	  expansion	  of	  cord	  blood	  (CB)	  CD34+	  cells	  with	  TPO	  as	  single	  growth	  factor.	  
Moreover,	   improvement	   of	   hematopoietic	   engraftment	   has	   been	   shown	   by	   co-­‐
transplantation	   of	   Mesenchymal	   Stem	   Cells	   (MSC).	   We	   investigated	   whether	   a	  
combination	   of	   both	   approaches	   would	   further	   enhance	   the	   outcome	   of	   CB	  
transplantation	   in	   NOD	   SCID	   mice.	   NOD	   SCID	   mice	   were	   transplanted	   with	   either	   CB	  
CD34+	  cells,	  CD34+	  cells	  with	  MSC,	  TPO	  expanded	  CD34+	  cells	  or	  TPO	  expanded	  CD34+	  
cells	  with	  MSC.	  We	  analyzed	  human	  platelet	   recovery	   in	   the	  peripheral	  blood	  (PB)	   from	  
day	  4	  after	  transplantation	  onwards	  and	  human	  bone	  marrow	  (BM)	  engraftment	  at	  week	  
6.	   The	   different	   transplants	   were	   assessed	   in	   vitro	   for	   their	   migration	   capacity	   and	  
expression	  of	  CXCR4.	  TPO	  expansion	  improved	  the	  early	  platelet	  recovery	  in	  the	  PB	  of	  the	  
mice.	  Co-­‐transplantation	  of	  MSC	  with	  CD34+	  cells	  improved	  BM	  engraftment	  and	  platelet	  
levels	   in	   the	   PB	   6	   weeks	   after	   transplantation.	   Combining	   TPO	   expansion	   and	  MSC	   co-­‐
transplantation	  however,	  neither	  resulted	  in	  a	  more	  efficient	  early	  platelet	  recovery	  nor	  in	  
better	  BM	  engraftment	  and	  even	  very	   low	  or	  absent	  BM	  engraftment	  occurred.	   In	  vitro,	  
MSC	   boosted	   the	   migration	   of	   CD34+	   cells,	   suggesting	   a	   possible	   mechanism	   for	   the	  
increase	   in	   engraftment.	   Our	   results	   show	   that	   co-­‐transplantation	   of	   MSC	   with	   TPO	  
expanded	  CD34+	  cells	  at	  most	  combines,	  but	  does	  not	  increase	  the	  separate	  advantages	  of	  






















































































Cord	   blood	   (CB)	   is	   an	   alternative	   hematopoietic	   graft	   source	   for	   almost	   20%	   of	   the	  
patients	   for	   whom	   no	   HLA	   matched	   donor	   can	   be	   found	   1-­‐4.	   However,	   CB	   contains	  
relatively	  low	  numbers	  of	  hematopoietic	  stem	  cells	  (HSCs),	  which	  translates	  into	  delayed	  
neutrophil	   recovery	   and	   slow	   and	   impaired	   platelet	   engraftment	   when	   compared	   to	  
transplantation	  with	   bone	  marrow	   (BM)	   or	   G-­‐CSF	  mobilized	   peripheral	   blood	   stem	   cell	  	  
(PBSC)	  grafts	  5-­‐7.	  Several	  strategies	  to	  overcome	  this	  are	  under	  investigation	  	  such	  as	  the	  
selection	  of	  CB	  units	  containing	  large	  cell	  numbers,	  double	  CB	  transplantation,	  the	  ex	  vivo	  
manipulation	  of	  CB	  cells	  and	  co-­‐transplantation	  of	  accessory	  cells,	  such	  as	  MSC	  8.	  Ex	  vivo	  
culture	  of	  CB	  cells	   ,	  depending	  on	  culture	  conditions	  and	  growth	  factors,	  often	  alters	  the	  
functionality	  of	  the	  cord	  blood	  cells	  and/or	  the	  composition	  of	  the	  cord	  blood	  graft	  9,10.	  In	  
this	  respect,	  ex	  vivo	  culture	  with	  TPO	  as	  single	  growth	  factor	  accelerates	  platelet	  recovery	  
in	  the	  PB	  of	  mice,	  without	  impairment	  of	  engraftment	  in	  the	  BM	  11-­‐13.	  These	  platelets	  are	  
derived	   from	   TPO	   induced	   lineage	   negative	   (CD34-­‐CD61-­‐Lin-­‐)	   cells	   preceding	  
megakaryocyte	  formation	  12.	  	  
Mesenchymal	   stem	   cells	   (MSC)	   are	   also	   investigated	   to	   boost	   engraftment.	   These	  
multipotent	  stromal	  cells	  are	  characterized	  by	  three	  characteristics,	  1)	  plastic	  adhesion	  in	  
culture,	  2)	  the	  expression	  of	  a	  set	  of	  distinct	  markers	  and	  3)	  the	  ability	  to	  differentiate	  into	  
three	  mesodermal	   lineages	   14.	  MSC	  can	  be	   isolated	   from	  both	  adult	   15,16	  and	   fetal	   tissues	  
17,18.	  MSC	  have	  anti-­‐proliferative,	  immunosuppressive	  and	  anti-­‐inflammatory	  effects	  19	  and	  
are	  currently	  evaluated	  in	  clinical	  studies	  for	  the	  treatment	  of	  immune	  mediated	  disorders	  
such	   as	  Crohn’s	   disease	   20,	   systemic	   lupus	   21	   and	   systemic	   sclerosis	   22.	   In	   hematopoietic	  
stem	   cell	   transplantation	   (HST),	   post-­‐transplant	   infusions	   of	   MSC	   23-­‐28	   as	   well	   as	   co-­‐
transplantation	  of	  MSC	  29,30	  are	  explored	  for	  the	  treatment	  and	  prophylaxis	  of	  graft	  versus	  
host	  disease	  and/or	  graft	  rejection.	  In	  animal	  models,	  co-­‐transplantation	  of	  MSC,	  improves	  
engraftment	   after	   HST	   18,31-­‐35.	   Clinical	   studies	   have	   so	   far	   shown	   variable	   results	   when	  
MSC	  co-­‐transplantation	  was	  compared	  to	  neutrophil	  and/or	  platelet	  recovery	  of	  historical	  
controls	  36,37.	  While	  improved	  neutrophil	  recovery	  is	  reported	  more	  consistently	  38,39,	  the	  
median	   time	   to	   platelet	   engraftment	   remained	   delayed,	   compared	   to	   unrelated	   BM	   or	  
PBSC	  transplants	  40.	  	  
Combining	  TPO	  expansion	  of	  CB	  CD34+	  cells	  and	  MSC	  co-­‐transplantation	  could	  enhance	  
post	   CB	   transplant	   PB	   platelet	   recovery	   as	   well	   as	   BM	   engraftment.	   In	   this	   study,	   we	  
therefore	  compared	  the	  engraftment	  potential	  of	  both	  approaches	  in	  an	  NOD	  SCID	  mouse	  
model.	  	  
	  
Materials	  and	  methods	  
	  
CD34+	   cell	   purification.	  Umbilical	   cord	   blood	   (CB)	  was	   collected	  with	  written	   consent	  
from	  the	  mother	  according	  to	  Netcord–FACT	  standards	  and	  with	  ethical	  permission	  from	  
the	  medical	  ethical	  board	  of	   the	  Leiden	  University	  Medical	  Center	  (LUMC).	  Mononuclear	  
cells	  were	   isolated	   from	   CB	   using	   a	   ficoll	   density	   gradient.	   The	   CD34+	   cell	   fraction	  was	  
isolated	   	   using	   magnetic	   CD34+	   isolation	   beads	   (Miltenyi	   Biotec,	   Bergisch	   Gladbach,	  
Germany)..	  The	  purity	  of	   the	   isolated	  CD34+	  cell	   fraction	  was	  verified	  by	   flow	  cytometry	  
(Beckman	  Coulter,	  Woerden,	  The	  Netherlands)	  with	  CD45-­‐FITC	  and	  CD34-­‐PE	   (Beckman	  
Coulter).	  The	  percentage	  of	  CD34+/CD45+	  cells	  in	  the	  isolated	  fraction	  was	  91±3%.	  	  
	  
Expansion	   of	   the	   CD34+	   cells.	   CD34+	   cells	   were	   cultured	   at	   37°C	   and	   5%	   CO2	   in	   a	  
humidified	  atmosphere	  in	  IMDM	  medium	  (Gibco,	  Breda,	  The	  Netherlands)	  supplemented	  
with	   20%	   (v/v)	  AB	  heparin	   plasma	   (Sanquin	  Blood	   Supply	   Foundation,	  Rotterdam,	  The	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Netherlands),	  0.5	  mg/ml	  human	  transferrin	  saturated	  with	  FeCl3.H20	  (Sigma,	  Zwijndrecht,	  
The	  Netherlands),	  0.34%	  (v/v)	  human	  serum	  albumin	  20%	  (Cealb®	  CLB,	  Amsterdam,	  The	  
Netherlands),	  1%	  (v/v)	  penicillin/streptomycin	   (Bio-­‐Whittaker,	  Verviers,	  Belgium),	  0.05	  
mM	   β-­‐mercapto-­‐ethanol	   (Sigma),	   and	   50	   ng/ml	   mpl-­‐ligand	   (TPO,	   kind	   gift	   from	   KIRIN	  
Brewery	  Ltd.,	  Japan).	  The	  cells	  were	  plated	  in	  24	  well	  sterile	  TC	  plates,	  at	  a	  concentration	  
of	   5x104	   cells/ml.	   At	   day	   7,	   the	   medium	  was	   refreshed	   by	   semi-­‐dilution,	   with	   medium	  
containing	  50	  ng/ml	  TPO.	  At	  day	  9	  the	  cells	  were	  split	  into	  two	  new	  wells	  and	  1:1	  diluted	  
with	  medium	  without	  TPO.	  At	  day	  10,	  the	  cells	  were	  harvested	  and	  the	  total	  cell	  expansion	  
was	   calculated	   and	   subsequently	   the	   composition	   of	   the	   cultured	   cells	  was	   analyzed	   by	  
flow	   cytometry	  using	  mouse-­‐anti-­‐human	  CD45,	   CD61,	   CD34,	   CD14	   and	  CD15	   antibodies	  
(all	  Beckman	  Coulter).	  	  
	  
Culture	  of	  mesenchymal	  stem	  cells.	  Mesenchymal	  stem	  cells	  were	  obtained	   from	  fetal	  
lung	  tissue	  as	  previously	  described	  18.	  The	  cells	  were	  cultured	  in	  M199	  supplemented	  with	  
10%	   FCS,	   1%	   pen/strep,	   20	   µg/ml	   EGF	   and	   8	   U/ml	   heparin,	   in	   gelatin	   coated	   tissue	  
culture	  flasks	  at	  37°C	  and	  5%	  CO2	  in	  a	  humidified	  atmosphere.	  
	  
Transplantation	   in	   NOD/scid	   mice.	   Female,	   5-­‐6	   weeks	   old,	   NOD	   SCID	   mice	   (Charles	  
River,	  France)	  were	  kept	  the	  animal	  facilities	  of	  the	  LUMC.	  The	  animal	  ethical	  committee	  
of	  the	  LUMC	  approved	  all	  animal	  experiments.	  The	  mice	  were	  irradiated	  sub	  lethally	  (3.5	  
Gy)	   	   24	   hours	   before	   i.v.	   transplantation	  with	   the	   different	   transplants:	   1)	   2*105	   CD34+	  
cells	   (hereafter	   referred	   to	   as	   CD34),	   2)	   2*105	   CD34+	   cells	   10	   days	   expanded	  with	   TPO	  
(hereafter	   referred	   to	   as	   CD34-­‐E),	   3)	   2x105	   CD34+	   cells	   +	   1x106	   FL	   MSC	   (hereafter	  
referred	  to	  as	  CD34/MSC)	  and	  4)	  2x105	  CD34+	  cells	  10	  days	  expanded	  with	  TPO	  +	  1x106	  
FL	   MSC	   (hereafter	   referred	   to	   as	   CD34-­‐E/MSC).	   A	   schematic	   representation	   of	   the	  
experiment	  is	  shown	  in	  figure	  1.	  	  
Blood	  collection	  via	  tail	  vein	  incision	  was	  performed	  twice	  weekly	  during	  the	  first	  3	  weeks	  
after	   transplantation	   and	   once	  weekly	   thereafter.	   Blood	   collection	   and	   human	   platelets	  
measurements	  were	  performed	  as	  described	  previously	  41.	  Briefly,	  human	  platelets	  were	  
stained	   with	   a	   non-­‐cross	   reactive	   mouse-­‐anti-­‐human	   CD41-­‐PE	   (Beckman	   Coulter)	   and	  
erythrocytes	  were	   lysed	  with	   IQTest3	   Lysing	   solution	   (Beckman	   Coulter).	   Flow-­‐Count™	  
fluorospheres	  (Beckman	  Coulter)	  were	  added	  to	  enable	  the	  measurement	  of	  the	  absolute	  
number	  of	  circulating	  human	  platelets.	  The	  detection	  limit	  was	  1x103	  platelets/ml	  of	  PB.	  
Analysis	  was	  performed	  with	  flow	  cytometry	  (EPICS®	  XL-­‐MCL,	  Beckman	  Coulter)	  running	  
system	  II	  software.	  
Six	  weeks	  after	  transplantation,	  mice	  were	  sacrificed	  and	  the	  bone	  marrow	  was	  obtained	  
from	  the	   femur.	  Cells	  were	  resuspended	   in	   IMDM	  and	  cells	  were	   labeled	  with	  goat-­‐anti-­‐
mouse-­‐CD45-­‐PE	   (LCA,	   Ly-­‐5,	   30-­‐F11,	   Pharmingen),	   mouse-­‐anti-­‐human	   CD45-­‐FITC	  
(Beckman	  Coulter),	  and	  the	  appropriate	  isotype	  controls.	  Subsequently	  erythrocytes	  were	  
lysed	  with	  IO	  Test	  3	  Lysing	  solution	  according	  to	  the	  manufactures	  procedures	  (Beckman	  
Coulter).	   Analysis	   was	   performed	   with	   flow-­‐cytometry	   (EPICS®	   XL-­‐MCL,	   Beckman	  
Coulter)	  running	  system	  II	  software.	  
	  
Migration	  experiments.	  Four	  different	  cell	  suspensions	  were	  prepared	  identical	  to	  the	  in	  
vivo	  experiment.	  After	  30	  minutes	  of	  incubation	  cells	  were	  analyzed	  for	  the	  expression	  of	  
CD45,	  CD34,	  CD61,	  CXCR4,	  CD49d	  and	  CD49e	  with	  flow	  cytometry	  and	  placed	  in	  the	  upper	  
compartment	   of	   a	   trans-­‐well	   plate	   [Costar,	   Amsterdam,	   the	   Netherlands],	   with	   a	   100	  
ng/ml	   SDF	   gradient	   in	   the	   lower	   compartment,	   both	   containing	   IMDM.	   (Gibco).	   Plates	  
were	   incubated	   for	   5	   hours	   at	   37ºC	   and	   5%	   CO2	   in	   a	   humidified	   incubator.	   After	  
incubation,	  cells	  were	  harvested	  from	  both	  compartments.	  After	  incubation	  all	  cells	  were	  
95	  
	  
analyzed	  for	   the	  expression	  of	  CD45,	  CD34,	  and	  CD61	  (all	  Beckman	  Coulter)	   to	  calculate	  
the	  number	  of	  cells	  that	  have	  migrated.	  
	  
Statistical	   Analysis.	   All	   statistics	   were	   done	   with	   SPSS,	   version	   20.	   All	   results	   are	  
presented	  as	  mean±SEM.	  To	  compare	  groups,	  a	  student’s	  T	  test	  (normally	  distributed)	  or	  
Mann	   Whitney	   test	   (not	   normally	   distributed)	   was	   used.	   Differences	   were	   considered	  
significant	   when	   p<0.05.	   If	   multiple	   groups	   were	   compared,	   an	   ANOVA	   or	   a	   Holm’s	  











Figure 1: flow chart of the transplantation experiment. Four different types of transplants were 
prepared (cell numbers/mouse): CD34: 2*105 un-manipulated CD34+ cells (control group) 
CD34/MSC: 2*105 un-manipulated CD34+ cells with 1*106 fetal lung MSC CD34-E/MSC: the total 
expansion product of 2*105 CD34+ cells expanded with TPO with 1*106 fetal lung MSC CD34-E: the 










Platelet	  recovery	  in	  the	  peripheral	  blood	  of	  NOD-­‐SCID	  mice	  
To	   study	   the	   different	   strategies	   to	   overcome	   delayed	   and	   reduced	   engraftment	   of	   CB	  
cells,	  mice	  were	  transplanted	  with	  either	  unmanipulated	  CD34+	  cells	  (CD34	  group),	  TPO	  
expanded	  CD34+	  cells	  (CD34-­‐E	  group),	  unmanipulated	  CD34+	  cells	  with	  MSC	  (CD34/MSC	  
group)	   or	   TPO	   expanded	   CD34+	   cells	   with	   MSC	   (CD34-­‐E/MSC	   group)	   while	   platelet	  
recovery	  as	  well	  as	  bone	  marrow	  engraftment	  were	  studied.	  	  
Similar	  to	  earlier	  studies	  11-­‐13,42,	  in	  the	  first	  week	  after	  transplantation,	  mice	  that	  received	  
TPO	  expanded	  cells	  (CD34-­‐E	  and	  CD34-­‐E/MSC	  groups)	  showed	  accelerated	  early	  platelet	  
(plt)	  recovery	  in	  the	  PB	  when	  compared	  to	  mice	  transplanted	  with	  only	  CD34+	  cells	  (CD34	  
group)	  (figure	  2A	  and	  2C),	  as	  shown	  by	  significantly	  higher	  platelet	  concentrations	  in	  the	  
PB	  of	  the	  mice	  8	  days	  after	  transplantation	  (CD34-­‐E	  group:7.8±2.5x103	  plt/ml	  PB,	  CD34-­‐
E/MSC	   group:	   8.3±2.7	   x103	   plt/ml,	   compared	   to	   the	   control	   group,	   CD34:	   1.4±0.6x103	  
plt/ml,	  p<0.005	   for	  both	  groups).	   	  The	  TPO	   induced	   increased	  PB	  platelet	  concentration	  
was	  present	  for	  two	  weeks	  after	  transplantation	  while	  after	  week	  2,	  the	  mean	  PB	  platelet	  
levels	   in	   all	   groups	   slowly	   increased.	   Co-­‐transplantation	   of	   MSC	   in	   contrast,	   did	   not	  	  
significantly	   increase	   early	   platelet	   repopulation	   as	   compared	   to	   	   CD34+	   cells	   or	   TPO	  
expanded	   CD34+	   cells	   respectively	   (CD34/MSC:	   1.9±0.8x103	   plt/ml	   compared	   to	   CD34:	  
1.4±0.6x103	   plt/ml	   and	   CD34-­‐E/MSC:	   8.3±2.7x103	   plt/ml	   compared	   to	   CD34-­‐E:	  
7.8±2.5x103	  plt/ml).	   Compared	   to	  unmanipulated	  CD34+	  grafts,	   all	  mice	   that	   received	   a	  
manipulated	   graft	   and/	   or	   additional	   MSCs	   showed	   higher	   platelet	   concentrations	   six	  
weeks	   after	   transplantation	   (mean	   platelet	   concentration	   ±SEM	   in	   PB:	   CD34/MSC:	  
207.4±68.2x103,	   CD34-­‐E:	   216.2±112.2x103	   and	   CD34-­‐E/MSC:	   127.0±60x103	   plt/ml)	   as	  
compared	   to	   the	   mice	   that	   received	   unmanipulated	   CD34+	   cells	   (CD34:	   49.8±21.0x103	  
plt/ml	   PB).	   However,	   only	   for	   the	   CD34/MSC	   group	   this	   difference	   was	   significant	  
(p<0.01).	  The	  mean	  increase	  of	   long	  term	  platelet	  engraftment	   in	  the	  CD34-­‐E	  group	  was	  
due	  to	  a	  wide	  SD	  not	  significant	  because	  a	  number	  of	  mice	  engrafted	  exceptionally	  well,	  
thereby	   increasing	   the	   mean	   value	   of	   the	   group.	   The	   median	   values	   of	   these	   groups,	  
18.0x103	   plt/ml	   PB	   for	   CD34-­‐E	   versus	   17.4x103	   plt/ml	   PB	   for	   CD34,	  were	   similar.	   Vice	  
versa,	   the	   (non-­‐significant)	   lower	   mean	   platelet	   concentration	   of	   the	   group	   that	   was	  











Figure 2. A: platelet concentration in the peripheral blood (PB) of each of the mice 8 days after 
transplantation. Bars represent the mean platelet concentration of each group. On average, both groups that 
were transplanted with TPO expanded cells had significantly higher concentrations of platelets in the PB 
(*p<0.02). B: platelet concentration of each of the mice 40 days after transplantation. Bars represent the 
mean platelet concentration of each group. On average, all groups had higher concentrations of platelets in 
the PB than the control group, but this difference was only significant for the group that was transplanted with 
CD34+ cells and MSC (*p<0.05). C: kinetics of platelet recovery in the mice throughout the experiment. 
























































Human	  engraftment	  in	  the	  bone	  marrow	  
The	  percentage	  of	  human	  CD45	  cells	  in	  the	  bone	  marrow	  6	  weeks	  after	  transplantation	  of	  
the	  mice	  is	  shown	  in	  figure	  3A.	  Co-­‐transplantation	  of	  MSC	  increased	  the	  engraftment	  when	  
compared	  to	  transplantation	  of	  CD34+	  cells	  alone	  with	  higher	  percentages	  of	  human	  cells	  
in	  the	  BM	  (CD34/MSC:	  24.5±6.3%	  vs.	  CD34:	  8.9±3.7%;	  p<0.05).	  In	   line	  with	  the	  6	  weeks	  
PB	  platelet	  counts,	  TPO	  expanded	  cells	  also	   induced	  engraftment,	  but	  again	  this	  was	  not	  
significant	  (CD34-­‐E:	  20.2±7.4%;	  p=0.402	  compared	  to	  the	  CD34	  group).	  	  
Interestingly,	  whereas	  co-­‐transplantation	  of	  MSC	  with	  CD34+	  cells	  significantly	  improved	  
the	  BM	  engraftment	  of	  the	  mice	  at	  week	  6,	  co-­‐transplantation	  of	  MSC	  with	  TPO	  expanded	  
CD34+	   cells	   did	   not	   enhance	   BM	   engraftment	   and	   seemed	   even	   less	   favorable	   when	  
compared	  to	  transplantation	  of	  TPO	  expanded	  cells	  alone	  (%human	  CD45	  cells	  in	  the	  BM	  
for	   CD34-­‐E/MSC:	   	   14.7±6.2%	   vs.	   20.2±7.4%	   for	   CD34-­‐E).	   Again,	   as	   seen	   with	   the	   low	  
platelet	  counts	  at	  week	  6,	  low	  or	  non-­‐engraftment	  in	  a	  subset	  of	  mice	  did	  account	  for	  this	  
difference.	  To	   study	   if	   this	   finding	  was	   related	   to	   the	  quality	  of	   a	  particular	  CB	  unit,	  we	  
compared	  the	  mean	  BM	  engraftment	  of	  mice	  that	  received	  cells	  from	  the	  same	  cord	  blood	  
unit	   (figure	   3B).	   Again,	   co-­‐transplantation	   of	   MSC	   with	   CD34+	   cells	   increased	   the	  
engraftment	   (on	   average	  7.1±-­‐2.1	   fold)	   for	   all	   of	   the	   five	  different	   cord	  blood	  units	   that	  
were	   used	   in	   this	   study.	   Co-­‐transplantation	   of	   MSC	  with	   TPO	   expanded	   cells,	   however,	  
again	  showed	  very	  low	  engraftment	  for	  one	  of	  the	  cord	  blood	  units	  and	  no	  engraftment	  for	  
a	   second	   unit	   (0-­‐0.1%	   of	   human	   CD45+	   cells	   in	   the	   bone	   marrow).	   Whereas	   co-­‐
transplantation	   of	   MSC	   with	   TPO	   expanded	   cells	   of	   these	   two	   specific	   units	   impaired	  
engraftment,	  co-­‐transplantation	  of	  MSC	  with	  the	  unmanipulated	  CD34+	  cells	  of	  these	  two	  
units	  increased	  the	  engraftment	  5	  and	  17	  fold	  respectively.	  The	  latter	  was	  in	  line	  with	  the	  
average	   increase	   in	   engraftment	   (7.1±2.1	   fold)	   when	   MSC	   are	   co-­‐transplanted	   with	  
unmanipulated	   CD34+	   cells,	  whilst	   they	   decreased	   the	   engraftment	   (1.1±0.4	   fold)	  when	  










Co-­‐transplantation	  of	  MSC	  with	  TPO	  expanded	  cells	  on	  different	  time	  points	  
TPO	  expanded	  grafts	  contain	  a	  higher	  cell	  number	  as	  compared	  to	  unmanipulated	  CD34+	  
cells.	  Thus,	  mice	  transplanted	  with	  CD34-­‐E	  grafts	  receive	  more	  cells.	  Co-­‐transplantation	  of	  
MSC	  with	  these	  high	  cell	  numbers	  might	  result	   in	  e.g.	  obstruction	  of	   the	   lung	  circulation	  
and	   impairment	   of	   the	   expected	   positive	   influence	   of	   MSC	   on	   marrow	   engraftment	  
contributing	  to	  the	  non-­‐engraftments	  we	  observed	  in	  some	  cases.	  To	  prevent	  this	  possible	  
blocking	  of	  circulatory	  beds	  by	  MSC,	  we	  performed	  a	  pilot	  experiment	  in	  which	  we	  infused	  
MSC	  4	  hours	  after	  TPO	  expanded	  cells.	  .	  As	  shown	  in	  figure	  4,	  this	  later	  timing	  of	  MSC	  co-­‐
transplantation	   did	   not	   significantly	   alter	   the	   level	   of	   platelets	   in	   the	   PB	   6	  weeks	   after	  
transplantation	  (Fig	  4A,	  125.8±58.2	  plt/ml	  PB	  for	  MSC	  transplantation	  concomitantly	  with	  
the	   hematopoietic	   cell	   transplantation	   vs.	   134.4±62.6	   x103	   plt/ml	   PB	   for	   MSC	  
transplantation	  4	  hours	  after	  hematopoietic	  cell	  transplantation,	  p=0.873).	  Moreover,	  the	  
percentage	  of	  human	  CD45+	  cells	  in	  the	  bone	  marrow	  was	  not	  significantly	  changed	  when	  


























Figure 3. A: Percentage of human CD45 cells as a percentage of the total CD45 cells in the BM of the mice 
6 weeks after transplantation. Bars represent mean values of each group. All groups had higher mean 
percentages of human CD45 in their BM than the control group, but this was only significant for the group 
that received CD34+ cells and MSC (p<0.05). B: The mean percentage of human CD45+ cells of the mice 
that were transplanted with cells from the same cord blood unit were calculated and compared for each cell 
type (CD34+ cells or TPO expanded cells) when transplanted with or without MSC, showing an increase or a 
decrease in engraftment when MSC were added to the CD34+ cells or the TPO expanded cells of this cord 
blood. Co-transplantation of MSC with CD34+ cells increased the engraftment of the cells of all of the cord 
blood units. Co-transplantation of MSC with TPO expanded only increased the engraftment of the cells of 
three cord blood units. The average fold increase in engraftment by the co-transplantation of MSC with 
CD34+ cells was 7.1±2.1, The average fold increase in engraftment by the co-transplantation of MSC with 




























Figure 4: Engraftment results of mice transplanted with TPO expanded cells 
and co-transplanted with MSC at the time of hematopoietic cell 
transplantation (Tx at t=0h) or 4 hours after transplantation (Tx at t=4h). Bars 
represent mean values of each group. No differences in the platelet 
engraftment (A) in the peripheral blood or the human CD45+ cell engraftment 
(B) in the BM were detected when the MSC were transplanted on different 
time points.  
	  
	  
Migration	   properties	   and	   expression	   of	   migration	   related	   molecules	   of	   the	  
transplanted	  cells	  
SDF-­‐1α	  is	  the	  main	  chemo-­‐attractant	  for	  hematopoietic	  cells	  to	  home	  to	  the	  bone	  marrow	  
and	  migration	  capacity	  of	  cells	  towards	  SDF-­‐1α	  is	  therefore	  a	  crucial	  step	  in	  engraftment	  
43-­‐46.	  To	  investigate	  if	  TPO	  expansion	  and/or	  MSC	  affect	  the	  migratory	  capacity	  of	  the	  cells,	  
we	  analyzed	  the	  migration	  capacity	  of	  the	  grafts	  towards	  a	  100	  ng/ml	  SDF-­‐1α	  gradient	  in	  
Transwell	  plates	  (figure	  5A).	  Addition	  of	  MSC	  improved	  the	  migration	  of	  the	  CD34+	  cells	  
by	   3	   fold	   (21.6±4.8%	  with	   MSC	   vs.	   6.7±2.4%	   for	   CD34+	   cells	   alone,	   p<0.05).	   Also	   TPO	  
expansion	  improved	  the	  migration	  of	  the	  remaining	  CD34+	  cells	  in	  the	  transplant	  8-­‐9	  fold	  
(48.7±8.9%	   p<0.005).	   Addition	   of	   MSC	   did	   not	   further	   enhance	   the	   already	   increased	  
migration	  of	  residual	  CD34+	  cells	  in	  the	  TPO	  expanded	  CB	  (57.2±10.5%).	  	  
Because	   TPO	   expansion	   generated	   CD34-­‐CD61-­‐Lin-­‐	   cells	   that	   establish	   PB	   platelet	  
recovery,	  we	   also	   investigated	   the	   effect	   of	  MSC	   on	  migration	   of	   this	   sub-­‐population	   12.	  
Figure	   5B	   in	   this	   respect	   shows	   that,	   similarly	   as	   with	   residual	   CD34+	   cells,	   co-­‐
transplantation	  of	  MSC	  does	  not	   	  alter	  the	  migration	  of	  CD34-­‐CD61-­‐	  cells	  (37.0±4.1%	  for	  
TPO	  expanded	  transplants,	  33.2±2.1%	  	  for	  TPO	  expanded	  cells	  with	  MSC,	  p=0.818).	  	  
The	   expression	   of	   CXCR4,	   the	   receptor	   for	   SDF1α,	   on	   (residual)	   CD34+	   (figure	   5C)	   or	  
CD34-­‐CD61-­‐Lin-­‐	  cells	   (figure	  5D)	   	  was	  analyzed	  with	   flow	  cytometry	  (figure	  5C	  and	  5D)	  
but	  was	  not	  significantly	  altered	  by	  their	  incubation	  with	  MSC	  nor	  by	  TPO	  expansion	  alone	  
or	   in	   combination	   with	   MSC.	   However,	   the	   expression	   of	   CD49d	   and	   CD49e	   was	  
upregulated	   in	  TPO	  expanded	  CD34+	  cells	  as	  opposed	  to	  non	  expanded	  CD34+	  cells	  and	  




Figure 5. A: Percentage of CD34+ cells that have migrated through a trans-well system towards the lower 
compartment of the plate containing medium with 100ng/ml SDF-1α gradient (black bars) or medium alone 
(gray bars, spontaneous migration). CD34+ cells are either un-manipulated cells (control group and group 
that was transplanted with CD34+ cells and MSC) or the CD34+ subpopulation of the cells after expansion 
with TPO. Both addition of MSC and TPO expansion improved the migration of the CD34+ cells significantly. 
Addition of MSC to TPO expanded cells did not improve the migration of the subpopulation (*p<0.05). B: 
Percentage of cells of the CD34-CD61-Lin- subpopulation found after TPO expansion of CD34+ cells that 
have migrated through a trans-well system towards the lower compartment of the plate containing medium 
with 100ng/ml SDF-1α gradient (black bars) or medium alone (gray bars, spontaneous migration). Addition of 
MSC to TPO expanded cells did not improve the migration of the subpopulation. C: Percentage of CD34+ 
cells expressing CXCR4, CD49d or CD49e. There was no difference in the expression of CXCR4 between 
the different transplants suggesting that the differences found in the transwell migration are not due a 
difference in the expression of the receptor for SDF-1α. TPO expanded cells did express higher percentages 
of CD49d and to a lesser extend CD49e (*p<0.0001).D: Percentage of cells of the CD34-CD61- 
subpopulation found after TPO expansion of CD34+ cells expressing CXCR4. No differences in the 











Several	   studies	   have	   shown	   that	   co-­‐transplantation	   of	  MSC	   improves	   the	   bone	  marrow	  
engraftment	  in	  animal	  models	  18,31-­‐35,	  but	  the	  effect	  on	  the	  speed	  of	  platelet	  recovery	  has	  
not	  been	  investigated.	  In	  this	  study,	  we	  observed	  that	  MSC	  co-­‐transplantation	  with	  either	  
unmanipulated	   CD34+	   cells	   or	   with	   TPO	   expanded	   CD34+	   cells	   had	   no	   effect	   on	   the	  
recovery	   of	   platelets	   in	   the	   peripheral	   blood	  within	   2	   weeks	   after	   transplantation.	   The	  
early	   platelet	   recovery	   seen	   after	   transplantation	   of	   CB	   cells	   expanded	   with	   TPO	  
originates	   from	  CD34-­‐CD61-­‐Lin-­‐	   cells.	   This	   population	   that	   is	   (partly)	   committed	   to	   the	  
megakaryocyte	   lineage	   is	   unique	   for	   CB	   and	   not	   observed	   among	   TPO	   expanded	   adult	  
stem	   cell	   sources	   and	   this	  maturation	   pattern	  may	   contribute	   to	   the	   delayed	   and	   slow	  
platelet	   recovery	   observed	   after	   CB	   transplantation.	   12,47.	   The	   absence	   of	   this	   Lin-­‐neg	  
population	  in	  unmanipulated	  CD34+	  CB	  explains	  the	  lack	  of	  improvement	  of	  early	  platelet	  
recovery	  when	  MSC	  are	  co-­‐transplanted	  with	  uncultured	  CB	  CD34+	  cells.	  Also,	  in	  line	  with	  
earlier	   studies	   in	   NOD	   SCID	   mice	   showing	   that	   MSC	   co-­‐transplantation	   improved	   BM	  
engraftment	   and	   repopulation	   for	   CD34+	   CB	   cells	   12,13,18,31-­‐34,	   we	   observed	   that	   MSC	  
boosted	  both	  PB	  platelet	  levels	  after	  6	  weeks	  and	  BM	  engraftment.	  
The	   mechanism	   behind	   the	   improved	   engraftment	   by	   MSC	   is	   still	   unknown.	   We	   found	  
enhanced	  SDF-­‐1α	  migration	  capacity	  of	  CD34+	  cells	  by	  MSC	  in	  vitro,	  which	  was	  not	  related	  
to	  a	  change	  in	  the	  expression	  of	  CXCR4.	  This	  suggests	  that	  MSC	  induced	  improvement	  of	  
engraftment	  might	  be	  partly	  attributed	  to	  this	  increased	  migration	  capacity.	  However,	  the	  
interaction	  between	  MSC	  and	  stem	  cells	  on	  homing	   is	  complex	  48,49	  and	  conclusive	  proof	  
for	  this	  or	  other	  mechanisms	  is	  still	  lacking.	  Homing	  of	  MSC	  to	  the	  marrow	  was	  studied	  as	  
determinant	   for	   the	   observed	   engraftment	   potentiating	   effect	   and	   these	   studies	   have	  
shown	  conflicting	  results.	  Both	  Noort	  et	  al.	  and	  Kim	  et	  al.	  did	  not	  find	  MSC	  in	  the	  BM	  of	  the	  
mice	   after	   transplantation	   18,34.	   Noort	   at	   al	   analyzed	   the	   presence	   of	   MSC	   in	   multiple	  
organs	  with	  RT	  PCR	  and	  did	  not	  find	  any	  MSC	  in	  the	  BM,	  spleen,	  liver	  or	  thymus,	  but	  only	  
sequestration	  of	  the	  MSC	  in	  the	  a	  lung.	  This	  ‘lung	  barrier’	  was	  corroborated	  by	  Schrepfer	  
et	  al	  50,	  who	  IV	  injected	  labeled	  MSC	  and	  found	  high	  bioluminescence	  in	  the	  lungs	  with	  in	  
vivo	  imaging	  and	  ex	  vivo	  analysis	  in	  contrast	  to	  only	  trace	  signals	  from	  other	  organs	  such	  
as	  the	  spleen,	  the	  tibia	  and	  the	  liver.	  Moreover,	  efforts	  from	  Noort	  et	  al	  to	  bypass	  the	  lung	  
barrier	  by	  intra-­‐cardiac	  injection	  did	  not	  result	   in	  the	  detection	  of	  MSC	  in	  the	  BM	  either.	  
Only	  Hiwase	  et	  al.	  suggested	  that	  MSC	  and	  HSC	  can	  migrate	  in	  conjunction	  to	  the	  marrow	  
32.	  Other	  mechanisms,	   induced	  by	  MSC	  secreted	  cytokines	  and	  growth	  factors	  might	  also	  
play	  a	  role.	  MSC	  are	  known	  to	  support	  and	  maintain	  blood	  vessels	  51	  and	  might	  contribute	  
to	   marrow	   regeneration	   by	   inducing	   vascularization.	   Even	   MSC	   mediated	  
immunomodulation	  enhancing	  allogeneic	  tolerance	  has	  to	  be	  considered	  36.	  	  
The	   aim	   of	   our	   study	   was	   to	   investigate	   whether	   co-­‐transplantation	   with	   MSC	   had	   a	  
synergistic	   effect	   on	   accelerated	   platelet	   recovery	   and/or	   improved	   BM	   engraftment	   of	  
TPO	   expanded	   CB.	   We	   observed	   that	   MSC	   did	   not	   potentiate	   short	   term	   platelet	  
engraftment	  of	  TPO	  expanded	  CD34+	   cells.	  This	   could	  be	  associated	  with	  an	  unchanged	  
migration	  pattern	  of	  CD34-­‐CD61-­‐Lin-­‐	  cells	  towards	  an	  SDF-­‐1α	  gradient	  in	  vitro	  since	  MSC	  
do	   not	   influence	   the	   homing	   capacity	   of	   the	   TPO	   generated	   CD34-­‐CD61-­‐Lin-­‐	   cells	  
responsible	  for	  early	  platelet	  repopulation.	  However,	  a	  causal	  role	  on	  the	  lack	  of	  synergy	  
in	  platelet	  recovery	  between	  the	  two	  populations	  is	  elusive.	  Furthermore	  the	  increase	  in	  
BM	  engraftment,	  seen	  with	  the	  co-­‐transplantation	  of	  MSC	  with	  unmanipulated	  CD34+	  cells	  
is	   not	   seen	  when	  MSC	   are	   co-­‐transplanted	  with	  TPO	   expanded	   cells.	   Strikingly,	   in	   some	  
situations	  the	  combination	  seemed	  to	  decrease	  the	  6	  week	  PB	  platelet	  numbers	  as	  well	  as	  
human	  CD45+	  BM	  engraftment.	  This	  could	  largely	  be	  attributed	  to	  the	  fact	  that	  some	  mice	  
treated	   with	   the	   combination	   of	   TPO	   expansion	   and	   MSC	   virtually	   showed	   non-­‐
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engraftment	  (only	  0-­‐0.1%	  of	  human	  CD45	  cells	  in	  the	  bone	  marrow).	  If	  these	  ‘non’	  or	  ‘very	  
low’	   engrafters	   were	   not	   taken	   into	   account	   when	   calculating	   the	   mean	   engraftment	  
percentage	  of	   this	   group,	   the	   level	  of	  human	  CD45+	  cells	   in	   the	  BM	  rose	   from	  14.7%	   to	  
22.0%,	  which	   is	   similar	   to	  mice	   	   transplanted	  with	   only	  TPO	   expanded	   cells	   (20.2%).	  A	  
synergy	   of	   the	   two	   approaches	   which	   each	   separately	   have	   shown	   to	   improve	   platelet	  
recovery	   or	   BM	   engraftment	   in	   NOD/SCID	   mice	   was	   clearly	   absent.	   Most	   importantly,	  
adding	  MSC	  to	  TPO	  expanded	  cells	  may	  result	  in	  engraftment	  failure.	  
These	  non	  or	  very	  low	  engraftment	  cases	  in	  the	  combined	  approach	  could	  hypothetically	  
be	   caused	   by	   a	   phenomenon	   called	   the	   lung	   barrier.	   Because	   of	   their	   larger	   size,	   MSC	  
might	  become	  trapped	  in	  the	  lung.	  In	  addition,	  MSC	  can	  adhere	  to	  hematopoietic	  stem	  cell,	  
further	   impairing	   their	   homing	   to	   the	   marrow	   50.	   The	   high	   cell	   numbers	   in	   the	   TPO	  
expanded	   transplants	   in	   combination	   with	   the	   MSC	   may	   be	   critical	   to	   develop	   this	  
complication.	   Although	   we	   did	   observe	   acute	   deaths	   in	   both	   groups	   that	   were	   co-­‐
transplanted	   with	   MSC,	   possibly	   caused	   by	   pulmonary	   embolism,	   non	   engrafters	   were	  
only	  found	  in	  the	  group	  with	  TPO	  expanded	  cells	  combined	  with	  MSC.	  To	  see	  whether	  the	  
simultaneous	   presence	   of	   high	   numbers	   of	   cells	   transplanted	   after	   TPO	   expansion	  
together	  with	  MSC	   influenced	   the	  engraftment,	  we	  performed	  additional	   experiments	   in	  
which	  we	   transplanted	   the	  MSC	   4	   hours	   after	   the	   transplantation	   of	   the	   TPO	   expanded	  
cells.	  Although	  no	  differences	   in	   the	  engraftment	  of	  both	  platelets	   in	   the	  PB	  and	  human	  
CD45	  cells	  in	  the	  BM	  after	  6	  weeks	  were	  discerned,	  one	  mouse	  again	  showed	  hardly	  any	  
BM	   engraftment	   after	   6	   weeks.	   Interestingly,	   this	   mouse	   was	   given	   MSC	   4	   hours	   after	  
infusion	   of	   TPO	   expanded	   cells.	   Thus,	   entrapment	   of	   MSC	   adhered	   to	   TPO	   expanded	  
progenitor	  cells	  in	  the	  lung	  does	  not	  seem	  to	  be	  an	  explanation	  for	  non-­‐engraftment.	  	  
TPO	  expanded	  CD34+	  cells	  migrate	  better	  in	  vitro	  than	  fresh	  CD34+	  cells	  or	  fresch	  CD34+	  
cells	  with	  MSC.	  Whether	  this	  improved	  in	  vitro	  migration	  also	  translates	  into	  better	  in	  vivo	  
homing	  is	  not	  definite.	  A	  previously	  conducted	  homing	  study	  with	  99mTc-­‐tropolone-­‐labeled	  
cells	   13	  which	   showed	  a	   similar	  proportion	   (approximately	  0.5%)	  of	   the	   fresh	  CD34+	  or	  
TPO	   expanded	   CD34+	   cells	   that	   were	   transplanted	   homed	   towards	   the	   femur.	   In	   these	  
experiments	  fresh	  CD34+	  cells	  or	  their	  expanded	  equivalent	  were	  transplanted,	  i.e.	  higher	  
numbers	  of	  cells	  were	  transplanted	  in	  the	  TPO	  expanded	  group.	  The	  absolute	  number	  of	  
homing	  cells	   is	   therefore	  higher	   in	   the	  group	   that	  was	   transplanted	  with	  TPO	  expanded	  
cells.	  However,	  the	  experiment	  did	  not	  discern	  the	  proportion	  of	  each	  of	  the	  three	  major	  
subpopulations	   found	   after	   TPO	   expansion	   that	   homed	   to	   the	  BM.	   	   Although	  more	   cells	  
homed	  to	  the	  BM	  in	  the	  mice	  that	  received	  TPO	  expanded	  cells	  and	  the	  largest	  population	  
of	  these	  cells	  (CD61+)	  migrated	  less	  in	  vitro	  than	  the	  two	  other	  populations	  (CD34+	  and	  
CD34-­‐CD61-­‐	  cells	  (48.7±8.9%	  and	  37.0±4.1%	  respectively	  vs.	  15.4±2.1%	  for	  CD61+	  cells),	  
we	  cannot	  with	  certainty	  conclude	  that	  TPO	  expanded	  CD34+	  cells	  home	  better	  to	  the	  BM	  
than	  fresh	  CD34+	  cells.	  	  Despite	  the	  higher	  migration	  rate	  of	  TPO	  expanded	  cells	  in	  vitro,	  
the	   lack	  of	   improvement	   in	  engraftment	   suggests	   that	  other	   characteristics	   such	  as	  TPO	  
induced	   changes	   to	   their	   immature	   characteristics,	   their	   stemness	   and	   thus	   long	   term	  
engraftment	  potential,	  are	  more	  important	  in	  this	  respect.	  
In	   this	   paper	   we	   additionally	   focused	   on	   the	   added	   engraftment	   effect	   by	   MSC	   co-­‐
transplantation	  with	  TPO	  expanded	  cells.	  It	  is	  likely	  that	  MSC	  do	  not	  improve	  the	  homing	  
capacity	   of	   TPO	   expanded	   CD34+	   cells	   since	   they	   do	   not	   affect	   migration	   in	   vitro	   and	  
transplantation	  of	  MSC	  four	  hours	  after	  the	  transplantation	  of	  CD34+	  cells	  does	  not	  alter	  
the	  engraftment	  of	  the	  cells.	  	  
Superior	   migration	   of	   TPO	   expanded	   cells	   over	   the	   fibronectin	   coated	   transwell	   plates	  
despite	   a	   lack	   of	   difference	   in	   CXCR4	   expression	   might	   be	   explained	   by	   their	   higher	  
expression	   of	   adhesion	  molecules	   for	  which	   fibronectin	   is	   a	   ligand,	   such	   	   as	   CD49d	   and	  
CD49e	  52,	  Blocking	  of	  CD49d	  and	  CD49e	  with	  antibodies	  reduces	  the	  migration	  of	  CD34+	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cells	   in	   fibronectin	  coated	  plates	  53.	   In	   the	  migration	  experiments,	  short	   term	  incubation	  
with	  MSC	  did	  not	  lead	  to	  a	  change	  in	  the	  expression	  of	  adhesion	  markers	  on	  CD34+	  cells.	  
The	   increased	  migration	  and	  enhanced	  engraftment	  of	  non	  expanded	  CD34+	  cells	   in	   the	  
presence	   of	   MSC	   can	   therefore	   not	   be	   explained	   by	   a	   change	   in	   adhesion	   molecule	  
expression.	  Strikingly,	  expansion	  with	  CD34+	  cells,	  either	  with	  MSC	  or	  TPO	  might	  change	  
the	   longer	   term	   the	   engraftment	   capacity	   of	   the	   cells.	   This	   was	   suggested	   by	   studies	  
showing	  that	  after	  transplantation	  of	  one	  CB	  unit	  expanded	  by	  culture	  ex	  vivo	  with	  MSC	  or	  
TPO	   and	   one	   unmanipulated	   unit,	   the	   unmanipulated	   CB	   graft	   establishes	   long-­‐term	  
engraftment	  42,54.	  	  
In	   conclusion,	   co-­‐transplantation	   of	   MSC	   can	   improve	   engraftment	   after	   6	   weeks	  while	  
TPO	  expansion	   improves	  early	  platelet	   recovery.	  MSC	  co-­‐transplantation	  combined	  with	  
TPO	  expansion	  at	  best	  combines	  but	  gives	  no	  synergy	  on	  either	  of	  these	  effects.	  However,	  
the	   combination	   of	   high	   cell	   numbers	   introduces	   the	   risk	   of	   non-­‐	   engraftment.	   More	  
precise	  characterization	  of	  these	  non	  engrafting	  events	  will	  be	  essential	  to	  combine	  these	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BACKGROUND:	  Cord	  blood	  (CB)	  contains	  CD45	  negative	  cells	   that	  have	  clinical	  potential	  
cellular	  therapy.	  Separate	  banking	  of	  these	  CD45-­‐	  cells	  could	  extend	  the	  use	  of	  CB	  beyond	  
hematopoietic	   stem	   cell	   transplantation	   (HST).	   The	   ‘dual’	   use	   of	   CB	   is	   only	   possible	   if	  
removal	  of	  the	  CD45-­‐	  cells	  does	  not	  compromise	  the	  hematopoietic	  quality	  of	  the	  graft.	  We	  
analyzed	  the	  influence	  of	  CD45-­‐	  cells	  on	  the	  hematopoietic	  properties	  of	  a	  CB	  graft.	  
	  
STUDY	   DESIGN	   AND	  METHODS:	   CB	  mononuclear	   cells	   were	   separated	   into	   CD45+	   and	  
CD45-­‐	   cells.	   Both	   fractions	   were	   analyzed	   for	   marker	   expression,	   the	   influence	   on	  
immunological	   responses,	   the	   capacity	   to	   generate	   hematopoietic	   colonies	   and	   the	  
influence	  on	  the	  engraftment	  of	  CB	  CD34+	  in	  NOD	  SCID	  mice.	  
	  
RESULTS:	  CD45-­‐	  cells	  neither	  stimulated	  an	  immunological	  response	  of	  PBMC	  nor	  affected	  
the	   response	   to	   CB	   CD45+	   cells	   and	  were	   not	   able	   to	   form	   hematopoietic	   colonies.	   Co-­‐
transplantation	  of	  CD45-­‐	  cells	  did	  not	  alter	  the	  engraftment	  of	  CB	  CD34+	  cells	  in	  NOD	  	  
SCID	  mice,	  whereas	  CD45+	  cells	  improved	  the	  engraftment.	  	  
	  
CONCLUSION:	  Removal	  of	  CD45-­‐	  cells	  does	  not	  compromise	  the	  hematopoietic	  quality	  of	  
cord	  blood	  in	  vitro	  and	  in	  the	  in	  vivo	  engraftment	  in	  NOD/SCID	  mice.	  This	  would	  allow	  for	  


















































































Cord	   blood	   (CB)	   is	   currently	   banked	   in	   public	   banks	   for	   the	   purpose	   of	   unrelated	  
allogeneic	   hematopoietic	   stem	   cell	   transplantation	   (HST)	   for	   patients	   lacking	   a	   suitable	  
related	  or	  unrelated	  donor.	  Besides	  the	  public	  banking	  of	  CB,	  private	  banks	  store	  donor-­‐
directed	  CB	  to	  provide	  engineered	  regenerative	  or	  immunomodulatory	  cells	  when	  needed	  
in	   the	   future.	   Indeed	   in	   addition	   to	   hematopoietic	   stem	   cells	   (HSC),	   CB	   contains	   cell	  
populations	  with	  non-­‐hematological	  clinical	  potential	  such	  as	  mesenchymal	  stem/stromal	  
cells	   (MSC)	   and	   endothelial	   cells	   (EC).1,2	   EC	   and	  MSC	   are	   used	   for	   regenerative	   cellular	  
therapy	  such	  as	  vascular	  repair	  and	  wound	  healing,	   3,4	  or	  as	  therapy	  for	   immune	  related	  
diseases.	   5	   In	   HST,	   MSC	   are	   used	   for	   the	   treatment	   or	   prophylaxis	   of	   graft	   versus	   host	  
disease	   (GvHD)6	   and	   the	   co-­‐transplantation	   of	   MSC	   and	   CB	   HSC	   is	   investigated	   for	   the	  
enhancement	  of	  engraftment.7	  	  
Isolation	   of	   the	   non-­‐hematopoietic	   cells	   from	   the	   hematopoietic	   fraction	   and	   separate	  
cryopreservation	   of	   these	   fractions	   could	   expand	   the	   use	   of	   CB	   to	   both	   HST	   and	   other	  
therapies.	  Before	  ‘dual’	  banking	  can	  be	  considered	  it	  must	  be	  ensured	  that	  the	  removal	  of	  
non-­‐hematopoietic	  cells	  leaves	  the	  hematopoietic	  quality	  of	  the	  CB	  graft	  uncompromised.	  
Most	   culture	   protocols	   for	   the	   culture	   of	   EPC	   or	   MSC	   from	   CB	   involves	   the	   overnight	  
culture	  of	  the	  whole	  mononuclear	  cell	  fraction	  (MNC),	  after	  which	  the	  non-­‐adherent	  cells	  
are	   removed.	   However,	   this	   does	   not	   allow	   for	   the	   dual	   use	   of	   the	   unit	   since	   the	  
hematopoietic	   cells	   are	   discarded	   in	   this	   process.	   Separation	   of	   the	   two	   fractions	  must	  
therefore	  be	  done	  on	  markers	   that	   identify	  both	  MSC	  and	  EPC	  or	  by	  depletion	   from	   the	  
hematopoietic	  cells	  using	  the	  pan	  hematopoietic	  marker	  CD45,	  or	  a	  set	  of	  hematopoietic	  
lineage	   markers.	   Endothelial	   cells	   can	   be	   identified	   by	   the	   expression	   of	   vascular	  
endothelial	  growth	  factor	  receptor	  2	  (VEGF-­‐R2)	  and	  VE	  Cadherin	  (CD144)	  and	  have	  been	  
identified	   in	   fresh	   cord	   blood,	   but	   the	   frequency	   of	   these	   cells	   is	   very	   low	   and	   highly	  
variable	  between	  donors.	  8	  MSC	  can	  be	  identified	  by	  a	  combination	  of	  distinct	  makers	  and	  
properties	  set	  by	  the	  international	  society	  for	  cellular	  therapy	  (ISCT).9	  Besides	  the	  ability	  
to	  adhere	  to	  plastic	  and	  to	  differentiate	  into	  3	  mesodermal	  linegaes,	  MSC	  should	  express	  
CD105,	   CD73	   and	   CD90,	   and	   lack	   expression	   of	   CD45,	   CD34,	   CD14,	   CD19	   and	   HLA-­‐DR.	  
Efforts	  to	  identify	  MSC	  like	  cells	  in	  CB	  based	  on	  marker	  expression	  alone	  have	  shown	  cell	  
types	   that	   express	   certain	   markers,	   but	   confirmation	   by	   culture	   experiments	   is	   still	  
needed	   to	   confidently	   state	   that	   these	   cells	   are	   indeed	   MSC.10	   Both	   MSC	   and	   EPC	   are	  
derived	  from	  the	  non-­‐hematopoietic	  CD45	  negative	  fraction	  of	  CB.8,11	  Separating	  the	  CD45	  
negative	  cells	  from	  the	  hematopoietic	  fraction	  might	  therefore	  preserve	  the	  possibility	  to	  
culture	  both	  cell	  types.	  	  
In	  this	  study	  we	  have	   investigated	  the	   influence	  of	  CD45-­‐	  cells	  on	  the	  engraftment	  of	  CB	  
cells.	   For	   this	   purpose	   we	   have	   determined	   the	   proportion	   of	   CD45-­‐	   cells	   among	   CB	  
mononuclear	   cell	   suspensions	   and	   analyzed	   these	   cells	   for	   the	   expression	   of	  
hematopoietic	   and	   non-­‐hematopoietic	  markers.	   In	   addition,	  we	   isolated	   the	   CD45-­‐	   cells	  
from	   the	   CD45+	   cells	   and	   analyzed	   their	   capacity	   to	   grow	   hematopoietic	   and	   non-­‐
hematopoietic	   cells	   in	   vitro.	   The	   influence	   of	   the	   CD45-­‐	   fraction	   on	   the	   immunological	  
responses	   of	   CB	   CD45+	   cells	   and	   adult	   PBMC	   was	   analyzed	   with	   mixed	   leukocyte	  
reactions.	   To	   investigate	   the	   influence	   of	   CD45-­‐	   cells	   on	   transplantation	   in	   vivo,	   we	   co-­‐
transplanted	  CD45-­‐	  or	  CD45+	  cells	  with	  CB	  CD34+	  cells	  and	  analyzed	  the	  engraftment	  in	  







Materials	  &	  methods	  
	  
Collection	   and	   processing	   of	   umbilical	   cord	   blood.	   Umbilical	   cord	   blood	   (CB)	   was	  
drawn	   from	   the	   umbilical	   vein	   from	   newborns	   and	   collected	   in	   Citrate	   Phosphate	  
Dextrose	   Adenine-­‐1	   (Macopharma,	   Utrecht,	   The	   Netherlands)	   after	   written	   informed	  
consent	  from	  the	  mother	  and	  approval	  by	  the	  ethical	  committee	  of	  the	  Leiden	  University	  
Medical	  Center	  (LUMC).	  Mononuclear	  Cell	  suspensions	  (MNC)	  were	  prepared	  from	  whole	  
cord	   blood	   by	   density	   gradient	   separation	   with	   Ficoll	   (1.077	   g/ml,	   pharmacy	   LUMC).	  
CD34+	  or	  CD45+	  and	  CD45-­‐	  cells	  were	  subsequently	  separated	  by	  Magnetic	  Activated	  Cell	  
Sorting	  (MACS,	  Miltenyi,	  Bergisch	  Gladbach,	  Germany).	  
	  
Phenotypic	  characterization.	  Before	  analysis	  all	  samples	  were	   lysed	  with	  IO3	  test	  RBC	  
lysis	  solution	  (Beckman	  Coulter,	  Woerden,	  the	  Netherlands).	  Samples	  were	  measured	  on	  a	  
Beckman	  Coulter	  Cytomics	  FC500	   flow	  cytometer.	  CD45	  FITC,	  CD45	  ECD	  and	  CD45-­‐PC7	  
conjugated	  monoclonal	   antibodies	   (Beckman	   Coulter,	  Woerden,	   The	   Netherlands)	   were	  
used	   to	  discriminate	  CD45-­‐	  and	  CD45+	  cells.	  The	   fractions	  were	   further	  analyzed	   for	   the	  
expression	   of	   CD2PE,	   CD3PE,	   CD4PE,	   CD8PE,	   CD14PE,	   CD15PE,	   CD19PE,	   CD33PE,	  
CD56PE,	  CD34PE,	  CD61PC7,	  CD90PC5,	  CD31FITC,	  CD146FITC	  (Beckman	  Coulter),	  CD133	  
PE	   (Miltenyi),	   GpA	   PE	   (Dako,	   Glostrup,	   Denmark),	   HLA-­‐ABC	   PE	   and	   HLA-­‐DR	   PE	   (BD	  
Biosciences,	  Breda,	  the	  Netherlands).	  	  	  
	  
Mixed	  Lymphocyte	  Reactions.	  Selected	  HLA	  class	  I	  antigens	  of	  both	  CB	  cells	  and	  PBMC	  
from	  healthy	  donors	  were	  determined	  by	  flow	  cytometry	  with	  custom	  made	  human	  allele	  
specific	  monoclonal	  HLA	  class	  I	  antibodies.	  Subsequently,	  an	  HLA	  class	  I	  mismatched	  pair	  
consisting	   of	   one	   CB	   donor	   and	   one	   healthy	   donor	   was	   selected	   based	   on	   HLA	   class	   I	  
antigen	  disparity.12	  The	  response	  of	  PBMC	  to	  CB	  CD45+	  cells	  and	  the	  immunomodulatory	  
capacity	  of	  the	  CB	  CD45-­‐	  cells	  was	  determined	  by	  culturing	  105	  PBMC	  with	  105	  irradiated	  
CB	   CD45+	   cells	   either	   with	   and	   without	   different	   concentrations	   of	   CB	   CD45-­‐	   cells	  
(2.5*104,	   5*104	   or	   1*105).	   Similarly,	   we	   analyzed	   the	   immunomodulatory	   effect	   of	   CB	  
CD45-­‐	  cells	  on	  the	  response	  of	  CB	  CD45+	  cells	  against	  PBMC	  (105	  CB	  CD45+	  cells	  cultured	  
with	   105	   irradiated	   PBMC	  with	   and	  without	   the	   addition	   of	   0,	   2.5*104,	   5*104	   or	   105	   CB	  
CD45-­‐	   cells).	  The	   cells	  were	   cultured	   for	  5	  days	   in	  medium	  (IMDM,	  Life	  Tech.	  with	  10%	  
human	  serum,	  Sanquin)	  at	  37˚C	  and	  5%	  CO2,	  after	  which	  immune	  function	  was	  measured	  
directly	   by	   quantification	   of	   intracellular	   ATP	   levels	   of	   T-­‐cells	   with	   an	   ATP-­‐luciferase	  
assay.13	  CD3	  cells	  were	  isolated	  with	  Dynal	  beads	  (Invitrogen,	  Breda,	  the	  Netherlands)	  and	  
lysed.	  Luciferase	  (Life	  Tech.)	  was	  added	  to	  the	  well	  and	   luminesce	  was	  measured	  with	  a	  
luminometer	  (Berthold	  technologies,	  Bad	  Wilbad,	  Germany).	  The	  ATP	  produced	  by	  the	  T	  
cells	   of	   each	   of	   the	   conditions	   was	   averaged	   (4	   wells/condition)	   and	   divided	   by	   the	  
average	  ATP	  content	  of	  the	  medium	  control	  in	  order	  to	  obtain	  a	  relative	  stimulation	  index	  
(SI)	  that	  was	  used	  to	  compare	  different	  experiments.	  	  
	  
Colony	  formation	  experiments.	  MNC,	  CD45-­‐	  and	  CD45+	  fractions	  were	  analyzed	  for	  the	  
capacity	  to	  grow	  hematopoietic	  colony	  forming	  units	  (CFU)	  and	  endothelial	  colonies.	  CFU	  
assays	   were	   performed	   as	   described	   before.14	   For	   the	   culture	   of	   endothelial	   cells	   the	  
isolated	   fractions	  were	   cultured	   in	   fibronectin	   coated	   flaks	   overnight	   in	   EGM-­‐2	   (Lonza,	  
Verviers,	   Belgium)	   after	   which	   non-­‐adherent	   cells	   were	   removed.	   Adherent	   cells	   were	  





Analysis	   of	   the	   influence	   of	   engraftment	   of	   CB	   CD45-­‐	   and	   CD45+	   cells.	   All	   animal	  
experiments	  were	  conducted	  with	  ethical	  approval	  of	  the	  Experimental	  Animal	  Committee	  
of	   the	   LUMC.	   CB	   CD34+	   cells,	   CD45+	   and	   CD45-­‐	   cells	   were	   isolated	   as	   described	   above.	  
Sublethally	  irradiated	  NOD	  SCID	  mice	  were	  transplanted	  with	  either	  105	  CD34+	  cells	  alone,	  
105	  CD34+	   cells+	  106	  CD45+	   cells,	   or	  105	  CD34+	   cells+106	  CD45-­‐	   cells.	  After	  6	  weeks	   the	  
mice	  were	  sacrificed	  and	  the	  femoral	  bone	  marrow,	  blood	  and	  spleen	  was	  harvested	  and	  
analyzed	   for	   the	   presence	   of	   human	   and	   mouse	   CD45+	   cells	   (human	   CD45-­‐PC7	   (BC),	  
murine	   CD45-­‐PE	   (BD))	   and	   human	   CD34+	   ,	   CD33+,	   CD19+	   cells	   (CD34PC5,	   CD19PE,	  
CD33FITC	  (BC)).	  
	  
Statistics.	   Statistics	   were	   done	   with	   SPSS	   version	   20	   using	   a	   Mann	   Whitney	   test.	  




Composition	  of	  the	  CD45-­‐	  fraction	  
From	  eight	  CB	  units	  the	  MNC	  were	  analyzed	  for	  the	  expression	  of	  hematopoietic,	  stem	  cell	  
and	   non-­‐hematopoietic	   markers.	   The	   suspensions	   contained	   on	   average	   29±3%	   CD45-­‐	  
cells	   of	   which	   the	   majority	   expressed	   red	   cell	   marker	   glycophorin	   A	   (GpA)	   or	  
platelet/megakaryocyte	  marker	  CD61	  (Table	  1,	  27.9±8.5%	  and	  46.9±11.2%	  respectively).	  
Cells	  expressing	  stem	  cell	  and/or	  non-­‐hematopoietic	  markers	  such	  as	  CD34,	  CD133,	  CD90,	  
CD146,	  CD31	  and	  CD271	  were	  only	  found	  in	  small	  quantities	  (Table	  1).	  Approximately	  1%	  
of	  the	  CD45-­‐	  cells	  expressed	  lineage	  markers	  other	  than	  GpA	  or	  CD61.	  Expression	  of	  HLA	  
Class	   I	   was	   similar	   between	   the	   CD45-­‐	   and	   CD45+	   fractions	   (31.6±5.9%	   vs	   35.0±5.8%	  
respectively),	  but	  only	  few	  CD45-­‐	  cells	  expressed	  HLA-­‐DR	  (2.3±1.1%)	  compared	  to	  CD45+	  




Table 1: Expression levels of hematopoietic, non-hematopoietic and immunological 
markers by cells of the CD45+ fraction and the CD45- fraction after density gradient 
separation of whole CB and MACS isolation of the fractions. The majority of CD45- cells 
were GpA or CD61 positive. Part of the CD45- cells expressed HLA class I but HLA class 
II expression was low compared to CD45+ cells. Expression of non-hematopoietic and 















46.92 (±11.24) 26.02 (±5.30) 
GPA 27.93 (±8.52) 4.17 (±0.80) 
Lineage markers 0.96 (±0.41) 91.58 (±1.76) 
CD38 0.03 (±0.01) 10.75 (±1.95) 
CD80 
immunological 
0.07 (±0.02) 0.07 (±0.03) 
HLA-ABC 31.64 (±5.94) 34.95 (±5.77) 
HLA-DR 2.34 (±1.16) 35.98 (±2.12) 
CD34 stem cell 0.47 (±0.14) 0.93 (±0.25) 
CD90 stem cell / mesenchymal  9.78 (±4.16) 4.58 (±1.84) 
CD271 mesenchyhmal  0.14 (±0.02) 0.29 (±0.08) 
CD146 endothelial 0.11 (±0.05) 0.08 (±0.02) 
CD31 hematopoietic / endothelial 3.78 (±2.03) 22.87 (±3.76) 
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The	  immunomodulatory	  capacity	  of	  CB	  CD45-­‐	  cells	  on	  CD45+	  cells.	  Mixed	  lymphocyte	  
reactions	  were	   performed	   to	   determine	   the	   immunomodulatory	   capacity	   of	   CD45-­‐	   cells.	  
CD45-­‐	  cells	  did	  not	  induce	  a	  proliferative	  response	  when	  compared	  to	  CD45+	  cells	  (Figure	  
1A,	  mean	  SI	  1.0±0.1	  vs.	  2.1±0.5,	  p<0.05).	  The	  addition	  of	  different	  concentrations	  of	  CD45-­‐	  
cells	  did	  not	  alter	  the	  proliferative	  response	  of	  PBMC	  stimulated	  by	  mismatched	  CB	  CD45+	  
cells	  (p>0.9).	  .	  The	  responder	  capacity	  of	  CD45+	  CB	  cells	  upon	  stimulation	  with	  PBMC	  was	  
low	  as	  compared	  to	  adult	  cells,	  but	  we	  did	  not	  observe	  an	  immunomodulatory	  effect	  of	  CB	  
CD45-­‐	  cells	  on	  the	  response	  of	  CB	  CD45+	  cells	  to	  mismatched	  PBMC	  (Figure	  1)	  
	  
CD45-­‐	  cells	  cannot	  generate	  hematopoietic	  colonies	  but	  are	  able	  to	  form	  endothelial	  
cells.	   To	   investigate	   the	   capacity	   of	   CD45-­‐	   cells	   to	   grow	   hematopoietic	   colonies,	   MNC,	  
CD45+	  and	  CD45-­‐	   cells	   from	  4	  different	  donors	  were	   cultured	   in	  Methocult	   for	  2	  weeks	  
(Figure	  1C).	  CD45-­‐	  cells	  from	  only	  one	  donor	  were	  able	  to	  grow	  a	  few	  colonies	  (3	  BFU-­‐E,	  5	  
CFU-­‐GM	   and	   2	   CFU-­‐GEMM),	   but	   this	   number	   was	   markedly	   lower	   than	   the	   number	   of	  
colonies	  grown	  from	  the	  CD45+	  cells	  from	  this	  donor	  (27	  BFU-­‐E,	  56	  CFU-­‐GM	  and	  27	  CFU-­‐
GEMM).	  From	  7	  donors	  the	  capacity	  to	  grow	  endothelial	  cells	  (EC)	  from	  CD45+	  and	  CD45-­‐	  
cells	  was	   investigated.	   All	   7	   CD45-­‐	   fractions	  were	   able	   to	   grow	  EC	   as	   confirmed	   by	   the	  
expression	   of	   CD31	   and	   CD146.	   In	   contrast,	   EC	   could	   only	   be	   grown	   from	   one	   of	   the	  
CD45+	  fractions	  (data	  not	  shown).	  
	  
The	  influence	  of	  CD45-­‐	  cells	  on	  the	  engraftment	  of	  CB	  CD34+	  cells	  in	  NOD-­‐SCID	  mice.	  
A	  total	  of	  36	  mice	  were	  transplanted	  with	  cells	  from	  4	  CB	  units.	  The	  mice	  were	  separated	  
into	  three	  groups	  (3	  mice/group),	  which	  were	  transplanted	  with	  CD34+	  cells	  alone,	  CD34+	  
cells	  +	  CD45+,	  or	  CD34+	  cells	  +	  CD45-­‐	   cells.	  Figure	  2A-­‐C	  shows	   the	  percentage	  of	  human	  
CD45	  cells	  (hCD45)	  in	  the	  bone	  marrow	  (BM),	  blood	  and	  spleen	  of	  the	  mice	  6	  weeks	  after	  
transplantation.	  The	  mean	  percentage	  of	  hCD45	   in	   the	  BM	  was	  higher	   in	   the	  group	   that	  
received	  CD34+	  cells	  +	  CD45+	  cells	  (33.6±9.2%	  human	  CD45+	  cells)	  	  as	  compared	  to	  mice	  
transplanted	  with	   CD34+	   cells	   alone	   (23.2±7.9%)	   or	   	  mice	   that	   received	   CD34+	   cells	   +	  
CD45-­‐	   cells	   (20.1±6.2%).	   There	  were	   no	   differences	   found	   in	   the	   distribution	   of	   human	  





Figure 1: In vitro characteristics of the CD45- cells. A: Influence of CD45- on the response of PBMC to 
CD45+ cells. 105 irradiated CB CD45+ cells were added to PBMC and cultured for 5 days. To analyze the 
influence of CD45- cells, different numbers of CD45- cells were added to the CD45+ cells and compared with 
the response of PBMC to CD45+ cells alone. T cell response was measured by quantification of intracellular 
ATP levels using an ATP/luciferase assay. The stimulation index is calculated by dividing the ATP produced 
by the T cells in the experimental conditions by the ATP produced by the T cells in the medium controls. 
Addition of CD45- cells to CD45+ cells did not alter the immunological response of PBMC and addition of 
CD45- did not elicit any response (*p<0.05). These results suggest that CD45- cells do not influence the 
immunological properties of a cord blood graft in vitro. B: Influence of CD45- cells on the response of CB 
CD45+ to PBMC. 105 irradiated PBMC were added to CB CD45+ cells and cultured for 5 days. To analyze 
the influence of CD45- cells, different numbers of irradiated CD45- cells were added to the PBMC cells and 
compared with the response of CB CD45+ cells to PBMC alone. T cell proliferation was measured with a 
Luciferase/Luciferin assay, the stimulation index is calculated by dividing the ATP produced in autologous 
control conditions by the ATP produced by the experimental conditions. Addition of CD45- cells to PBMC 
cells did not alter the immunological response of CB CD45+ cells.C: Number of myeloid colonies cultured 
from MNC, purified CD45+ cells or purified CD45- cells. Part of the MNC fraction was separated into 
CD45+ and CD45- cells. All fractions were analyzed for their capacity to generate colony forming units (CFU) 
in a standard Methocult culture. Shown is the mean±SEM number of CFU formed by each fraction of 4 
separate experiments. Cells from the CD45- fraction were scarcely able to generate colonies and CD45+ 
cells generated more CFU than equal numbers of MNC (consisting of CD45+ and CD45- cells). These 





The	  majority	  of	   the	  CD45-­‐	   fraction	  of	  CB	  consists	  of	  GpA+	  cells	   and	  of	  CD61+	  cells.	  GpA	  
expressing	  cells	  partly	  consist	  of	  NRBC	  resistant	   to	  ammonia	  based	  red	  blood	  cell	   (RBC)	  
lysis	   buffer	   and	   the	   remainder	   of	   the	   GpA+	   cells	   consists	   of	   larger	   RBC	   that	   are	   not	  
properly	   lysed.	   The	   number	   of	   NRBC	   in	   the	   CB	   HST	   grafts	   has	   been	   correlated	   to	  
engraftment,	  but	  this	  was	  explained	  by	  a	  correlation	  between	  the	  number	  of	  NRBC	  and	  the	  
number	  of	  HSC	  and	  not	  causal	  of	  direct	  support	  of	  NRBC	  to	  engraftment.15	  The	  CD61+	  cells	  
in	   the	   CD45-­‐	   fraction	   of	   CB	   are	   likely	   mature	   megakaryocytes	   that	   have	   lost	   CD45+	  
expression	  or	  large	  platelet	  complexes.	  Although	  these	  cells	  do	  not	  have	  a	  nucleus,	  they	  do	  
appear	  in	  the	  MNC	  fraction	  when	  measured	  with	  flow	  cytometry	  since	  their	  forward	  and	  
sideward	  scatter	   fluorescence	   is	  similar	  to	  that	  of	  mononuclear	  cells.	  CD61+	  cells	  do	  not	  












































Figure 2:  Influence of CD45+ and CD45- cells on the engraftment of CB CD34+ cells. CD34+, CD45- 
and CD45+ cells we isolated from the MNC fraction of CB and transplanted into sublethally irradiated NOD 
SCID mice. A, B, C: Percentage of human CD45 cells of the total number of CD45 cells in the bone marrow, 
blood and spleen of NOD-SCID mice 6 weeks after transplantation. Only the co-transplantation of CD45+ 
cells increased the mean percentage of human CD45+ cells in the BM of the mice. D: Percentage of CD19, 
CD33 and CD34 of the human CD45 cells in the bone marrow of NOD-SCID mice, 6 weeks after 
transplantation. No significant differences were found in the distribution of the different hematopoietic cells in 





The	  expression	  of	  HLA	  class	  I	  antigen	  in	  the	  CD45-­‐	  fraction	  can	  probably	  be	  explained	  by	  
these	   mature	   megakaryocytes	   and	   platelets	   in	   the	   CD45-­‐	   fraction	   that	   have	   lost	   CD45	  
expression	  and	  by	  NRBC	  expressing	  HLA.17	  The	  immune	  cells	  in	  a	  CB	  graft	  provide	  a	  graft	  
versus	  leukemia	  (GvL)	  and	  can	  cause	  graft	  versus	  host	  disease	  (GvHD)	  and	  both	  of	  these	  
effects	   could	   be	   altered	   by	   the	   CD45-­‐	   cells	   in	   the	   graft.	   However,	   as	   expected	   by	   the	  
absence	  of	  class	  II	  bearing	  cells,	  isolated	  CD45-­‐	  cells	  do	  not	  elicit	  a	  T	  cell	  response	  of	  adult	  
PBMC	  and	  addition	  of	  CD45-­‐	  cells	  did	  not	  alter	  the	  response	  of	  PBMC	  to	  CB	  CD45+	  cells.	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Furthermore,	  the	  addition	  of	  CD45-­‐	  cells	  to	  isolated	  CD45+	  cells	  did	  not	  alter	  the	  (already	  
weak)	  responder	  capacity	  against	  the	  PBMC.	  The	  number	  of	  myeloid	  colonies	  that	  can	  be	  
formed	  in	  culture	  is	  a	  predictor	  of	  neutrophil	  and	  platelet	  engraftment	  after	  CB	  HST.18	  In	  
this	  study,	  the	  CD45-­‐	  cells	  of	  only	  one	  of	  five	  donors	  was	  able	  to	  form	  a	  small	  number	  of	  
hematopoietic	   colonies,	   and	   this	  number	  was	  10	   fold	   lower	   that	   the	  number	  of	   colonies	  
formed	  by	  the	  CD45+	  cells	  of	  the	  same	  donor.	  All	  other	  CD45-­‐	  fractions	  did	  not	  show	  any	  
growth	  of	  hematopoietic	  qualities,	  suggesting	  that	  the	  colonies	   formed	  by	  this	  particular	  
donor	  might	  be	   caused	  by	   contamination	  with	  CD45+	  cells.	  This	   suggests	   that	   all	  CD45-­‐	  
cells	  do	  not	  have	  hematopoietic	  progenitor	  potential.	  Furthermore,	  only	  CD45-­‐	  cells	  were	  
able	   to	   form	  endothelial	   colonies,	   showing	   that	   the	  non-­‐hematopoietic	  potential	  of	  CB	   is	  
preserved	  after	  isolation	  of	  the	  CD45-­‐	  fraction.	  
In	  mouse	  models,	  co-­‐transplantation	  endothelial	  cells	  and	  MSC	  have	  shown	  to	  improve	  the	  
engraftment	   of	   CB	   CD34+	   cells.19,20	   Removal	   of	   the	   progenitors	   of	   these	   cells	   might	  
negatively	   influence	   engraftment.	   However,	   in	   such	   studies,	   the	   cultured	   cells	   and	  
transfused	   cell	   numbers	   that	   are	   used	   are	   much	   higher	   than	   in	   un-­‐cultured	   CB.	   Co-­‐
transplantation	  of	  isolated	  CD45-­‐	  fraction	  did	  not	  enhance	  engraftment	  of	  CB	  CD34+	  cells,	  
whereas	  co-­‐transplantation	  of	  CD45+	  cells	   increased	  engraftment,	  showing	  that	  removal	  
of	  the	  CD45-­‐	  fraction	  does	  not	  impair	  the	  engraftment	  of	  CD34+	  cells.	  No	  differences	  were	  
seen	  in	  the	  percentage	  of	  myeloid,	  lymphoid	  or	  stem	  cells	  in	  the	  bone	  marrow,	  regardless	  
of	   whether	   the	   CD34+	   cells	   were	   transplanted	   with	   CD45+	   or	   CD45-­‐	   cells	   or	   without	  
additional	  cells,	  suggesting	  that	  removal	  of	  CD45-­‐	  cells	  does	  not	  skew	  the	  differentiation	  
of	  cells	  towards	  a	  specific	  lineage.	  
In	  conclusion,	  CD45-­‐	  cells	  do	  not	  seem	  to	  influence	  the	  immunological	  properties	  of	  a	  graft	  
and	   they	   are	   not	   needed	   for	   proper	   engraftment	   after	   transplantation	   in	   the	  NOD	   SCID	  
model.	  This	  would	  allow	  for	  removal	  of	  the	  CD45-­‐	  fraction	  of	  a	  CB	  unit	  and	  the	  use	  of	  this	  
fraction	  for	  other	  purposes.	   	  The	  dual	  use	  of	  CB	  could	  expand	  the	  applicability	  of	  CB	  and	  
thereby	  may	  (in	  the	   future)	  compensate	   for	  the	  costs	  of	   the	  collection	  and	  storage	  of	  CB	  
HSC.	   Currently	   only	   1%	   of	   the	   stored	   units	   have	   been	   used	   for	   transplantation.	   	   Dual	  
banking	  could	  stimulate	  collection	  and	  storage	  in	  parallel	  with	  private	  banks,	  leaving	  the	  
hematopoietic	   part	   for	   unrelated	   HST	   and	   the	   non-­‐hematopoietic	   cells	   for	   future	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25	  Years	  of	  cord	  blood	  transplantation	  
Since	   the	   first	   cord	   blood	   transplantation	   (CBT)	   in	   1989,	   over	   30,000	   CBT	   have	   been	  
performed	   worldwide.	   Especially	   in	   the	   last	   15	   years	   there	   has	   been	   a	   considerable	  
increase	   in	  cord	  blood	  transplantation	  (CBT).	  Given	  the	  minimum	  dose	  of	  cells	  per	  kg	  of	  
recipient	  bodyweight	  that	  is	  needed	  for	  a	  successful	  outcome,	  CBT	  of	  a	  single	  cord	  blood	  
unit	  was	  initially	  limited	  to	  children.	  The	  number	  of	  CBT	  performed	  in	  patients	  older	  than	  
16	   years	   has	   steadily	   increased	   and	   in	   2011	   accounted	   for	   54%	   of	   all	   CBT	   in	   the	   USA,	  
although	  it	  must	  be	  noted	  that	  this	  only	  accounted	  for	  6%	  off	  all	  allogeneic	  HST	  in	  adults.	  1	  
According	   to	   the	   Center	   for	   International	   Blood	   and	   Marrow	   Transplant	   Research	  
(CIBMTR),	  this	  increase	  can	  mostly	  be	  attributed	  to	  the	  steady	  increase	  of	  the	  number	  of	  
banked	   CB	   units	   which	   makes	   it	   easier	   to	   find	   two	   (partially)	   matched	   units	   for	   a	  
particular	  patient	  for	  double	  CBT	  (dCBT).	  The	  increase	  in	  CBT	  is	  reflected	  by	  the	  fact	  that	  
research	   focusing	  on	   the	   improvement	  of	  CBT	   is	   still	   active	  and	  currently	   there	  are	  418	  
ongoing	  clinical	  trials	  involving	  CBT.	  2	  
Despite	  the	  major	  contribution	  of	  CBT	  over	  the	  last	  25	  years,	  several	  problems	  need	  to	  be	  
improved	   to	   make	   cord	   blood	   the	   best	   choice	   for	   unrelated	   donor	   HST.	   The	   most	  
important	   problem	   in	   this	   respect	   is	   the	   higher	   chance	   of	   graft	   failure	   and	   delayed	  
engraftment,	   which	   are	   both	   related	   to	   the	   low	   number	   of	   HSPC	   in	   a	   cord	   blood	   graft.	  
Another	   problem	   is	   the	   relatively	   high	   cost;	   CBT	   is	   on	   average	   more	   expensive	   than	  
matched	  unrelated	   bone	  marrow	  or	   peripheral	   blood	   stem	   cell	   (PBSC)	  HST.	   3	   The	  main	  
cost	   drivers	   in	   this	   respect	   are	   laboratory	   costs	   such	   as	   tests,	   imaging,	   injections	   and	  
radiation)	  and	   the	  number	  of	   inpatient	  days,	  both	  accounting	   for	  approximately	  30%	  of	  
the	  total	  cost.	  The	  time	  that	  the	  patient	  has	  to	  stay	  in	  hospital	  is	  directly	  related	  to	  delayed	  
engraftment	  seen	  after	  CBT.	  Another	  aspect	  of	  cost	  is	  the	  high	  acquisition	  price	  of	  a	  cord	  
blood	   unit,	   especially	   when	   the	   patient	   is	   transplanted	   with	   two	   cord	   blood	   units.	   4	  
Because	   of	   these	   problems	   in	   recent	   years	   the	   increase	   in	   the	   number	   of	   CBT	   has	  
stagnated	   (figure	   1).	   A	   more	   efficient	   and	   or	   alternative	   use	   of	   banked	   CBs	   would	   be	  
extremely	  important	  to	  reduce	  and	  compensate	  logistic	  costs	  while	  faster	  engraftment	  of	  a	  







Figure 1: Number of allogeneic transplantations per donor source in centers that are registered with 
the CIBMRT for patients older than 20 years (A) and younger than 20 years (B). Figure adapted 
from the CIBMTR summary slides 2014 5 (UCB: umbilical cord blood, BM: bone marrow, PB: 





This	  thesis	  focuses	  firstly	  on	  possibilities	  to	  improve	  the	  engraftment	  after	  CBT	  by	  the	  co-­‐
transplantation	  of	  mesenchymal	   stem	  cells	   (MSC)	  (chapter	  1),	   the	   in	  vitro	  expansion	  of	  
CB	   (chapters	   2&3)	   or	   a	   combination	   of	   both	   expansion	   and	   MSC	   co-­‐transplantation	  
(chapter	  4).	  Secondly,	  by	  investigating	  the	  use	  of	  CB	  for	  other	  cellular	  therapies	  without	  
compromising	  the	  potential	   for	  HST	  a	  reduction	  of	  the	  cost	  for	  a	  CB	  product	   is	  (chapter	  
5).	  
 
Co-­‐transplantation	  of	  mesenchymal	  stem	  cells	  and	  CB	   to	  enhance	   the	  engraftment	  
of	  HSC:	  practical	  considerations	  
For	  large-­‐scale	  application	  of	  co-­‐transplantation	  of	  MSC	  for	  HST,	  there	  is	  a	  need	  for	  an,	  of	  
the	   shelf,	   low	   cost	   source	   of	  MSC.	   In	   this	   thesis	   we	   studied	   the	   engraftment	   enhancing	  
effect	  three	  different	  sources	  of	  MSC,	   fetal	   lung	  (chapter	  4),	  adult	  bone	  marrow	  and	  the	  
Wharton’s	   Jelly	  of	   the	  umbilical	  cord	  (chapter	  1).	  We	   initially	  used	   fetal	   lung	  MSC	  since	  
this	   source	   of	   MSC	   was	   previously	   used	   and	   shown	   to	   significantly	   improve	   the	  
engraftment	   of	   CB	   CD34+	   cells.	   6	   However,	   these	  MSC	   are	   harvested	   from	   aborted	   fetal	  
tissues	   and	   besides	   ethical	   opposition	   to	   the	   use	   of	   such	   tissues,	   it	   is	   doubtful	   that	   the	  
limited	  availability	  of	  this	  source	  is	  compatible	  with	  clinical	  applications	  on	  a	  large	  scale.	  	  
In	  chapter	  1	  we	  show	  that	  the	  engraftment	  enhancing	  capacity	  of	  MSC	  harvested	  from	  the	  
Wharton’s	  Jelly	  (WJ)	  of	  the	  umbilical	  cord	  is	  similar	  to	  that	  of	  BM	  derived	  MSC.	  WJ	  in	  this	  
respect	  is	  a	  more	  attractive	  source	  for	  the	  clinical	  application	  of	  MSC	  for	  several	  reasons:	  
1)	  The	  umbilical	  cord	  is	  considered	  to	  be	  waste	  material	  and	  is	  therefore	  practical	  free	  of	  
ethical	  constraints.	  In	  contrast,	  MSC,	  harvest	  from	  the	  bone	  marrow	  and	  adipose	  tissue	  as	  
other	   possible	   sources	   both	   require	   invasive	   and	   more	   or	   less	   painful	   procedures,	   i.e.	  
aspiration	  of	  BM	  from	  the	  pelvis	  and	  liposuction	  respectively.	  Most	  ethical	  review	  boards	  
are	  therefore	  reluctant	  to	  harvest	  MSC	  from	  these	  sources	  from	  non-­‐related	  donors	  on	  a	  
large	  scale.	  2)	  If	  the	  umbilical	  cord	  containing	  the	  WJ	  is	  collected	  concurrently	  with	  the	  CB,	  
the	  costs	  of	  HLA	  typing	  and	  infection	  screening	  of	  the	  donor,	  but	  also	  part	  of	  the	  collection	  
logistics	  can	  be	  shared	  between	  both	  products,	  logically	  resulting	  in	  a	  reduction	  of	  the	  cost	  
of	  both	  CB	  and	  a	  WJ	  MSC	  product.	  3)	  Finally,	  WJ	  MSC	  are	  of	  fetal	  origin	  and	  therefore	  have	  
a	   lower	   chance	   of	   viral	   transmission	   such	   as	  Epstein	  Barr	   virus	   and	   cytomegalovirus.	  A	  
disadvantage,	  however,	   is	   that	   cord	  collections	  are	   far	   from	  sterile	  while	  BM	  or	  adipose	  
aspiration	   can	   be	   done	   in	   a	   closed	   aseptic	   manner.	   Indeed,	   when	   we	   developed	   the	  
protocol	   for	   the	   isolation	   of	   WJ	   MSC	   (chapter	   1),	   we	   were	   initially	   confronted	   with	   a	  
variety	   of	   infections	   ranging	   from	   opportunistic	   bacteria	   to	   fungal	   infections.	   These	  
infections	  could	  be	  virtually	  prevented	  by	  implementing	  a	  stringent	  disinfection	  protocol	  
in	   which	   both	   ends	   of	   the	   umbilical	   cord	   are	   clamped	   to	   prevent	   influx	   of	   collection	  
medium	  into	  the	  cord,	  followed	  by	  sterilization	  of	  the	  outside	  of	  the	  cord	  with	  first	  iodine	  
and	  then	  70%	  ethanol.	  We	  have	  chosen	  an	  ‘explant’	  method	  to	  isolate	  the	  MSC	  instead	  of	  
digestion	  of	  the	  cord	  tissue	  with	  enzymes	  7,8	  because	  it	  is	  less	  laborious	  and	  cost	  intensive	  
than	  digestion	   of	   the	   tissue	  with	   enzymes.	   	   This	  method,	   despite	   challenges,	   has	   shown	  
that	  isolation	  and	  culture	  of	  WJ	  MSC	  can	  be	  performed	  with	  GMP	  compliance.	  7,8	  Moreover,	  
since	   the	   engraftment	   enhancing	   effect	   of	  WJ	  MSC	   is	   similar	   to	   that	   of	  BM	  MSC	  WJ	  MSC	  
could	  be	  a	  suitable	  alternative	  for	  BM	  MSC	  and	  probably	  more	  convenient	  for	  large	  scale	  
clinical	  application.	  	  	  
	  
Co-­‐transplantation	  of	  mesenchymal	  stem	  cells	  and	  CB	   to	  enhance	   the	  engraftment	  
of	  HSC:	  scientific	  considerations	  
A	  large	  conceptual	  problem	  for	  all	  clinical	  applications	  of	  MSC,	  including	  the	  enhancement	  
of	  HST	  engraftment,	  is	  the	  variability	  of	  the	  MSC	  between	  cultures.	  	  Although	  all	  harvested	  
and	  cultured	  cells	  fulfill	  the	  minimal	  criteria	  defining	  them	  as	  MSC,	  9	  these	  products	  of	  the	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cultures	   comprise	   a	   heterogeneous	   collection	   of	   cells,	   	   showing	   large	   variations	   with	  
respect	   to	   	   more	   detailed	   immuno-­‐phenotypes,	   proliferative	   capacity,	   differentiation	  
capacity	   and	   the	   ability	   to	   secrete	   cytokines.	   10	   Moreover,	   with	   still	   inconclusive	  
knowledge	  on	  the	  mechanism(s)	  by	  which	  MSC	  exert	  their	  effects,	  we	  can	  only	  expect	  to	  
find	   associations	   between	   general	   in	   vitro	   tests	   and	   the	   actual	   in	   vivo	   results.	   These	  
associations	  between	  the	  in	  vitro	  capacities	  on	  the	  one	  hand	  and	  the	  in	  vivo	  effects	  on	  the	  
other	  hand	  however,	  would	  be	  of	  great	  importance	  to	  develop	  in	  vitro	  quality	  control	  tests	  
as	   release	   criteria	   for	   an	   effective	   therapeutic	   functionality.	   In	   chapters	   1	   and	   4	   we	  
therefore	   analyzed	   different	   in	   vitro	   characteristics	   of	   MSC	   to	   see	   whether	   these	  
characteristics	  could	  be	  correlated	  to	  the	  engraftment	  enhancing	  effect	  of	  MSC.	  
In	   theory,	   the	   engraftment	   enhancing	   effect	   of	   MSC	   can	   be	   achieved	   via	   1)	   local	  
mechanisms,	  e.g.	  repair	  of	  the	  stromal	  tissues	  in	  the	  BM	  or	  secretion	  of	  factors	  that	  assist	  
in	  proliferation	  and/or	  differentiation	  of	   the	  HSC	   in	  the	  BM,	  or	  2)	  systemic	  mechanisms,	  
e.g.	  through	  an	  immunological	  effect	  on	  or	  assistance	  in	  the	  homing	  of	  the	  HSC	  to	  the	  BM.	  	  
The	  BM	  niche	  is	  likely	  to	  be	  the	  key	  target	  of	  MSC	  therapy.	  This	  niche	  consists	  of	  stromal	  
cells	  such	  as	  pericytes,	  osteoblasts,	  osteoclasts	  and	  adipocytes	  that	  are	  important	  for	  the	  
maintenance	   and	   proliferation	   of	   HSC.	   11	   This	   tissue	   is	   damaged	   by	   chemotherapy	   or	  
irradiation	  of	  the	  recipient	  of	  HST	  and	  repair	  of	  the	  stromal	  components	  of	  marrow	  could	  
be	  established	  by	  the	  homing	  of	  the	  MSC	  to	  the	  BM	  and	  their	  subsequent	  differentiation.	  
Interestingly,	   analysis	  of	   the	   in	  vitro	   capacity	   to	  differentiate	   into	  osteoblast,	   adipocytes	  
and	   chondrocytes	   (chapter	   1)	   showed	   that	   WJ	   MSC	   are	   limited	   and	   variable	   in	   this	  
respect	   compared	   to	   BM	   MSC.	   Since	   MSC	   from	   both	   sources	   were	   equally	   potent	   in	  
enhancing	   the	   engraftment	   of	   CB	   CD34+	   cells,	   it	   is	   unlikely	   that	   differentiation	   into	  
stromal	  tissues	  of	  the	  recipient	  is	  responsible	  for	  the	  engraftment	  enhancing	  effect	  in	  our	  
model.	  Moreover,	  and	  of	  considerable	  importance,	  homing	  of	  intravenously	  injected	  MSC	  
to	  the	  BM	  has	  so	  far	  not	  been	  convincingly	  shown.	  	  6,12	  
Another	   mechanism	   for	   the	   engraftment	   enhancement	   effect	   could	   be	   related	   to	   the	  
immuno-­‐modulatory	   capacity	   of	  MSC.	   12,13	   The	   in	   vitro	   experiments	   in	   chapter	   1	   show	  
that	  the	  capacity	  of	  MSC	  to	  suppress	  an	  immunological	  response	  is	  similar	  between	  MSC	  
derived	   from	   WJ	   or	   BM.	   Notwithstanding	   this	   possibility,	   the	   3	   fold	   engraftment	  
enhancement	   mediated	   by	   MSCs	   of	   both	   sources	   is	   not	   likely	   due	   to	   their	   immune	  
modulating	   capacities	   since	   transplantation	   was	   performed	   with	   purified	   stem	   cells	   in	  
immune	  deficient	  NOD	  SCID	  mice	  and	  our	  model	  was	  therefore	  devoid	  of	  immunologically	  
active	  cells.	  	  	  
Finally,	  the	  engraftment	  enhancing	  effect	  of	  MSC	  could	  be	  attributed	  to	  the	  ability	  of	  MSC	  
to	   assist	   HSC	   homing	   to	   the	   BM.	   In	   chapter	   4	   we	   show	   that	   MSC	   can	   improve	   the	  
migration	  of	  non	  expanded	  CD34+	  cells	  in	  transwell	  plates	  with	  an	  SDF-­‐1α	  gradient.	  SDF-­‐
1α	  is	  main	  chemoattractant	  of	  the	  BM,	  and	  expression	  of	  its	  receptor	  CXCR4	  is	  associated	  
with	  the	  homing	  of	  HSC	  to	  the	  BM.	  14	  	  
Interestingly,	   this	   increased	  migration	  was	   not	   related	   to	   the	   expression	   of	   CXCR4,	   the	  
receptor	   for	   SDF-­‐1α,	   by	   the	   CD34+	   cells.	   This	   could	   be	   explained	   by	   the	   in	   vitro	  
experimental	   conditions.	   The	   plates	   are	   coated	   with	   fibronectin,	   a	   ligand	   for	   adhesion	  
receptors	  CD49d	  and	  CD49e.	  15	  Earlier	  studies	  have	  shown	  that	  migration	  of	  CD34+	  cells	  
on	  fibronectin	  coated	  plates	  is	   increased	  compared	  to	  non-­‐coated	  plates,	  and	  blocking	  of	  
the	   adhesion	   receptors	   CD49d	   and	   CD49e	   diminishes	   this	   increase.	   16	   Indeed,	  we	   could	  
show	  that	  incubation	  of	  the	  CD34+	  cells	  with	  fetal	  lung	  MSC	  did	  upregulate	  the	  expression	  
of	  CD49d	  and	  CD49e,	  which	  could	  explain	  the	  increased	  migration	  described	  in	  chapter	  5.	  
On	   the	  other	  hand,	   in	  chapter	  2	   CD34+	  migration	  was	  not	   increased	  by	  BM	  or	  WJ	  MSC	  
despite	  a	   similar	  upregulation	   in	  CD49d	  and	  CD49e	  as	  was	  observed	   for	   fetal	   lung	  MSC.	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These	   inconsistent	   results	   leave	   doubt	   that	   enhancement	   of	   migration	   after	   incubation	  
with	  BM	  or	  WJ	  MSC	  is	  the	  main	  cause	  for	  enhancement	  of	  in	  vivo	  engraftment.	  	  
Lastly,	  the	  number	  of	  passages	  of	  the	  cultured	  MSC	  may	  play	  a	  role.	  A	  study	  that	  looked	  at	  
the	  long	  term	  outcomes	  of	  MSC	  treatment	  for	  GvHD	  and	  hemorrhagic	  cystitis	  showed	  that	  
in	   the	  GvHD	  patients	   the	  one	  year	  survival	   rate	  was	  only	  21%	   in	   the	  patients	   that	  were	  
transplanted	  with	  MSC	  that	  were	  cultured	  for	  3	  or	  more	  passages,	  as	  opposed	  to	  75%	  in	  
the	  patients	  that	  were	  treated	  with	  MSC	  from	  passage	  1	  or	  2	  17.	  	  	  
Currently	  there	  are	  seven	  clinical	  trials	   involving	  the	  co-­‐transplantation	  of	  mesenchymal	  
stem	  cells	   listed	  on	  the	  website	  of	   the	  U.S.	  National	   Institutes	  of	  Health.	  2	  Whether	  these	  
small	  scale	  studies	  that	  mostly	  focus	  on	  the	  safety	  of	  MSC	  co-­‐transplantation	  18-­‐23	  will	  give	  
definite	  answers	  on	  engraftment	  mechanisms	  is	  doubtful	  and	  more	  detailed	  and	  larger	  in	  
vivo	  studies	  on	  the	  mechanism	  behind	  engraftment	  enhancement	  are	  therefore	  needed	  to	  
conclusively	  elucidate	  this	  mechanism.	  	  
	  
Co-­‐transplantation	  of	  mesenchymal	  stem	  cells	  and	  CB	   to	  enhance	   the	  engraftment	  
of	  HSC:	  safety	  concerns	  
There	   are	   several	   safety	   concerns	   with	   respect	   to	   the	   clinical	   application	   of	   MSC.	   24	   In	  
order	  to	  obtain	  a	  sufficient	  number	  of	  MSC	  for	  transplantation,	  primary	  MSC	  are	  cultured	  
for	  several	  passages.	  During	  this	  culture	  it	  is	  possible	  that	  the	  cells	  acquire	  DNA	  mutations	  
and	   chromosomal	   aberrations	   which	   can	   lead	   to	   malignant	   transformation	   of	   the	   cells	  
after	   transplantation.	   Fortunately,	   so	   far	   such	  malignant	   transformations	   have	   not	   been	  
observed	   in	   vivo	   or	   in	   vitro.	   25	   Another	   concern	   is	   ectopic	   tissue	   formation	   of	   the	  
transplanted	   cells,	   but	   a	   study	   that	   analyzed	   tissue	   samples	   from	  31	  patients	   that	  were	  
infused	  with	  MSC	   found	   no	   signs	   of	   this	   formation.	   Furthermore,	   the	   detection	   of	   DNA	  
derived	   from	   the	  MSC	   donor	   correlated	   negatively	   with	   the	   time	   after	   infusion,	   i.e.	   the	  
detectable	   levels	   of	   DNA	   coming	   from	   the	   MSC	   decreased	   with	   time,	   showing	   that	   the	  
transplanted	  MSC	  gradually	  disappear	  26.	  	  
Another	   safety	   concern	  associated	  with	   the	   co-­‐transplantation	  of	  MSC	  and	  HSC	  apply	   to	  
possibly	  unwanted	  immunomodulatory	  capacities	  of	  the	  MSC.	  Although	  MSC	  can,	  next	  to	  
their	  engraftment	  enhancing	  effect,	  prevent	  GvHD,	  their	  immunomodulatory	  capacity	  can	  
also	   be	   detrimental	   for	   the	   outcome	   of	   transplantation.	   In	   this	   respect,	   co-­‐transplanted	  
MSC	  might	  theoretically	  suppress	  the	  graft	  versus	  leukemia	  (GvL)	  effect	  and	  consequently	  
increase	  the	  chance	  of	  relapse.	  A	  pilot	  study	  from	  2008	  showed	  that	  in	  a	  group	  of	  patients	  
that	  was	  co-­‐transplanted	  with	  MSC	  6	  out	  of	  10	  patients	  relapsed	  compared	  to	  only	  3	  out	  of	  
15	   patients	   in	   the	   control	   group.	   27	   However,	   another	   study	   that	   compared	   historical	  
controls	  with	  patients	  that	  were	  co-­‐transplanted	  with	  MSC	  did	  not	  find	  such	  an	  increase	  in	  
relapse	  incidence,	  but	  did	  find	  a	  MSC	  associated	  reduction	  in	  GvHD.	  28	  	  
Finally,	   the	   immunosuppressive	   effect	   of	   MSC	   could	   lead	   to	   a	   higher	   infection	   rate	   in	  
patients	   that	   are	   co-­‐transplanted	   with	   MSC.	   One	   of	   the	   mechanisms	   by	   which	   MSC	  
suppress	  immune	  responses	  is	  the	  induction	  of	  indoleamine	  2,3-­‐dioxygenase	  (IDO),	  which	  
catalyzes	   the	  conversion	   from	  tryptophan	   to	  kynurenine.	   29	  Kynurenine	  decreases	  T-­‐cell	  
cytotoxicity,	  30	  which	  can	  make	  the	  patient	  more	  vulnerable	  to	  infections	  such	  as	  CMV	  and	  
EBV	  and	  opportunistic	  fungal	  infections.	  The	  previously	  mentioned	  study	  on	  the	  long	  term	  
follow	  up	  of	  MSC	  treated	  patients	   found	  a	  high	   incidence	  of	   fungal	   infections	   in	  patients	  
with	   acute	   steroid	   resistant	  GvHD	   that	   responded	  well	   to	   the	   therapy.	   17	   The	   long	   term	  
effect	  of	  immune	  suppression	  by	  MSC	  also	  seems	  to	  play	  a	  role	  in	  the	  survival	  rate	  of	  these	  
patients	   as	   they	   also	   show	   a	   high	   mortality	   rate	   due	   to	   infections	   two	   years	   after	  
treatment.	  	  	  
Notwithstanding	   the	   so	   far	   excellent	   safety	   record	  of	  MSC	   treatment,	   larger	   randomized	  
studies	   with	   longer	   follow	   up	   are	   needed	   to	   elucidate	   not	   only	   how	   MSCs	   exert	   their	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beneficial	  effects	  in	  vivo	  but	  also,	  vice	  versa,	  if	  they	  can	  induce	  	  relapse,	  	  infection	  	  or	  other	  
longer	  term	  unwanted	  side	  effects.	  These	  studies	  should	  take	  the	  conditioning	  regime,	  the	  
specific	  disease	  and	  the	  GvHD	  course	  and	  treatment	  as	  parameters	  into	  account.	  	  
	  
Clinical	  application	  of	  CB	  expansion	  with	  TPO:	  practical	  considerations	  
As	   mentioned	   in	   the	   introduction	   of	   this	   thesis,	   the	   clinical	   application	   of	   the	  
transplantation	   of	   TPO	   expanded	   cells	   would	   be	   most	   suitable	   for	   patients	   undergoing	  
unexpanded	   CB	   HST	   that	   are	   refractory	   to	   platelet	   transfusions.	   Although	   we	   show	   in	  
chapter	   2	   that	   the	   engrafted	   TPO	   expanded	   cells	   exhibit	   the	   potential	   for	   long	   term	  
engraftment,	  recovery	  of	  CD45+	  cells	  in	  the	  blood	  is	  delayed.	  Furthermore,	  the	  long	  term	  
engraftment	   capacity	   is	   decreased	   as	   compared	   to	   non	   expanded	   CB	   cells	   and	  
transplantation	  of	  a	  single	  graft	  of	  TPO	  expanded	  CD34+	  cells	   is	   therefore	  not	  advisable.	  	  
Transplantation	   of	   TPO	   expanded	   cells	   in	   combination	   with	   a	   non	   expanded	   unit	   to	  
safeguard	  long	  term	  engraftment	  therefore	  seems	  to	  be	  the	  best	  alternative.	  Important	  in	  
this	  respect	  is	  that	  the	  TPO	  expanded	  cells	  responsible	  for	  short	  term	  platelet	  recovery	  did	  
not	   reduce	   or	   affect	   the	   long-­‐term	   engraftment	   of	   non-­‐expanded	   CD34+	   cells	   nor	  	  
influence	  the	  platelet	  recovery	  of	  these	  cells	  (chapter	  2).	  	  
For	  further	  translation	  of	  the	  in	  vivo	  experiments	  with	  immune	  deficient	  mice	  into	  clinical	  
use,	  we	  still	  need	  to	  monitor	  the	  functionality	  of	  platelets	  derived	  from	  the	  TPO	  expanded	  
cells	  that	  have	  engrafted;	  platelets	  derived	  from	  non-­‐expanded	  CD34+	  cells	  that	  engrafted	  
in	   NOD	   SCID	   mice	   have	   shown	   this	   functionality	   in	   in	   vitro	   assays	   31,	   GMP	   compliant	  
upscaling	  of	   our	   expansion	  protocol	   to	   a	   therapeutic	   transplant	   size	   	  would	  be	   the	  next	  
step	  towards	  clinical	  implementation.	  What	  is	  already	  convenient	  of	  the	  current	  protocol	  
is	  the	  use	  of	  the	  clinical	  grade	  Nplate	  (romiplostim),	  an	  analog	  of	  TPO,	  which	  is	  registered	  
to	   treat	   thrombocytopenic	   patients	   32	   and	   the	   fact	   that	   the	   expansion	  medium	  does	   not	  
contain	  animal	  components	  such	  as	  fetal	  bovine	  serum.	  	  
	  
Combining	  TPO	  expansion	  and	  the	  co-­‐transplantation	  of	  MSC	  for	  the	  improvement	  
of	  CB	  transplantation.	  
Transplantation	   of	   expanded	   cells	   and	   the	   co-­‐transplantation	   of	  MSC	   both	   seem	   potent	  
strategies	  for	  the	  enhancement	  of	  CB	  engraftment.	  Combining	  these	  strategies	  could	  be	  a	  
way	  to	  synergistically	  improve	  the	  outcome	  of	  CB	  transplantation.	  In	  chapter	  4	  we	  report	  
on	  TPO-­‐	  expanded	  CB	  CD34+	  cells,	  shown	  to	  accelerate	  platelet	  recovery	  in	  the	  peripheral	  
blood	   (PB)	   33-­‐36	   with	   co-­‐transplantation	   of	   MSC,	   shown	   to	   improve	   bone	   marrow	  
engraftment.	   While	   both	   strategies	   themselves	   provided	   the	   benefits	   of	   each	   of	   the	  
separate	  strategies,	  combining	  both	  methods	  did	  not	  yield	  any	  synergistic	  effect	  and	  even	  
led	   to	   non	   engraftment	   events.	   Graft	   failure	   of	   CBT	   is	   believed	   to	   be	   caused	   by	   the	   low	  
number	  of	  stem	  cells	  and/or	  HLA	  disparity	  between	  the	  donor	  and	  the	  the	  recipient.	  Both	  
these	  mechanisms	  however	  are	  not	  likely	  to	  play	  a	  role	  in	  the	  non-­‐engraftment	  events	  we	  
observed	  in	  our	  in	  vivo	  experiments	  since	  identical	  grafts	  (and	  cell	  numbers)	  without	  MSC	  
were	  able	  to	  reconstitute	  the	  bone	  marrow	  and	  immune	  cells	  are	  lacking	  in	  our	  model.	  We	  
excluded	  that	  the	  non	  engraftment	  events	  in	  chapter	  4	  might	  be	  due	  to	  the	  high	  amounts	  
of	   infused	   cells	   when	   the	   TPO	   expanded	   cells	   and	   MSC	   were	   combined	   and	   possibly	  
concomitant	   lung	   entrapment	   of	   hematopoietic	   stem	   cells,	   since	   transplantation	   of	   the	  
MSC	   four	   hours	   after	   the	   transplantation	   of	   the	   TPO	   expanded	   cells	   still	   resulted	   in	   a	  
mouse	  without	   engraftment.	  Without	   any	   synergistic	   effect	   of	   the	   co-­‐transplantation	   of	  
MSC	  and	  TPO	  expanded	  cells	  on	  either	  platelet	  recovery	  or	  engraftment	  we	  feel	  that	  this	  





Expansion	  of	  long-­‐term	  engraftment	  capacity	  of	  CB	  HSC	  in	  one	  of	  two	  transplanted	  
cords:	  general	  considerations	  
Since	   several	   expansion	  protocols	   are	  known	   to	   increase	   the	   graft	   size	   	   to	   cell	   numbers	  
that	   should	   ensure	   successful	   engraftment,	   37-­‐39	   it	   is	   still	   considered	   to	   be	   a	   risk	   	   to	  
transplant	   only	   one	   expanded	   unit	   into	   an	   adult	   patient.	   So	   far	   all	   clinical	   trials	   using	  
expanded	  cells	  have	  therefore	  combined	  the	  expanded	  graft	  with	  a	  non	  expanded	  graft	  37-­‐
40	   to	   ensure	   the	   long	   term	   engraftment	   capacity	   of	   the	   transplant.	   Expansion	   of	   HSC	  
inevitably	   leads	  to	  a	  certain	  degree	  of	  differentiation	  of	  the	   long	  term	  repopulating	  stem	  
cell	  pool	  whereby	  the	  immaturity	  and	  self	  renewal	  capacity	  is	  lost	  leading	  to	  reduction	  in	  
long	  term	  repopulation	  capacity.	  	  	  	  	  
Preservation	  of	  the	  long	  term	  repopulating	  capacity	  cannot	  be	  assessed	  properly	  with	  in	  
vitro	  models	  while	  animal	  models	  also	  have	  intrinsic	  limitations.	  Clinical	  studies	  that	  have	  
used	  expanded	  cells	   in	  combination	  with	  a	  unit	  of	  non	  expanded	  cells,	  showed	  that	   long	  
term	  engraftment	  is	  usually	  skewed	  towards	  or	  eventually	  totally	  dependent	  on	  the	  non-­‐
expanded	   unit	   38,40.	   However,	   because	   of	   this	   double	   transplant	   approach	   it	   remains	  
difficult	  to	  assess	  whether	  expanded	  cells	  indeed	  lose	  their	  long	  term	  engraftment	  ability	  
or	   that	  non-­‐expanded	  cells	  eventually	  out-­‐compete	   the	  expanded	  cells	   in	   this	  respect.	   In	  
light	   of	   this	   possibility,	   in	   chapter	   2	   we	   specifically	   studied	   graft	   dependent	   blood	  
recovery	  and	  engraftment	  in	  double	  graft	  transplantations	  of	  a	  TPO	  expanded	  and	  a	  non	  
expanded	   CB	   graft	   in	   NOD	   SCID	  mice.	   By	   the	   use	   of	   HLA	   allele	   specific	   antibodies,	   the	  
progeny	   of	   the	   different	   grafts	   could	   be	   distinguished	   in	   the	   blood,	   BM	   and	   spleen.	  
Although	   the	  PB	  of	   the	  mice	   contained	  platelets	   that	  originated	   from	   the	  TPO	  expanded	  
graft	   up	   to	   20	   weeks	   after	   transplantation,	   thus	   showing	   that	   TPO	   expansion	   does	   not	  
deplete	  the	  capacity	  of	  the	  CB	  cells	  to	  differentiate	  into	  megakaryocytes	  and	  platelets,	  the	  
chimerism	  of	  the	  cells	  in	  the	  blood,	  BM	  and	  spleen	  at	  20	  weeks	  was	  skewed	  towards	  the	  
non	  expanded	  graft.	  This	  suggests	  that	   long	  term	  engraftment	  of	  the	  TPO	  expanded	  cells	  
occurs	  but	  was	  less	  efficient	  than	  that	  of	  the	  non-­‐	  expanded	  cells.	  	  
Two	   mechanisms	   by	   which	   the	   non-­‐expanded	   unit	   becomes	   dominant	   should	   be	  
considered.	  So	  far,	  by	  looking	  at	  clinical	  experience	  with	  double	  CB	  transplantation	  of	  two	  
non	   expanded	   units,	   immunological	   processes	   and	   the	   viability	   and	   cell	   number	   of	   the	  
individual	  units	  seem	  to	  be	  the	  most	  important	  factors	  in	  the	  establishment	  of	  dominance.	  	  
The	   number	   of	   specific	   immune	   competent	   T	   cells	   such	   as	   CD3	   (CD4+CCR7+)	   cells	   in	  
either	  graft	  seems	  to	  be	  associated	  to	  the	  establishment	  of	  dominance	  of	  that	  particular	  CB	  
unit.	  41-­‐43	  The	  remaining	  number	  of	  these	  types	  of	  cells	  in	  an	  expanded	  graft	  in	  this	  respect	  
will	  depend	  on	  the	  type	  of/nature	  of	  expansion	  protocol.	  If	  the	  cells	  are	  expanded	  for	  the	  
mononuclear	  fraction	  of	  the	  cord	  blood	  unit,	  the	  immune	  competent	  cells	  are	  likely	  to	  be	  
affected	  by	  the	  culture	  conditions	  while	  in	  isolated	  and	  expanded	  CD133+	  and	  CD34+	  cells	  
the	  immune	  competent	  cells	  are	  completely	  removed.	  	  	  	  
In	   the	   latter	   approach,	   the	   non	   expanded	   cells	   will	   clearly	   have	   the	   immunological	  
advantage	  in	  a	  graft	  vs	  graft	  response	  leading	  to	  eventual	  dominance	  of	  this	  unit.	  In	  our	  in	  
vivo	  model	   that	  was	  devoid	  of	   immune	   competent	   cells,	   the	  observed	  dominance	  of	   the	  
non	  expanded	  cells	  should	  be	  	  attributable	  to	  another	  mechanism	  and	  possibly	  dependent	  
on	  the	  number	  of	  (long	  term	  repopulating)	  stem	  cells	  that	  was	  higher	  in	  the	  non-­‐expanded	  
units.	  	  	  	  
The	  immune	  competence	  of	  grafts	  is	  not	  only	  important	  for	  engraftment	  and	  dominance	  in	  
case	   of	   double	   transplant	   strategies,	   it	   is	   even	   more	   important	   if	   one	   realizes	   that	   the	  
(minor)	  HLA	  mismatch	  between	  the	  graft	  and	  the	  patient	  is	  critical	  for	  the	  GvL	  effect.	  GvL	  
is	  essential	  to	  prevent	  disease	  relapse	  and	  in	  essence	  required	  for	  total	  donor	  chimerism	  
and	   eventual	   complete	   	   disease	   remission.	   44	   Expanded	   and	   non-­‐expanded	   CB	   	   contain	  
only	  low	  numbers	  of	  effective	  immunocompetent	  T	  	  cells	  but	  nevertheless	  show	  a	  similar	  
131	  
	  
relapse	  rate	  as	  seen	  with	  matched	  unrelated	  donor	  grafts.	  However,	  in	  the	  case	  of	  relapse,	  
additional	  blood	   from	  a	  CBT	  donor	  cannot	  be	  harvested	   for	  donor	   lymphocyte	   infusions	  
(DLI).	   45	   A	   solution	   for	   this	   might	   be	   the	   expansion	   of	   T	   cells	   from	   the	   CD34	   negative	  
fraction	  after	  isolation	  of	  the	  stem	  cells	  prior	  to	  expansion.	  46	  	  
As	   mentioned	   above	   the	   main	   challenge	   is	   the	   expansion	   of	   the	   true	   long	   term	  
repopulating	  hematopoietic	  stem.	  47	  The	  CD34+	  cell	  population	  in	  CB	  is	  a	  heterogeneous	  
population	  containing	  only	  a	  limited	  number	  of	  immature	  progenitors	  (long	  repopulating	  
HSC)	   with	   the	   ability	   of	   complete	   self	   renewal	   and	   mostly	   consists	   of	   more	   mature	  
progenitors	   (short	   term	   repopulating	   HSC)	   and	   committed	   myeloid	   or	   lymphoid	  
progenitors.	  48,49	  	  
Earlier	  expansion	  protocols	  used	  a	  combination	  of	  cytokines	  that	   led	  to	  a	  high	  degree	  of	  
differentiation	  and	  which	  coincides	  with	   the	  maturation	  of	   the	  most	   immature	  cells	  and	  
thus	  loss	  of	  the	  long	  term	  repopulating	  capacity	  of	  the	  graft.	  Although	  a	  single	  long	  term	  
repopulating	  cell	  is	  capable	  of	  eventual	  complete	  reconstitution	  of	  the	  bone	  marrow,	  50	  the	  
speed	  to	  attain	  this	  is	  most	  critical	  for	  limiting	  morbidity	  and	  the	  mortality	  of	  the	  patients.	  
More	   recent	   expansion	   protocols	   focus	   on	   the	   preservation	   of	   the	   true	   long	   term	  
repopulating	  stem	  cell	  (LT	  HSC)	  by	  adding	  small	  molecules	  to	  the	  expansion	  medium.	  An	  
example	   of	   one	   of	   these	   small	   molecules	   is	   Stemregenin	   1	   (SR1),	   an	   arylhydrocarbon	  
receptor	  (AHR)	  antagonist.	  AHR	  is	  an	  important	  regulator	  of	  hematopoietic	  stem	  cells	  	  51	  
and	  culture	  with	  SR1	  has	  shown	  to	  increase	  the	  number	  of	  LT	  HSC	  in	  vitro	  and	  in	  immune	  
deficient	  mouse	  models.	  52,53	  Because	  of	  the	  promising	  experimental	  results,	  a	  phase	  1	  trial	  
has	   started	   to	   evaluate	   the	   clinical	   efficacy	   of	   expansion	  with	   SR1.	   54	  Other	   examples	   of	  
small	   molecules	   that	   can	   increase	   the	   expansion	   of	   LT	   HSC	   are	   transcriptional	   such	   as	  
UM171,	   a	   pyrimidoindole	   derivative,	   55	   and	   valproic	   acid,	   and	   histone	   deacetylase	  
inhibitor.	  56	  However,	  as	  mentioned	  before,	  long	  term	  repopulation	  is	  difficult	  to	  assess	  in	  
vitro	   or	   in	   animal	   models,	   and	   larger	   scale	   clinical	   trials	   are	   needed	   to	   investigate	   the	  
value	  of	  these	  expansion	  strategies.	  	  
	  
CB	  engraftment	  stimulating	  protocols:	  logistic	  considerations.	  
In	  chapter	  3	  we	  show	  that	  the	  engraftment	  capacity	  of	  CB	  CD34+	  cells	  expanded	  with	  TPO	  
before	   and	   after	   cryopreservation	   is	   similar.	   However,	   as	   discussed	   in	   this	   chapter,	  
expansion	  before	  cryopreservation	  is	  logistically	  largely	  impractical	  since	  it	  is	  not	  known	  
which	   cord	   blood	   unit	   is	   going	   to	   be	   needed	   for	   transplantation	   and	   expansion	   of	   all	  
collected	   units	   would	   be	   an	   extremely	   costly	   exercise.	   	   However,	   expansion	   from	   a	  
cryopreserved	   unit	   is	   neither	   an	   easy	   option	   since	   it	   needs	   to	   be	   performed	   in	   a	   GMP	  
certified	   cell	   culture	   facility	   and	   not	   all	   transplantation	   centers	   have	   such	   a	   facility	  
available.	   A	   solution	   for	   this	   would	   be	   to	   centralize	   the	   expansion	   of	   the	   CB	   unit	   upon	  
request	  at	  the	  CB	  banks.	  	  
In	   general,	   the	   engraftment	   enhancing	   strategies	   for	   CB	   transplantation	   that	   were	  
investigated	   in	   this	   thesis	   have	   shown	   their	   merit	   in	   in	   vivo	   models,	   but	   before	   these	  
strategies	   can	   be	   applied	   clinically,	   several	   practical	   and	   scientific	   issues	   have	   to	   be	  
addressed.	  The	  most	  complicating	  issue	  in	  this	  respect	  is	  that	  before	  actual	  use	  in	  patients	  
becomes	  possible,	  that	  the	  manufacturing	  of	  the	  involved	  cellular	  products,	  either	  ex	  vivo	  
culture	  of	  HSC	  or	  the	  culture	  of	  accessory	  cells	  such	  as	  MSC	  or	  regulatory	  T	  cells,	  not	  only	  
require	  GMP	  grade	  facilities,	  but	  also	  highly	  qualified	  personnel	  and	  rigorous	  compliance	  
to	  laboratory	  protocols.	  Indeed,	  the	  various	  manipulations	  needed	  for	  these	  cell	  therapies	  
make	   them	   so	   called	   advanced	   therapy	   medicinal	   products	   (ATMP)	   	   falling	   under	  
medicinal	   regulations	   and	   new	   approval	   for	   each	   change	   in	   the	  manufacturing	   protocol	  
has	  to	  be	  applied	  for.	  	  
132 
	  
Because	  of	   	  all	   these	  practical	  and	  regulatory	  hurdles,	   it	  would	  probably	  be	  advisable	   to	  
prepare	   the	   grafts	   for	   these	   still	   experimental	   cell	   therapies	   in	   the	   specialized	  
transplantation	   centers	   or	   blood	   bank	   facilities	   that	   are	   not	   only	   equipped	   to	   process	  
cellular	  products	  under	  GMP	  conditions	  but	  also	   to	   facilitate	  validated	  GCP	  grade	  assays	  
including	  immune	  and	  engraftment	  monitoring.	  Only	  under	  such	  conditions	  fast	  advance	  
of	  knowledge	  is	  ensured	  and	  can	  reverse	  translation	  of	  outcomes	  lead	  to	  optimization	  of	  
these	  therapies.	  	  	  	  	  	  
	  
The	  use	  of	  CB	  for	  other	  purposes	  than	  HST	  
CB	   also	   contains	   non-­‐hematopoietic	   cells	   that	   might	   be	   useful	   for	   regenerative	   or	  
immunomodulatory	  cell	  therapies.	  The	  best	  known	  examples	  of	  these	  cells	  are	  endothelial	  
progenitor	  cells	  (EPC)	  and	  MSC.	  The	  number	  of	  endothelial	  progenitor	  cells	  and	  MSC	  in	  CB	  
is	  however	  very	   low	  e.g.	   for	  2.99±2.45	  endothelial	  progenitor	  cells	  per	  108	  mononuclear	  
cells	  (MNC),	  57	  or	  0-­‐2.3	  MSC	  per	  108	  MNC,	  58	  and	  the	  culture	  of	  these	  cells	  has	  proven	  to	  be	  
difficult.	   58	   What	   factors	   influence	   the	   number	   of	   non-­‐hematopoietic	   cells	   in	   CB	   	   is	  
unknown,	  although	  	  the	  gestational	  age	  of	  the	  cord	  blood	  seems	  to	  play	  a	  role.	  59	  CB	  that	  
was	  collected	  after	  24	  to	  28	  weeks	  of	  gestation	  seems	  to	  contain	  more	  MSC,	  whereas	  CB	  
from	  weeks	  33-­‐36	  predominantly	  contains	  EPC.	  
The	  regenerative	  potential	  of	  the	  non	  hematopoietic	  cells	  from	  CB	  is,	  with	  the	  exception	  of	  
MSC	   immunotherapy,	   mostly	   useful	   in	   an	   autologous	   setting	   since	   therapies	   such	   as	  
wound	  repair	  and	  bone	  or	  cartilage	  grafting	  requires	  the	  transplantation	  of	  live	  tissue	  that	  
can	  be	  rejected	  by	  the	  host	   if	   the	  cells	  are	  of	  an	  allogeneic	  origin.	  Publically	  stored	  CB	  is	  
exclusively	  banked	   for	   the	  purpose	  of	  allogeneic	  HST.	  Because	  only	  a	   few	  percent	  of	   the	  
stored	   CB	   units	   is	   actually	   used	   for	   this	   purpose,	   CB	   banking	   is	   a	   costly	   activity.	   The	  
number	   of	   privately	   banked	  CB	  units	   is	   almost	   double	   the	  number	   of	   publically	   banked	  
units	  and	  virtually	  not	  used.	  60	  	  
Private	   CB	   banking	   initiatives	   successfully	   advertise	   autologous	   stored	   CB	   as	   superior	  
treatment	   of	   (future)	   hematological	  malignancies	   of	   the	   child	   itself	   or	   one	   of	   its	   family	  
members.	  The	  theoretical	  chance	  of	  needing	  the	  CB	  for	  the	  advertised	  purpose	  is	  only	  1	  in	  
2700	  banked	  units	  which	  are	  estimated	  to	  be	  of	  potential	  benefit	  for	  the	  donor	  itself	  or	  its	  
family.	  61	  Finding	  a	  way	  to	  utilize	  a	  single	  CB	  unit	  for	  both	  autologous	  (non-­‐hematopoietic)	  
and	  allogeneic	  (HSCT)	  purposes	  could	  have	  considerable	  advantages,	  as	   the	   ‘dual’	  use	  of	  
banked	   CB	   could	   be	   partly	   paid	   for	   by	   additional	   interest	   and	   financial	   support	   of	   the	  
donors.	  	  
To	  explore	  this	  ‘dual	  banking’	  strategy	  we	  investigated	  in	  chapter	  5	   if	  the	  hematopoietic	  
cells	  in	  CB	  could	  be	  separated	  from	  the	  non-­‐hematopoietic	  cells	  based	  on	  the	  expression	  
of	   the	  pan	  hematopoietic	  marker	  CD45.	  We	  specifically	   investigated	  whether	  removal	  of	  
the	  CD45	  negative	  cells	  would	  affect	  the	  in	  vitro	  and	  in	  vivo	  hematopoietic	  potential	  of	  the	  
graft.	  The	  ability	  to	  form	  hematopoietic	  colonies	  in	  culture	  is	  correlated	  to	  the	  platelet	  and	  
neutrophil	   engraftment	   capacity	   of	   a	   CB	   unit.	   62	   Removal	   of	   the	   CD45-­‐negative	   cells	  
neither	  affected	  the	  number	  of	  hematopoietic	  colonies	  that	  were	  formed	  by	  CD45-­‐postive	  
cells	   in	   a	   standard	   methocult	   assay.	   In	   agreement	   the	   CD45-­‐	   negative	   cells	   showed	   no	  
hematopoietic	   colony	   forming	   capacity.	   In	   mixed	   lymphocyte	   cultures,	   the	   CD45-­‐	   cells	  
were	   not	   immunogenic	   themselves	   and	   did	   not	   influence	   the	   PBMC	   response	   to	   CD45-­‐
postive	  cells	  or	  vice	  versa.	  We	  therefore	  hypothesize	  that	  CD45-­‐negative	  cell	  removal	  will	  
not	   likely	   influence	   the	   immunological	   properties	   of	   the	   remaining	   graft,	   which	   is	  
important	   for	   both	   the	   incidence	   of	   GvHD	   and	   the	   GvL	   effect.	   Although	   our	   NOD-­‐SCID	  
transplant	   model	   does	   not	   test	   immunologic	   mechanisms,	   co-­‐transplantation	   of	   CD45-­‐
negative	  cells	  with	  CD34+	  cells	  did	  not	  change	  engraftment	   in	  NOD	  SCID	  mice	  of	  CD34+	  
cells	   alone.	   In	   contrast,	   co-­‐transplantation	   of	   CD45-­‐postive	   with	   CD34+	   cells	   clearly	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showed	  the	  added	  engraftment	  enhancing	  potential	  of	  the	  CD45+	  population.	  The	  possible	  
non-­‐hematopoietic	  use	  of	  the	  remaining	  CD45-­‐	  cells	  after	  CD45+	  immuno-­‐separation	  was	  
shown	  by	  the	  fact	  that	  endothelial	  cell	  colonies	  could	  be	  cultured	  from	  the	  isolated	  CD45-­‐	  
cells	  but	  not	  from	  the	  CD45+	  cells.	  	  
Our	  results,	  although	  preliminary,	  suggest	  that	  CD45-­‐negative	  cells	  from	  CB	  might	  be	  used	  
separately	  without	  altering	  the	  HST	  capacity	  of	   the	  CD45-­‐postive	  cells.	  However,	   it	  must	  
be	   noted	   that	   our	   transplant	   model	   does	   not	   allow	   for	   the	   testing	   of	   immunological	  
mechanisms.	  Our	  findings	  should	  therefore	  be	  confirmed	  in	  models	  that	  better	  reflect	  the	  
human	   setting	   in	   this	   respect.	   There	   are	   several	   practical	   and	   logistic	   obstacles	   for	   this	  
‘dual-­‐use’	  banking	  initiative.	  Firstly,	  the	  time	  that	  cells	  are	  needed	  for	  either	  autologous	  or	  
allogeneic	  use	  will	   usually	  not	   coincide.	  This	  will	  make	  pre-­‐cryopreservation	   separation	  
and	  separate	  storage	  more	  preferable	  with	  respect	  to	  the	  quality	  of	  the	  cells,	  but	  this	  will	  
increase	  the	  cost	  of	  banking.	  Again,	  the	  problem	  with	  this	  strategy	  is	  that	  it	  is	  not	  known	  
beforehand	  which	  specific	  cell	  type	  of	  which	  particular	  donor	  will	  be	  needed	  in	  the	  future	  
and	   culturing	   and	   banking	   a	   variety	   of	   different	   cell	   types	   would	   increase	   the	   cost	   for	  
processing	  and	  banking	  of	   the	  CB	  unit.	  Therefore,	  post	   cryopreservation	   separation	  and	  
culture	  is	  more	  practical	  and	  likely	  to	  be	  the	  only	  option	  that	  can	  be	  considered.	  However,	  
although	  endothelial	  progenitor	  cells	  can	  be	  cultured	  from	  cord	  blood	  that	  was	  stored	  for	  
over	  20	  years,	  63	  the	  culture	  of	  MSC	  from	  frozen	  CB	  is	  very	  difficult.	  58	  Loss	  of	  cells	  by	  the	  
freeze	   thaw	   procedures	   combined	   with	   the	   already	   low	   and	   variable	   number	   of	   non-­‐
hematopoietic	  cells	  in	  CB	  will	  therefore	  limit	  the	  number	  of	  successful	  	  cell	  cultures	  from	  
cryopreserved	  CB.	  	  
For	  MSC,	  considered	  as	  one	  of	  the	  most	  promising	  cell	  types	  for	  cell	  therapies	  that	  can	  also	  
be	   used	   in	   an	   allogeneic	   setting,	   it	   is	   important	   to	   realize	   that	   they	   can	   be	  more	   easily	  
obtained	   from	   the	  Wharton’s	   Jelly	   of	   the	  UC	   itself	   and	  private	  CB	  banks	  have	   started	   to	  
offer	   the	  storage	  of	   these	  cells.	   In	   this	   respect	   it	  must	  be	  noted	   that	  WJ	  MSC	  show	  clear	  
aberrances	  from	  the	  typical	  MSC	  phenotype	  and	  its	  therapeutic	  use	  can	  therefore	  not	  be	  
extrapolated	   from	   findings	   obtained	  with	   other	  MSC	   sources.	   In	   chapter	   1	   we	   found	   a	  
limited	  and	  variable	  differentiation	  capacity	  into	  osteoblast,	  adipocytes	  and	  chondrocytes	  
which	  was	  previously	  shown	  by	  earlier	  studies.	  64	  However,	  and	  perhaps	  more	  important,	  
WJ	   MSC	   were	   shown	   to	   possess	   important	   in	   vitro	   immunomodulatory	   and	   in	   vivo	  
engraftment	   enhancing	   capacities	   that	   are	   similar	   to	   BM	   MSC,	   which	   	   are	   much	   more	  
difficult	  to	  	  obtain.	  	  
In	  conclusion,	  new	  use	  of	  cord	  and	  cord	  blood	  cells	  seem	  possible.	  Adapted	  cord	  and	  cord	  
blood	  banking	  strategies	  and	  manipulation	  strategies	  (most	  likely	  post	  cryopreservation)	  
are	   however,	   needed	   for	   this	   new	   use	   and	   the	   cost	   for	   this	   is	   considerate	   and	   should,	  
depending	  on	  the	  development	  of	  the	  progress	  in	  cellular	  therapies	  be	  weighed	  carefully.	  
This	  new	  use	  not	  only	  involves	  creating	  greater	  HST	  efficacy	  of	  cord	  blood	  but	  also	  non-­‐
hematopoietic	   like	   regenerative	   and	   more	   specific	   immunomodulatory	   indications.	  
Isolation	  of	  the	  CD45-­‐postive	  cell	  from	  CB	  for	  the	  use	  in	  HSCT,	  in	  this	  regard	  could	  make	  
the	   remaining	   CD45-­‐negative	   cells	   a	   new	   asset	   for	   these	   purposes.	   	   The	   logistics	   and	  
methodology	   to	  optimize	  such	  new	  therapeutic	  vistas	  need	  consistent	  bench	  to	  bed	  side	  
synergies	   between	   scientists	   and	   clinicians,	   but	   also	   dedicated	   grants	   supporting	   this	  
vision	  and	  international	  and	  multicenter	  collaboration.	  	  	  
	  
CB	   transplantation	   or	   haploidentical	   transplantation:	   the	   choice	   of	   the	   right	   graft	  
source	  
Despite	  many	  scientific	  and	  clinical	  advances,	  the	  increase	  in	  CB	  transplantation	  seems	  to	  
have	  stagnated	  in	  the	  last	  years	  (Figure	  1).	  This	  stagnation	  might	  be	  due	  to	  center	  specific	  
preferences	  in	  using	  other	  unrelated	  donor	  transplants	  	  such	  as	  haploidentical	  grafts	  from	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a	  child	  or	  parent	  of	   the	  patient	   65	  or	   the	  use	  of	  mismatched	  (un)related	  donor	   	  grafts.	   66	  
Another	   reason	   is	   that	   high	   incidence	   of	   graft	   versus	   host	   disease	   (GvHD),	   which	   was	  
historically	   a	   big	   problem	   with	   haploidentical	   graft	   transplantation	   67,68,	   is	   more	  
manageable.	   Besides	   T-­‐cell	   depletion	   as	   a	  main	   preventive	  measure,	   large	   progress	   has	  
been	  made	  in	  the	  understanding,	  treatment	  [9]	  and	  prevention	  of	  GvHD,	  such	  as	  the	  post-­‐
transplant	   administration	   of	  methotrexate	   [10,11].	   Additionally,	   experimental	   therapies	  
are	   now	   being	   investigated	   such	   as	   the	   treatment	   with	   MSC	   infusions	   both	  
prophylactically	   28,69	   or	   when	   first	   line	   treatment	   for	   GvHD	   with	   corticoids	   fails.	   70-­‐75	  
Alternatively,	   co-­‐transplantation	   of	   regulatory	   T	   cells	   has	   shown	   promising	   results	   in	  
prevention	  of	  GvHD.	   76,77	   This	   improved	   treatment	   and	  prevention	  of	  GvHD	  has	   revived	  
the	  interest	  in	  haploidentical	  HST.	  	  
Haploidentical	   grafts	   also	   have	   other	   advantages	   over	   CB	   grafts.	   78-­‐80	   One	   of	   these	  
advantages	   favoring	   haploidentical	   HST	   is	   the	   low	   acquisition	   cost.	   Secondly,	   a	  
haploidentical	   donor	   graft	   is	   usually	   quickly	   available	   since	   nearly	   every	   patient	   has	   a	  
haploidentical	  sibling,	  child	  or	  parent.	  In	  contrast,	  for	  CB,	  despite	  the	  increasing	  number	  of	  
banked	  units,	   the	  variability	  of	   the	  cell	  dose	   in	   the	  banked	  units	  still	   limits	   the	  choice	  of	  
sufficiently	   large	   grafts.	   Thirdly,	   the	   immune	   reconstitution	   after	   haploidentical	  
transplantation	   is	   still	   faster	   compared	   to	   CB	   transplantation	   and	   reduces	   the	   risk	   of	  
infection,	   the	   largest	   cause	  of	  non-­‐relapse	  mortality,	   especially	   in	   the	   first	   three	  months	  
after	   transplantation	   81.	   A	   last	   and	   often	   mentioned	   advantage	   of	   non-­‐CB	   grafts	   is	   the	  
possibility	   of	   post-­‐transplant	   donor	   lymphocyte	   infusions	   (DLI)	   to	   prevent	   or	   treat	  
relapse.	   Whether	   this	   applies	   to	   haploidentical	   grafts	   is	   however	   debatable	   since	  
haploidentical	   DLI	   –although	   possible-­‐	   carries	   again	   a	   very	   high	   risk	   of	   GVHD	   and	   is	  
therefore	   very	   rarely	   applied.	   	   Conversely	   the	   strong	  T	   cell	   depletion	  needed	   to	   control	  
GVHD	   in	   the	   case	   of	   haploidentical	   GvHD	   is	   offset	   by	   a	   higher	   relapse	   rate,	   	   and	   T	   cell	  
replete	   grafts	   82	   or	   post-­‐transplant	   DLI	   83	   in	   these	   patients	   again	   increases	   the	   risk	   of	  
GvHD.	  Hence,	  development	  of	  more	  practical	  relapse	  treatment	  solutions	  for	  both	  CB	  and	  
haploidentical	   transplantations	   is	   therefore	   needed	   and	   crucial	   for	   choice	   of	   the	   most	  
suitable	  graft	   source.	   In	   this	   respect,	  DLI	   from	  CB	   in	   the	  near	   future	   is	   likely	   to	  become	  
possible	  by	  –	  although	  costly	  -­‐	  expansion	  of	  T	  cells	  from	  the	  CD34	  negative	  fraction	  of	  the	  
graft.	  46	  	  
Finally,	   it	   is	   good	   to	   realize	   that	  most	   comparisons	   between	   different	   graft	   sources	   are	  
based	   on	   different	   studies	   performed	   in	   separate	   centers	   with	   retrospective	   outcome	  
analyses.	   Moreover,	   variability	   in	   patient	   groups	   and	   diseases	   treated	   in	   these	   studies	  
make	   these	   comparisons	   even	   more	   complicated.	   While	   certain	   graft	   sources	   might	   be	  
better	  in	  the	  treatment	  of	  a	  certain	  group	  of	  patients	  or	  of	  a	  certain	  disease,	  the	  experience	  
of	   a	   center	   with	   a	   certain	   transplant	   platform/approach	   is	   probably	   one	   of	   the	   most	  
critical	  determinants	  to	  optimize	  the	  disease	  and	  patient	  related	  outcome.	  	  
Prospective	   randomized	   and	   multicenter	   studies	   not	   only	   covering	   morbidity	   and	  
mortality	   but	   also	   treatment	   costs	   and	   quality	   of	   life	   issues	   are	   therefore	   needed	   to	  
correctly	  evaluate	  the	  pros	  and	  cons	  of	  each	  graft	  source.	  84,85	  The	  continuing	  research	  on	  
the	  enhancement	  of	  CB	  transplantation,	  such	  as	  HSC	  and	  lymphocyte	  expansion,	  however,	  
is	  accelerating	  and	  could	   improve	   the	  outcome	   for	  CB	  recipients	   in	   such	  a	  way	   that	   this	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Umbilical	   cord	   blood	   (CB)	   is	   an	   alternative	   for	  mobilized	   peripheral	   blood	   stem	   cell	   or	  
bone	   marrow	   grafts	   when	   a	   patient	   needs	   allogeneic	   hematopoietic	   stem	   cell	  
transplantation	   (HST).	  However,	   CB	  HST	   is	   associated	  with	   increased	   incidence	   of	   graft	  
failure	   and	   delayed	   engraftment	   and	   immune	   reconstitution	   compared	   to	   other	   graft	  
sources,	  which	  is	  caused	  by	  the	  relatively	  low	  numbers	  of	  stem	  cells	  in	  a	  cord	  blood	  unit.	  
There	  are	  a	  number	  of	  strategies	  that	  can	  be	  used	  to	  increase	  the	  number	  of	  stem	  cells	  in	  a	  
cord	  blood	  graft,	  including	  double	  CB	  transplantation,	  ex	  vivo	  expansion	  of	  CB	  and	  the	  co-­‐
transplantation	  of	  accessory	  cells	  such	  as	  mesenchymal	  stem	  cells	   (MSC).	  For	   this	   thesis	  
we	  investigated	  different	  aspects	  of	  the	  application	  of	  these	  strategies.	  	  
The	  co-­‐transplantation	  of	  MSC	  has	  shown	  promising	  results	  in	  animal	  models.	  It	  enhances	  
the	  engraftment	  of	  the	  stem	  cells	  leading	  to	  higher	  numbers	  of	  cells	  in	  the	  hematopoietic	  
organs	  of	  the	  recipient.	  The	  majority	  of	  MSC	  used	  in	  the	  clinic	  are	  derived	  from	  the	  bone	  
marrow	  of	  healthy	  donors.	  The	  harvest	  of	  these	  MSC	  is	  a	  costly	  procedure	  and	  involves	  a	  
certain	  risk	  for	  the	  donor,	  and	  is	  therefore	  ethically	  constrained.	  	  	  
We	  compared	  in	  vitro	  characteristics	  and	  the	  engraftment	  enhancing	  capacity	  of	  BM	  MSC	  
with	  MSC	  from	  the	  Wharton	  Jelly	  of	  the	  umbilical	  cord	  (WJ	  MSC).	  These	  MSC	  have	  several	  
advantages	   over	   BM	  MSC	   such	   as	   a	   low	   collection	   costs	   and	   a	   relatively	   low	   chance	   of	  
transmissible	   infections.	  Furthermore,	  being	  a	  waste	  product,	  WJ	  MSC	  are	   free	  of	  ethical	  
constraints.	   Although	   less	   capable	   of	   differentiating	   into	   mesodermal	   lineages,	  WJ	   MSC	  
have	   a	   similar	   capacity	   to	   inhibit	   immunological	   responses	   in	   vitro	   and	   to	   enhance	   the	  
engraftment	  of	  CB	  CD34+	  cells	  in	  vivo.	  WJ	  MSC	  would	  therefore	  be	  a	  good	  alternative	  for	  
the	  use	  of	  BM	  MSC	  from	  healthy	  donors.	  	  
Ex	  vivo	  expansion	  of	  CB	  has	  successfully	  been	  applied	  in	  several	  phase	  I/II	  clinical	  trials.	  
Our	   lab	  has	  previously	  developed	  a	  protocol	   for	   the	   expansion	  of	  CB	  CD34+	   cells,	   using	  
only	   TPO,	  which	   can	   improve	   platelet	   recovery	   in	   the	   peripheral	   blood.	   Expanded	   cells	  
with	   this	   capacity	  would	  be	  especially	  helpful	   for	  patients	   that	  are	   refractory	   to	  platelet	  
transfusions,	   since	   these	  patient	  have	  an	   increased	   risk	  of	  dying	   from	  hemorrhage	  after	  
HST.	  For	  clinical	  application	  of	  these	  expanded	  cells,	  co-­‐transplantation	  of	  non	  expanded	  
cells	   is	   necessary	   to	   safeguard	   the	   long	   term	   reconstitution	   of	   all	   blood	   cells.	   We	  
investigated	  the	  transplantation	  of	  expanded	  cells	  and	  non	  expanded	  CB	  cells	  and	  did	  not	  
find	  any	  difference	  with	  respect	  to	  recovery	  of	  CD45+	  cells	  in	  the	  peripheral	  blood	  of	  the	  
mice	   or	   BM	   and	   spleen	   engraftment	   when	   compared	   to	   the	   transplantation	   of	  
unmanipulated	   cells	   from	   two	   CB	   units.	   Platelet	   recovery	  was	   significantly	   improved	   in	  
the	  first	  weeks	  after	  transplantation,	  which	  suggests	  that	  this	  strategy	  would	  be	  favorable	  
over	  the	  transplantation	  of	  two	  unmanipulated	  units.	  We	  further	  investigated	  if	  the	  order	  
of	  cryopreservation	  and	  expansion,	   i.e.	  before	  or	  after	   the	  banking	  of	   the	  CB	  unit,	  would	  
influence	   the	   outcome	  of	   transplantation.	   Although	   the	   number	   of	   cells	   that	   are	   formed	  
after	   expansion	   are	   higher	   when	   the	   CB	   cells	   are	   expanded	   before	   the	   cells	   are	  
cryopreserved,	   we	   did	   not	   find	   any	   significant	   differences	   in	   the	   engraftment	   capacity	  
compared	   to	   cells	   that	  were	   expanded	   after	   cryopreservation	   of	   the	   CB	   cells.	   The	   latter	  
even	  proved	  to	  be	  more	  efficient	  in	  the	  recovery	  of	  platelets	  in	  the	  peripheral	  blood	  of	  the	  
mice.	   This	   suggests	   that	   our	   expansion	   protocol	   can	   be	   applied	   to	   all	   CB	   units	   that	   are	  
currently	  stored	  in	  CB	  banks.	  	  
Lastly	  we	  tried	  to	  combine	  the	  co-­‐transplantation	  of	  MSC	  with	  the	  transplantation	  of	  TPO	  
expanded	   cells.	   Each	   strategy	   by	   itself	   can	   either	   improve	   overall	   engraftment	   or	   early	  
platelet	  recovery	  in	  the	  peripheral	  blood.	  A	  combination	  of	  both	  strategies	  could	  therefore	  
further	   improve	   the	   outcome	   of	   CB	   transplantation.	   However,	   we	   found	   that,	   although	  
each	  single	  strategy	  improved	  the	  outcome	  of	  transplantation	  in	  the	  way	  we	  expected,	  the	  
combination	   of	   strategies	   did	   neither	   further	   improve	   early	   platelet	   recovery	   nor	  
engraftment.	   Furthermore,	   we	   encountered	   events	   of	   non	   engraftment	   in	   several	   mice,	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which	   suggest	   that	   the	   combination	   of	   MSC	   and	   expanded	   cells	   can	   lead	   to	   unwanted	  
adverse	  events.	  We	  could	  not	  determine	  the	  cause	  of	  these	  adverse	  events	  and	  therefore	  
concluded	   that	   this	   strategy	   cannot	  be	   translated	   into	   a	   clinical	  protocol	  until	   the	   cause	  




WJ	  MSC	  are	  a	  promising	  source	  of	  MSC	  for	  clinical	  application.	  We	  therefore	  recommend	  
that	  the	  protocol	  for	  the	  collection	  of	  the	  umbilical	  cord	  and	  processing	  of	  the	  cells	  should	  
be	  translated	  into	  a	  GMP	  grade	  protocol.	  	  
	  
Transplantation	  of	  TPO	  expanded	  cells	  in	  combination	  with	  unmanipulated	  cells	  seems	  to	  
be	  safe	  with	  respect	  to	  the	  early	  recovery	  of	  platelets	  and	  the	  long	  repopulation	  of	  the	  BM.	  
The	   expansion	   protocol	   could	   therefore	   be	   translated	   into	   a	   GMP	   grade	   protocol	   and	  
simultaneously	   scaled	   up	   from	   culturing	   small	   quantities	   of	   cells	   to	   whole	   CB	   units.	   A	  
phase	  I	  clinical	  trial	  with	  TPO	  expanded	  cells	  in	  combination	  with	  unmanipulated	  CB	  cells	  
would	   be	   an	   option	   if	   there	   is	   demand	   from	   clinicians	   that	   have	   a	   sufficient	   number	   of	  

















































































Navelstrengbloed	  (NB)	   is	  een	  alternatief	  voor	  gemobiliseerd	  perifeer	  bloed	  of	  beenmerg	  
grafts	   voor	   patiënten	   die	   een	   allogene	   hematopoietische	   stamceltransplantatie	   (HST)	  
nodig	  hebben.	  NB	  HST	  wordt	  echter	  geassocieerd	  met	  een	  verhoogde	  incidentie	  van	  graft	  
failure	   en	   vertraagde	   engraftment	   en	   immuun-­‐reconstitutie	   in	   vergelijking	   met	   andere	  
bronnen	  voor	  HST	  grafts.	  Dit	  wordt	  veroorzaakt	  door	  het	  relatief	  lage	  aantal	  stamcellen	  in	  
een	  NB	  eenheid.	  Er	  zijn	  een	  aantal	  strategieën	  die	  het	  aantal	  stamcellen	  in	  een	  NB	  eenheid	  
kunnen	  vergroten,	  waaronder	  transplantatie	  van	  2	  NB	  eenheden,	  ex	  vivo	  expansie	  van	  NB	  
en	  de	  co-­‐transplantatie	  van	  accessoire	  cellen	  zoals	  mesenchymale	  stamcellen	  (MSC).	  Voor	  
dit	  proefschrift	  hebben	  wij	  verschillende	  aspecten	  van	  deze	  strategieën	  onderzocht.	  
De	  co-­‐transplantatie	  van	  MSC	  heeft	   in	  diermodellen	  veelbelovende	  resultaten	   laten	  zien.	  
Het	   verbeterd	  de	   engraftment	   van	  de	  hematopoietische	   stamcellen,	  wat	   leidt	   tot	  hogere	  
aantallen	  cellen	   in	  de	  hematopoietische	  organen	  van	  de	  ontvanger.	  De	  meerderheid	  van	  
de	  MSC	  die	  in	  de	  kliniek	  gebruikt	  worden	  komen	  van	  het	  beenmerg	  van	  gezonde	  donoren.	  
Het	  oogsten	  van	  deze	  MSC	  is	  een	  kostbare	  procedure	  en	  draagt	  een	  zeker	  risico	  met	  zich	  
mee	  voor	  de	  donor	  en	  is	  daarom	  ethisch	  gezien	  niet	  wenselijk.	  We	  hebben	  daarom	  de	  in	  
vitro	   eigenschappen	   en	   de	   engraftment	   vergrotende	   capaciteit	   van	   BM	  MSC	   vergeleken	  
met	  MSC	  afkomstig	  van	  een	  andere	  bron:	  de	  Wharton’s	  Jelly	  van	  de	  navelstreng.	  Deze	  MSC	  
hebben	  een	  aantal	  voordelen	  vergeleken	  met	  BM	  MSC,	  zoals	  lage	  kosten	  voor	  collectie	  en	  
een	   relatief	   lage	   kans	   op	   overdraagbare	   infecties.	   Er	   zijn	   bovendien,	   aangezien	  WJ	  MSC	  
geoogst	  worden	  van	  een	  afval	  product,	  geen	  ethische	  bezwaren	  voor	  het	  gebruik	  van	  deze	  
cellen.	  Hoewel	  deze	  cellen	  minder	  capaciteit	  hebben	  om	  te	  differentiëren	  in	  mesodermale	  
cellijnen,	   hebben	   WJ	   MSC	   een	   vergelijkbare	   capaciteit	   om	   in	   vitro	   immunologische	  
reacties	  te	  remmen	  en	  de	  engraftment	  van	  NB	  CD34+	  cellen	  in	  vivo	  te	  vergroten.	  WJ	  MSC	  
zouden	   daarom	   een	   goed	   alternatief	   zijn	   voor	   het	   gebruik	   van	   BM	   MSC	   van	   gezonde	  
donoren.	  
De	   ex	   vivo	   expansie	   van	   NB	   is	   succesvol	   toegepast	   in	   verschillende	   fase	   I/II	   klinische	  
studies.	   Ons	   lab	   heeft	   een	   protocol	   ontwikkeld	   voor	   de	   expansie	   van	   NB	   CD34+	   cellen,	  
alleen	  gebruik	  makend	  van	  TPO,	  dat	  het	  herstel	  van	  plaatjes	  in	  het	  perifere	  bloed	  (PB)	  kan	  
verbeteren.	   Geëxpandeerde	   cellen	  met	   deze	   capaciteit	   zouden	   in	   het	   bijzonder	   geschikt	  
zijn	   voor	   patiënten	   die	   refractoir	   zijn	   voor	   plaatjestransfusies	   aangezien	   deze	   patiënten	  
een	   verhoogd	   risico	   hebben	   om	   te	   overleiden	   van	   bloedingen	   na	   een	   HST.	   Voor	   de	  
klinische	   applicatie	   van	   deze	   geëxpandeerde	   cellen	   is	   het	   noodzakelijk	   om	   niet	  
geëxpandeerde	   cellen	  mee	   te	   transplanteren	   om	   de	   lange	   termijn	   reconstitutie	   van	   alle	  
bloedcellen	   veilig	   te	   stellen.	   We	   hebben	   de	   transplantatie	   van	   geëxpandeerde	   en	   niet	  
geëxpandeerde	   onderzocht	   en	   vonden	   geen	   verschil	  met	   betrekking	   tot	   het	   herstel	   van	  
CD45+	  cellen	  in	  het	  PB	  van	  de	  muizen	  of	  de	  engraftment	  in	  het	  beenmerg	  en	  milt	  als	  we	  
dit	   vergeleken	   met	   de	   transplantatie	   van	   cellen	   van	   twee	   niet	   gemanipuleerde	   NB	  
eenheden.	   Het	   herstel	   van	   plaatjes	   was	   significant	   verbeterd	   in	   de	   eerste	   week	   na	   de	  
transplantatie,	   wat	   suggesteerd	   dat	   deze	   strategie	   favorable	   is	   vergeleken	   met	   de	  
transplantatie	   van	   twee	   niet	   gemanipuleerde	   NB	   eenheden.	   Vervolgens	   hebben	   we	  
onderzocht	  of	  de	  volgorde	  van	  cryopreservatie	  en	  expansie,	  i.e.	  voor	  of	  na	  het	  opslaan	  van	  
de	  NB	  eenheid,	  de	  uitkomst	  van	  de	  transplantatie	  beïnvloed.	  Hoewel	  het	  aantal	  cellen	  dat	  
gevormd	  wordt	  na	  expansie	  hoger	  is	  als	  de	  NB	  cellen	  geëxpandeerd	  worden	  voor	  de	  cellen	  
gecryopreserveerd	   worden,	   vonden	   we	   geen	   significante	   verschillen	   in	   de	   engraftment	  
capaciteit	   vergeleken	  met	   cellen	  die	  geëxpandeerd	  werden	  na	  cryopreservatie.	  Expansie	  
post	   cryopreservatie	   leidde	  zelfs	   tot	   een	  bet	  plaatjesherstel	   in	  het	  perifere	  bloed	  van	  de	  
muizen.	   Dit	   duidt	   erop	   dat	   ons	   expansieprotocol	   toegepast	   kan	   worden	   op	   alle	   NB	  
eenheden	  die	  momenteel	  opgeslagen	  zijn	  in	  de	  NB	  banken.	  
Tot	  slot	  hebben	  we	  geprobeerd	  de	  co-­‐transplantatie	  van	  MSC	  en	  de	  expansie	  van	  TPO	  te	  
combineren.	   Elke	   afzonderlijke	   strategie	   kan	   ofwel	   de	   engraftment,	   ofwel	   het	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plaatjesherstel	  in	  het	  perifere	  bloed	  verbeteren.	  Een	  combinatie	  van	  deze	  strategieën	  zou	  
dus	   de	   uitkomst	   van	   een	   NB	   transplantatie	   nog	   verder	   kunnen	   verbeteren.	  We	   vonder	  
echter	   dat,	   hoewel	   elke	   afzonderlijke	   strategie	   de	   uitkomst	   van	   de	   transplantatie	   naar	  
verwachting	  verbeterde,	  een	  combinatie	  van	  beide	  strategieën	  noch	  het	  plaatsjes	  herstel	  
noch	  de	   engraftment	   verder	   kon	   verbeteren.	  Bovendien	   observeerden	  we	   zelfs	   gevallen	  
van	  non	  engraftment	  in	  meerdere	  muizen,	  wat	  erop	  duidt	  dat	  de	  combinatie	  van	  MSC	  en	  
geëxpandeerde	   cellen	   tot	   ongewenste	   neveneffecten	   kan	   leiden.	   We	   konden	   niet	  
vaststellen	  wat	  de	  oorzaak	  van	  de	  neveneffecten	  was	   en	  hebben	  daarom	  geconcludeerd	  
dat	  deze	  strategie	  niet	  in	  een	  klinisch	  protocol	  vertaald	  kan	  worden	  totdat	  de	  oorzaak	  van	  
deze	  neveneffect	  is	  verhelderd.	  	  
	  
Aanbevelingen	  
WJ	  MSC	  zijn	  een	  veelbelovende	  bron	  voor	  het	  gebruik	  van	  MSC	  in	  klinische	  applicaties.	  We	  
bevelen	   daarom	   aan	   dat	   het	   protocol	   voor	   de	   collectie	   van	   de	   navelstreng	   en	   het	  
verwerken	  van	  de	  cellen	  vertaald	  moet	  worden	  in	  een	  GPM	  geaccrediteerd	  protocol.	  	  
Transplantatie	   van	   TPO	   geëxpandeerde	   cellen	   in	   combinatie	   met	   niet	   geëxpandeerde	  
cellen	  lijkt	  veilig	  te	  zin	  m.b.t.	  het	  versnelde	  herstel	  van	  plaatjes	  in	  het	  perifere	  bloed	  en	  de	  
lange	  termijn	  repopulatie	  van	  het	  beenmerg.	  Het	  expansie-­‐protocol	  zou	  daarom	  vertaald	  
moeten	  worden	  in	  een	  GMP	  protocol	  en	  gelijktijdig	  opgeschaald	  moeten	  worden	  van	  het	  
kweken	   van	   kleine	   aantallen	   cellen	   tot	   gehele	  NB	   eenheden.	   Een	   fase	   1	   klinische	   studie	  
met	  TPO	  geëxpandeerde	  cellen	  in	  combinatie	  met	  niet	  gemanipuleerde	  NB	  cellen	  zou	  een	  
optie	  zijn	  als	  er	  een	  vraag	  is	  vanuit	  clinici	  dat	  een	  voldoende	  aantal	  patiënten	  voordeel	  zou	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List	  of	  acronyms	  
	  
AB	  	   	   antibody	  
ALL	  	   	   acute	  lymphoblastic	  leukemia	  
AML	  	   	   acute	  myeloid	  leukemia	  
BFU-­‐E	  	   	   burst	  forming	  unit	  erythrocyte	  
BM	  	   	   bone	  marrow	  
CAFC	   	   cobblestone	  area	  forming	  cell	  
CB	  	   	   cord	  blood	  
CBT	  	   	   cord	  blood	  transplantation	  
CFU	  	   	   colony	  forming	  unit	  
CFU-­‐GM	  	   	   CFU	  granulocyte	  macrophage	  
CFU-­‐GEMM	  	   CFU	  granulocyte	  erythrocyte	  monocyte	  megakaryocyte	  	  
CFU-­‐Mk	  	   	   CFU	  megakaryocyte	  	  
CTE	   	   cryopreserved/thawed/expanded	  
dCB	  	   	   double	  cord	  blood	  
DLL-­‐1	  	   	   delta	  like	  ligand	  1	  
DMSO	  	   	   dimethyl	  sulfoxide	  
ECT	   	   expanded/cryopreserved/thawed	  
FCS	   	   fetal	  calf	  serum	  
Flt3L	  	   	   Flt3	  ligand	  	  
G-­‐CSF	   	  	   granulocyte	  colony-­‐stimulating	  factor	  
GM-­‐CSF	   	   granulocyte-­‐macrophage	  colony-­‐stimulating	  factor	  
GMP	   	   good	  manufactoring	  practice	  
GvHD	  	   	   graft	  versus	  host	  disease	  
GvL	  	   	   graft	  versus	  leukemia	  
HLA	  	   	   human	  leukocyte	  antigen	  
HSC	  	   	   hematopoietic	  stem	  cell	  
HSPC	  	   	   hematopoietic	  stem	  and	  progenitor	  cells	  
HST	  	   	   hematopoietic	  stem	  cell	  transplantation	  
IL-­‐X	   	   interleukin-­‐X	  
IMDM	   	   Iscove’s	  modified	  Dulbecco’s	  medium	  
Lin-­‐	  	   	   lineage	  negative	  
LUMC	   	   Leiden	  University	  Medical	  Center	  
MDS	  	   	   myelodysplastic	  syndrom	  
MNC	  	   	   mononuclear	  cells	  
MMUD	   	  	   mismatched	  unrelated	  donor	  
MSC	  	   	   mesenchymal	  stem/stromal	  cell	  
MUD	  	   	   matched	  unrelated	  donor	  
NBB	  	   	   navelstrengbloedbank	  
NOD	  SCID	  	  	   non	  obese	  diabetic	  severe	  combined	  immuno	  deficient	  
NRM	  	   	   non	  relapse	  mortality	  
PB	  	   	   peripheral	  blood	  
PBMC	  	   	   peripheral	  blood	  mononuclear	  cells	  
PBS	  	   	   phosphate	  buffered	  saline	  
PBSC	  	   	   peripheral	  blood	  stem	  cells	  
rCD34+	  	   	   residual	  CD34+	  cells	  (after	  TPO	  expansion)	  
RFS	  	   	   relapse	  free	  survival	  
SCF	  	   	   stem	  cell	  factor	  	  
SEM	  	   	   standard	  error	  of	  mean	  
TEPA	  	   	   tetraethylenepentamine	  
TNC	  	   	   total	  nucleated	  cell	  count	  
TPO	  	   	   thrombopoietin	  
T-­‐reg	  	   	   regulatory	  T	  cell	  
UC	  	   	   umbilical	  cord	  
UCB	   	   umbilical	  cord	  blood	  
WBC	   	   white	  blood	  cell	  
WJ	  	   	   Wharton	  Jelly	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